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!Abstract 
Cannabis is the most widely used illicit drug in the world, however in the past decade 
there has been increasing interest in its utility as a source of potential therapeutics. 
Although cannabis contains approximately 100 cannabinoid constituents, the majority 
of its effects are produced by Δ9-tetrahydrocannabinol (THC) interacting with the 
endogenous cannabinoid system. Despite THC’s reported beneficial properties as an 
analgesic, antiemetic, and anti-spasticity drug, its psychoactivity has curtailed its 
therapeutic use. In contrast cannabidiol (CBD), which is also found in cannabis, has a 
much better symptom profile, producing antipsychotic, anti-inflammatory, and 
anxiolytic effects without psychoactivity. 
There has been increasing interest over the past decade in combining CBD 
with THC to inhibit THC’s unwanted symptom profile. This is the rationale behind 
the generation of medications such as Sativex® and Bediol®, which both contain 
~1:1 CBD to THC dose ratios and are currently used for the treatment of spasticity in 
multiple sclerosis and pain relief respectively. However, although cannabis has been 
legalized for medicinal purposes in a number of countries, there is a limited evidence 
base regarding to what extent CBD might modulate the pharmacological effects of 
THC at equal doses. The potency of recreational cannabis strains, as measured by 
THC concentrations, has increased dramatically over the past 50 years to the point 
where little to no CBD remains. If conclusive evidence for CBD reducing the adverse 
effects of THC can be attained, this would help support the strategy of breeding CBD 
back into the plant to create a “healthier” form of cannabis for recreational and 
medicinal use. The scientific examination of pharmacological interactions between 
THC and CBD is therefore of major medical and public health significance. 
x
!One aspect of the interaction between CBD and THC that has not been 
adequately studied is the impact of their combination on behaviour and neurobiology. 
Human research has shown that the presence of CBD in smoked cannabis is 
associated with decreases in schizophrenia-like symptoms, as well as anxiety, mood 
disruption and cognitive deficits. Human imaging studies have shown that CBD has 
opposing effects to THC on brain activation in distinct brain regions, however no 
study has yet examined the impact of the co-administration of these compounds. 
Animal research demonstrates great complexity in the interaction between THC and 
CBD, and suggests more research is needed to illuminate the nature of these 
interactions using dosing regimens and dose ratios relevant to human consumption. 
This thesis will endeavour to examine whether CBD is able to ameliorate the 
pharmacological effects of THC following acute and repeated dosing in adulthood 
and adolescence using mice.  
Although it has been proposed that medicinal strains of cannabis and 
therapeutic formulations would be safer with a more balanced concentration ratio of 
CBD and THC, our understanding of the brain circuitry mediating interactions 
between CBD and THC are unknown. In Chapter 2 we investigated whether CBD 
modulated THC-induced c-Fos expression in the brain using a 1:1 dose ratio. Male 
C57BL/6 mice were treated with vehicle, CBD, THC or a combination of CBD and 
THC (10!mg/kg i.p. for both cannabinoids) to examine effects on locomotor activity,
anxiety-related behaviour, body temperature and brain c-Fos expression (a marker of 
neuronal activation). CBD potentiated THC-induced locomotor suppression but 
reduced the hypothermic and anxiogenic effects of THC. CBD alone had no effect on 
these measures. THC increased brain activation, as measured by c-Fos expression, in 
11 of the 35 brain regions studied. CBD co-administration suppressed THC-induced 
xi
!c-Fos expression in 6 of these brain regions. This effect was most pronounced in the
medial preoptic nucleus and lateral periaqueductal grey. Treatment with CBD alone 
diminished c-Fos expression only in the central nucleus of the amygdala compared 
with vehicle. These data confirm that CBD modulated the neuropharmacological 
actions of THC and provide new information regarding brain regions involved in the 
interaction between CBD and THC. 
Few studies have assessed the impact of repeated CBD and THC co-
administration on the brain and behaviour. In Chapter 3 we extended upon the 
findings of Chapter 2 by examining whether CBD modulated the repeated effects of 
THC on behaviour and neuroadaptive changes in the mesolimbic dopamine pathway 
over 15 days of daily treatment. After inducing acute locomotor suppression, repeated 
THC caused rebound locomotor hyperactivity that was modestly inhibited by CBD. 
CBD also slightly reduced the acute effects of THC on sensorimotor gating. These 
subtle effects were found at a 1:1 CBD:THC dose ratio but were not accentuated by a 
5:1 dose ratio. CBD did not alter the trajectory of enduring THC-induced anxiety nor 
tolerance to the pharmacological effects of THC. There was no evidence of CBD 
potentiating the behavioural effects of THC. However we demonstrated for the first 
time that repeated co-administration of CBD and THC synergistically increased 
histone 3 acetylation (H3K9/14ac) in the VTA and ΔFosB expression in the nucleus 
accumbens. These changes suggest that while CBD may have protective effects 
acutely, its long-term molecular actions on the brain are more complex and may be 
supradditive. 
Repeated THC treatment during adolescence has been associated with long-
term neurobehavioral deficits, even after prolonged abstinence. In Chapter 4 we 
therefore aimed to examine whether CBD modulated persisting behavioural deficits 
xii
!promoted by adolescent THC exposure in mice at a 1:1 CBD:THC dose ratio. We 
found that in contrast to previous rodent studies, no lasting effects of adolescent THC 
exposure were observed across a broad array of behavioural domains including 
locomotor activity, novel object recognition, social interaction, sensorimotor gating 
and depression-like behaviour. Adolescent CBD exposure similarly did not influence 
the majority of the behaviours examined. Surprisingly however we found adolescent 
CBD treatment reduced depression-like behaviour in adulthood, three weeks 
following the final exposure to CBD and in the absence of detectable brain CBD 
concentrations. This is a promising finding and reinforces the notion that CBD might 
be useful in the treatment of mood disorders. 
In Chapter 5 we summarize the main findings of this thesis, the implications 
of its findings for human use and propose future directions that could be explored. 
The thesis supports to an extent the notion that CBD reduces the neurobehavioural 
effects of THC, however there were notable exceptions to this rule underscoring great 
complexity in the interaction between these two phytocannabinoid constituents. 
!
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"It was an interesting experiment, but I can't write too 
enthusiastic an endorsement for this drug you fellows are 
synthesizing. The feeling of well-being would not, in my 
estimation, equal that from about three highballs, and the 
penalty seemed to me to be pretty severe.  
The outstanding impressions were the feeling of detachment 
from myself and the extreme hunger. Are these both 
associated with the same part of the molecule? If not, you 
might hydrogenate out some of the bad effects and thereby 
obtain a wonderful aperitif." 
-- Marihuana, 1942 
xiv
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1. Introduction to cannabis
Obtaining a drug that maintains therapeutic benefits while controlling for 
psychoactive side effects has been a challenge for cannabinoid medicines. Its dual 
nature has been reported from the beginning of modern medicine, with human 
consumption producing psychoactive symptoms (euphoria, dissociation, paranoia, 
depression, and in some cases psychosis), cognitive disruption (including memory 
and attention deficits) and unpleasant physical symptoms (including bloodshot eyes, 
dry mouth, loss of coordination, and cardiovascular disturbance) (Adams, 1942; 
Johnson and Domino, 1971; Keeler, 1967). This is often simultaneous to reported 
medicinal benefits including analgesia, nausea suppression, reduced spasticity, 
appetite stimulation, bronchodilation, seizure suppression and sleepiness (Academies, 
2017; Clendinning, 1843; Sallan et al., 1975; Weil et al., 1968; Whiting et al., 2015). 
The weight loss cannabinoid drug Rimonabant remains a cautionary tale after it was 
withdrawn from the market due to adverse psychiatric reactions including anxiety, 
depression and suicidal ideation (Aagaard et al., 2016; EMEA, 2009). Focus has since 
returned to the cannabis plant itself, particularly whether it is possible to create a safer 
and more tolerable symptom profile from interactions of chemicals within the plant 
itself. 
1.1 Cannabis the plant and the chemicals it contains 
The term “cannabis” refers to plant matter from the cannabis genus, most commonly 
Cannabis sativa although also encapsulating the C. indica and C. ruderalis species 
(see Figure 1A). Species classification within the genus is still debated, particularly 
given enthusiastic crossbreeding by both recreational and industrial growers (Flores-
Sanchez and Verpoorte, 2008; Hazekamp and Fischedick, 2012; Laursen, 2015; 
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Sawler et al., 2015). While there are anecdotal reports of differences in the 
pharmacological effects between C. sativa and C. indica strains, heterogeneity in the 
plant means that phenotypic similarity does not necessarily guarantee genetic 
similarity (Sawler et al., 2015). Currently it is uncertain whether these labels still refer 
to phenotype strain traits (the tall, thin leafed sativa versus the short, fat leafed indica, 
see Figure 1B) or if these labels are vernacular terms for plants with particular drug 
effects but independent of strain ancestry (Hazekamp and Fischedick, 2012). This 
question is only in the embryonic stages of being addressed by the literature (Gould, 
2015b; Sawler et al., 2015), but they are generally considered as a single diverse 
species, Cannabis Sativa L (ElSohly et al., 2017). 
Of the 500 different chemicals isolated from cannabis, approximately 120 are 
classified as phytocannabinoids or plant-derived cannabinoids (see Figure 1B) 
(ElSohly et al., 2017; Gould, 2015a). Cannabis also contains other compounds 
including terpenoids and flavonoids which may contribute to the overall drug effect 
(McPartland and Pruitt, 1999). The heaviest density of cannabinoids is produced in 
resinous glandular trichomes (see Figure 1C, 1D) on the flowering head of the 
unfertilized female plant (Taschwer and Schmid, 2015). The composition of the 
cannabis plant varies dependent on strain, with its pharmacological activity the 
product of multiple chemical compounds. 
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Figure 1. The heterogeneous cannabis plant. Images include variations in A) species (adapted from 
Gould (2015a)) and B) the multitude of cannabinoid constituents (adapted from Gould (2015a)). Also 
displayed are cannabis trichomes at a C) macroscopic level and D) microscopic level (Happyana et al., 
2013). 
stems of the latter. The specific cells of trichomes were separated
and collected using LMD. Cannabinoids in the dissected samples
were analyzed bymeans of liquid chromatography–mass spectrom-
etry (LCMS) and cryogenic nuclearmagnetic resonance (NMR).Main
hypothesis is to prove if disk cells in the head are the only cannab-
inoid biosynthesizing cells or if stem cells fulfill same function or
contribute by precursor delivery for final biosynthesis in assumed
disk cells. Our results suggest that cannabinoid biosynthesis is not
only limited to the expected head cells, but also stems of Cannabis
capitate-stalked trichomes might play a role in cannabinoids pro-
duction. Main difference is the quantitative ratio bringing up the
question of biosynthesis regulation in Cannabis trichomes.
2. Results and discussion
2.1. Distribution and density of trichomes
Trichomes are basically divided into two general categories:
non-glandular and glandular (Schilmiller et al., 2008). There are
three different trichome classes on C. sativa L., namely capitate-
stalked, capitate-sessile and bulbous trichomes and those are cat-
egorized as glandular trichomes (Fig. 2). To study the distribution
and density of trichomes on medicinal C. sativa L., we subjected
slices of bracts, floral leaves, stems, and leaves to scanning electron
microscopy (SEM) analysis and calculated the numbers of all tri-
chome types according to the monography of the European
Pharmacopoea.
The appearance of capitate-stalked trichomes was champignon-
like, characterized by a gland (head) and a stem (Fig. 2B). The SEM
studies revealed their presence only on the flowers during the
flowering period, with particularly high density observed on the
bracts and the floral leaves. Moreover, capitate-stalked trichomes
on the bracts were more crowded than those on the floral leaves
(Table 1). The presence of cannabinoid-rich capitate-stalked tric-
homes on the bracts and the floral leaves accounts for the abun-
dance of cannabinoids in the flower.
Subsequent analyses revealed presence of hair-like capitate-
sessile trichomes (Fig. 2C) on flowers, stems, and leaves in both
Fig. 2. Trichomes of Cannabis sativa L.: (A) trichomes on the flower, (B) capitate-stalked trichome, (C) capitate-sessile trichome, (D) bulbous trichome, (E) trichomes on the
bract, (F) trichomes on the stem, (G) trichomes on the adaxial surface of a floral leaf; a big capitate-sessile trichome is indicated with an arrow, (H) trichomes on the abaxial
surface of a leaf; present abundant small capitate-sessile and bulbous trichomes.
N. Happyana et al. / Phytochemistry 87 (2013) 51–59 53
A"
B"
C" D"
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like, characterized by a gland (head) and a stem (Fig. 2B). The SEM
studies revealed their presence only on the flowers during the
flowering period, with particularly high density observed on the
bracts and the floral leaves. Moreover, capitate-stalked trichomes
on the bracts were more crowded than those on the floral leaves
(Table 1). The presence of cannabinoid-rich capitate-stalked tric-
homes on the bracts and the floral leaves accounts for the abun-
dance of cannabinoids in the flower.
Subsequent analyses revealed presence of hair-like capitate-
sessile trichomes (Fig. 2C) on flowers, stems, and leaves in both
Fig. 2. Trichomes of Cannabis sativa L.: (A) trichomes on the flower, (B) capitate-stalked trichome, (C) capitate-sessile trichome, (D) bulbous trichome, (E) trichomes on the
bract, (F) trichomes on the stem, (G) trichomes on the adaxial surface of a floral leaf; a big capitate-sessile trichome is indicated with an arrow, (H) trichomes on the abaxial
surface of a leaf; present abundant small capitate-sessile and bulbous trichomes.
N. Happyana et al. / Phytochemistry 87 (2013) 51–59 53
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1.2 Cannabinoid biosynthesis 
Biosynthesis of the main cannabinoids in cannabis (see Figure 2) begins with 
cannabigerolic-acid (CBG-A), which is converted into multiple other cannabinoid 
acid molecules via catalytic enzyme action (Fellermeier and Zenk, 1998). This can be 
achieved by tetrahydrocannabinolic-acid (THC-A) synthase to create THC-A or by 
cannabidiolic–acid (CBD-A) synthase to create CBD-A through proton transfer 
(Taura et al., 2007). The final composition of these two acids is determined by the 
amount of synthase enzymes; selective breeding or growing conditions may bias the 
plant to produce one over the other (Aizpurua-Olaizola et al., 2016; Weiblen et al., 
2015). Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) result from 
decarboxylation of their acid forms over time, either by heating or passively by air 
oxygen (Dussy et al., 2005; Verhoeckx et al., 2006; Wang, 2016). THC-A and CBD-
A therefore occur in raw plant matter and cannabis preparations that do not use heat 
such as oils and tinctures, but THC and CBD predominate when plant matter is dried, 
smoked or baked.  
When plant samples are analysed both acidic and neutral compounds are often 
grouped together as THC and CBD-related compounds, and are loosely grouped into 
three chemotypes: drug type cannabis (predominantly THC), intermediate type 
cannabis (THC:CBD ~1:1), and hemp type cannabis (high CBD) (ElSohly et al., 
2017). Most other cannabinoids exist only as a small percentage of plant content in 
comparison to THC and CBD. The exceptions are cannabigerol (CBG), the result of 
decarboxylation from CBG-A; cannabichromene (CBC), created through 
cannabichromenic acid synthase action like THC-A and CBD-A, or cannabinol 
(CBN), produced from degraded THC via oxidation (see Fig. 2) (Aizpurua-Olaizola 
et al., 2016; Morimoto et al., 1998). The ratio of the cannabinoids in the cannabis 
plant is determined by genetics, environment and method of consumption. 
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Figure 2. Cannabinoid biosynthesis pathway. 
1.3 The entourage effect – the whole of cannabis is greater than the 
sum of its parts? 
After THC was first isolated from cannabis (Gaoni, 1964) it was thought to be the 
primary cause of cannabis psychoactivity as it dose-dependently produced cannabis-
like psychoactive effects as well as euphoria and sleep (Hollister et al., 1968; Isbell et 
al., 1967). In contrast, CBD, CBN, CBC and CBG were considered inactive due to a 
lack of cannabis-like response in either animals or humans (Fernandes et al., 1974; 
Mechoulam et al., 1970; Valle, 1969). However, researchers began to suspect that 
these other chemicals did contribute to the final cannabis effect, as pure THC extracts 
did not produce the same effects as full plant extracts even when THC levels were 
equivalent (Carlini et al., 1974; Galanter et al., 1973; Karniol and Carlini, 1972). It 
was soon found that CBD either blocked or potentiated THC effects when these 
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constituents were combined, decreasing anxiety, euphoria and cardiac symptoms 
while enhancing food intake, catalepsy and hypothermia (Fernandes et al., 1974; 
Karniol and Carlini, 1972; Karniol et al., 1974; Lemberger et al., 1976). There has 
been increased interest in this hypothesis in the last ten years, particularly as recent 
observational studies report that recreational users who prefer strains high in CBD 
have better psychological symptom profiles that users of strains devoid of CBD 
(Morgan and Curran, 2008; Morgan et al., 2010a; Morgan et al., 2010b), and that 
CBD may also inhibit the brain-activating effects of THC (Bhattacharyya et al., 2010; 
Demirakca et al., 2011). This has led to the hypothesis that CBD may be useful in 
protecting against the negative neuropsychopharmacological effects of THC, 
which has consequences both for cannabis-based medicines and recreational 
users.  
1.4 Public health implications of CBD in cannabis-based medicines 
Curtailing THC psychoactivity is of great interest for the newly developed 
cannabinoid class of medicines. Current legal cannabinoid-based medications are 
generally isolated chemicals typical of modern pharmaceuticals. These include 
dronabinol (THC), capsules approved for the treatment of chemotherapy-induced 
nausea and vomiting (Smith et al., 2015; Tafelski et al., 2016); nabilone, a synthetic 
THC analogue, formulated in capsules used for chronic pain in cancer treatment 
(Tsang and Giudice, 2016); and recently Epidiolex®, an oral formulation of plant-
derived CBD shown to be effective in reducing seizures in childhood epilepsy 
in a phase III placebo-controlled trial (Devinsky et al., 2017; Gofshteyn et al., 
2016; O'Connell et al., 2017).  
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The medication closest to whole plant cannabis is Sativex® sublingual spray, 
which is used for muscular spasms and pain in multiple sclerosis. It contains 
nabiximols, an approximate 1:1 ratio mix of THC and CBD (Zettl et al., 2016). 
Sativex® has had widespread use with an estimated 45,000 patient years of treatment 
(Etges, 2016). It is generally well tolerated although a third of patients report some 
form of adverse event (Etges, 2016; Fernandez, 2016). A meta-analysis of adverse 
events from randomized controlled trials show that compared to placebo multiple 
sclerosis patients treated with Sativex® were more likely to report nervous system 
(54.5% versus 26.4%), gastrointestinal (29.6% and 19.4%) and psychiatric adverse 
events (18.5% versus 5.6%), specifically events like dizziness, diarrhoea and anxiety 
(Wade et al., 2010). In addition, observational studies report 20 - 30% of patients 
experience adverse events, half of whom then cease use – this indicates the 
tolerability of the drug might be improved (Etges, 2016; Fernandez, 2016; 
Flachenecker et al., 2014). While safety data is being continually collected, less than 7 
years have passed since it was first registered for use in 2010 (Fernandez, 2016) – it 
may be many years before long-term side effects are apparent. Use is also restricted to 
treating spasticity in MS patients – expansions to other conditions like epilepsy, 
Alzheimer’s disease and pain are curtailed by the lack of both clinical and preclinical 
evidence regarding its efficacy (Maccarrone, 2016).  
The lack of approved whole plant derivatives are in part due to difficulties in 
standardizing and testing a living plant containing more than 500 separate chemicals 
but that is also subject to pesticide or insect contamination and limited biological shelf 
life (Peschel, 2016; Schrot and Hubbard, 2016). So far only the Netherlands has 
produced standardized pharmacy-grade cannabis plant matter to be smoked, eaten or 
vaporized (Gieringer, 2012; Sacca et al., 2016). These include Bedrocan® (18% 
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THC, <1% CBD), Bedriobinol® (11% THC, <1% CBD) and Bediol® 6% THC, 7% 
CBD) varieties, which are provided as dried flower top products for a number of 
health conditions (Fischedick et al., 2010; Hazekamp and Heerdink, 2013). Drugs 
such as Sativex® containing specific cannabinoid ratios may provide a middle ground 
between the unpredictability of whole plant compounds and the psychoactivity of 
isolated compounds. 
1.5 Potency studies of recreational cannabis 
Cannabis research has historically focused on recreational users and the harms of 
cannabis. Like for any drug, increased cannabis potency as gauged by increasing THC 
concentrations promotes greater toxicity. However, there is an emerging body of 
research examining whether other cannabinoid components in the plant, particularly 
CBD, may modulate the effects of THC on the brain. Cannabinoid ratios vary widely 
due to natural plant heterogeneity and the large numbers of both industrial and 
recreational growers. However, street cannabis contains predominately THC with 
relatively low levels of other cannabinoids. Multiple potency studies of recreational 
cannabis since the 1960s have consistently reported THC concentrations to be 
increasing, while CBD concentrations are declining to low concentrations (Dujourdy 
and Besacier, 2017; ElSohly et al., 2016; ElSohly et al., 2000; Pijlman et al., 2005; 
Potter et al., 2008). In two recent studies, ElSohly et al. (2016) reported that since 
1995 cannabis seized by the Drug Enforcement Administration in the United States 
had shown a shift from 1:14 to 1:80 CBD:THC ratios due to increased grower 
selection of sinsemilla (female plants) - at these levels CBD is almost inconsequential 
(see Figure 3A). In comparison Niesink et al. (2015) reported that although THC 
levels in the Netherlands has peaked, cannabinoid variation has decreased to leave a 
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purely THC-rich plant (Niesink et al., 2015). A recent potency analysis in Australia 
revealed very similar results, with the mean THC content 100-fold higher than CBD 
content (14.88 versus 0.14 weight/weight %) (Swift et al., 2013) (see Figure 3B). 
These results suggest that drug phenotype (high THC/low CBD) cannabis is 
predominating over the intermediate (or equal THC and CBD) phenotype. If the 
hypothesis that CBD creates a less harmful plant is correct, then the adverse effects of 
current THC-rich street cannabis might be mitigated by the introduction of more 
balanced CBD-rich strains. The rising level of THC in recreational cannabis 
increases potential risks for negative health consequences in users, and evidence 
for or against the proposed beneficial nature of CBD will have major public 
health implications for both recreational and medicinal users. 
Figure 3. Average cannabis potency over time is increasing in A) the United States (ElSohly et al., 
2016). (B) In Australia, samples taken in 2010 – 2011 (Swift et al., 2013) indicate average THC 
concentration is far higher than CBD (note: –diols and acids are combined to create total weight). 
cause of the overall increase in potency of conﬁscated
samples. Figure 3 shows the proportion of the number of
marijuana versus sinsemilla samples seized by year. On
examination of the prevalence of high-potency cannabis
samples over time, it is clear that the proportion of the higher
potency samples (7%–12% and .12% THC) has been
increasing over time. Table 3 shows the prevalence of samples
of THC concentration of ,3%, 3%–7%, 7%–12%, and
.12%. Figure 4 shows a graphic representation of the
potency distribution of cannabis samples over the period of
this report. The percentage of ,3% samples and 3%–7%
samples has been declining over time, whereas the percent-
age of 7%–12% samples and .12% samples has been
increasing, re ulting in an overall increase in the potency of
conﬁscated cannabis over the years.
Domestically produced materials are seized in many cases
as the plants are still in production. Therefore, the degree of
maturity and the THC content for many of these specimens is
not reﬂective of what the potency would be at the time of
distribution. We have examined the average potency of mature
cannabis samples from domestically produced materials
seized in states that have legalized marijuana for medical
use versus states where marijuana is still illegal. We found the
average Δ9-THC concentration for the period 1995–2010 to be
8.73% 6 6.08% for samples from states with laws allowing
medical use of the drug and 5.42% 6 4.90% for samples from
states still operating under the federal law.
An additional important cannabinoid in cannabis of current
interest is CBD. There has been signiﬁcant interest in CBD
over the last few years and in cannabis preparations of high
CBD content because of the reported activity of CBD as an
antiepileptic agent (7,8), particularly its promise for the treat-
ment of intractable pediatric epilepsy (9). Furthermore, it is
perceived by some investigators that marijuana users prefer,
or use, materials that have reasonably high levels of CBD
along with THC. Examining the CBD content in the cannabis
samples over the years does not support this notion. As
shown in Figure 2, the CBD concentration has declined from
! .5% in 2004 to ,.2% in 2014. Figure 5 shows the
distribution of the number of cannabis samples by CBD
content against the overall average by year. Although con-
ﬁscated cannabis samples generally have low CBD content,
its concentration has declined even further in the last few
years. Plotting the ratio of THC to CBD over time (Figure 6)
Figure 5. Cannabidiol (CBD) con-
centration distribution in cannabis
samples conﬁscated by the Drug
Enforcement Administration and aver-
age CBD by year, 1995–2014.
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centration of Δ9-tetrahydrocannabinol
to cannabidiol in Drug Enforcement
Administration specimens by year,
1995–2014.
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However, without knowledge of the sources of these samples, it
is not possible to identify whether urban and rural seizures are
likely to represent cannabis grown using different cultivation
methods. That is, it is possible that Cannabis Cautioning samples
obtained in rural seizures had been grown in urban locations, and
vice versa. To address this issue, samples of known origin were also
tested (Figure 4 and 5), with indoor samples sourced from Sydney,
and outdoor samples seized from the North Coast area of NSW.
Differences Indoor/Outdoor Cannabinoid Levels
Results showed no differences in cannabinoid levels between
Known Provenance seizures from indoor or outdoor grown crops,
although there was much cross-over in distributions, and there was
a trend towards higher THCtot values in indoor grown seizures.
Discussion
These analyses confirm global trends towards the dominance of
THC content in contemporary cannabis, with these Australian
data showing average values similar, if not slightly higher, than
recent international studies (Table 1). While there was wide
variation in cannabinoid levels, high mean and median values of
THCtot and low values of CBDtot and other potentially therapeutic
cannabinoids are similar to those reported internationally in
samples of cannabis identified as sinsemilla, commonly referred to
as ‘‘skunk’’ [3,5,7].
This pattern of high THC/low CBD cannabis has become a
focus of concerns over the potential mental health impacts of
current cannabis use patterns. Given existing data on the potential
modulating effects of CBD on the adverse effects of THC, these
data lend support to the proposition that cannabis currently
available in Australia exhibits a profile that may render some
cannabis users vulnerable to potential adverse mental health
impacts of their use. However, there remains scant research on this
issue other than small scale surveys and laboratory studies
demonstrating biological plausibility. For example, while there
have been noted increases in treatment seeking for cannabis use
internationally across the past decade, particularly in young
people, there are other conceivable explanations apart from
increased potency. These might include improved treatment
availability and schemes where users are diverted from the
criminal justice system into treatment [33]. Further, while
Australian hospital separations for cannabis-induced psychosis
increased over the 2000s, particularly among older age groups
[28], modelling research does not indicate increases in levels of
schizophrenia commensurate with increases in cannabis use
[34,35].
There are also several possible moderators of the impacts of
cannabis potency on cannabis users. While there is mixed evidence
on use trends, overall cannabis use appears to be stabilising or
declining in some regions (e.g., Western Europe, USA and
Australia) after increased use throughout the 1990s and early
2000s [8,26]. Further, effective potency, that is the amount of THC
and other relevant cannabinoids actually absorbed by the user,
may vary according to such factors as natural variations in the
cannabinoid content of plants, the part of the plant consumed
(e.g., more potent buds versus leaf material), route of administra-
tion (e.g., oral vs. smoking) and user titration of dose to
compensate f r diffe ing levels of THC in different smoked
material [10,36]. In smoking cannabis, only approximately 30% of
THC-A is thought to be converted to free THC [37] with THC,
rather than THC-A, providing the main psychoactive effects when
cannabis is smoked or vaporized. Thus, THCtot may not
Figure 1. Chromatograms of analysed cannabinoids. A) Chromatogram of calibration standard mixture of all analysed cannabinoids at 100 mg/
ml. B) Representative chromatogram of a typical ‘‘Cannabis Cautioning’’ seized sample.
doi:10.1371/journal.pone.0070052.g001
Figure 2. The levels of THC-A, THC and THCtot measured in
n=206 Cannabis Cautioning seizures from NSW. Levels of
cannabinoids are expressed as % of total weight of sample (w/w%).
THCtot levels are obtained from adding the amount of free THC seen in
the cannabis to the amount found in the non-psychoactive from of
THC-A while adjusting for the differing molecular weight of the
cannabinoid and c rboxylic conjugative components of each cannabi-
noid (THCtot = THC+THC-A*(314.46/358.47)).
doi:10.1371/journal.pone.0070052.g002
Figure 3. The levels of CBDtot, CBGtot, THC-V, CBN and CBC
measured in n=206 Cannabis Cautioning seizures from NSW.
Levels of cannabinoids are expressed as % of total weight of sample (w/
w%). Note the differing scales relative to Figure 2. Note that the CBGtot
levels of two samples are not shown on the graph as they are out of
scale (values = 15.83% and 13.77%).
doi:10.1371/journal.pone.0070052.g003
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obtained in rural seizures had been grown in urban locations, and
vice versa. To address this issue, samples of known origin were also
tested (Figure 4 and 5), with indoor samples sourced from Sydney,
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demonst ating biological plausibility. For example, while there
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increased potency. These might include improved treatment
availability and schemes where users are diverted from the
criminal justice system into treatment [33]. Further, while
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on use trends, overall cannabis use appears to be stabilising or
declining in some regions ( .g., Western Europe, USA and
Australia) after incr ased use throughout the 1990s and early
2000s [8,26]. Further, effective potency, that is the amount of THC
and other relevant cannabinoids actually absorbed by the user,
may vary according to such factors as natural variations in the
cannabinoid content of plants, the pa t f the lant consumed
(e.g., more potent buds versus leaf material), route of administra-
tion (e.g., oral vs. smoking) and user titration of dose to
compensate for differing levels of THC in different smoked
material [10,36]. In smoking cannabis, only approximately 30% of
THC-A is thought to be c nverted to free THC [37] with THC,
rather than THC-A, providing the main psychoactive effects when
cannabis is smoked or vaporized. Thus, THCtot may not
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ml. B) Representative chromatogram of a typical ‘‘Cannabis Cautioning’’ seized sam le.
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Figure 2. The levels of THC-A, THC and THCtot measured in
n=206 Cannabis Cautioning seizures from NSW. Levels of
cannabinoids are expressed as % of total weight of sample (w/w%).
THCtot levels are obtained from adding the amount of free THC seen in
the cannabis to the amount found in the non-psychoactive from of
THC-A while adjusting for the differing molecular weight of the
cannabinoid and carboxylic conjugative components of each cannabi-
noid (THCtot = THC+THC-A*(314.46/358.47)).
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Figure 4. Synthesis, metabolism and receptor targets of (A) anandamide and (B) 2-AG from Iannotti 
et al. (2016). Also displayed are (C) the developmental trajectories in rodents of endocannabinoid
system players (adapted from Lee et al., (2016)). 
2. The endocannabinoid system and the brain 
The pharmacological effects of cannabis, particularly its psychoactivity, are the 
product of THC’s interaction with the endocannabinoid system (ECS) in the central 
nervous system (CNS). The ECS currently consists of two main cannabinoid 
receptors, cannabinoid receptor 1 and 2 (CB1 and CB2); two major endogenous 
ligands, anandamide and 2-arachidonoylglycerol (2-AG); and the family of enzymes 
Figure 3. Corticolimbic endocannabinoid signaling changes dynamically across rodent 
development
(A) Distinct endocannabinoid signaling profiles in early life, adolescence and adulthood. 
Components of the endocannabinoid system are represented schematically within a synapse 
(adapted from(Long et al., 2012). (B) Developmental trajectories of the components of the 
endocannabinoid system. CB1 receptor (CB1) expression peaks with the onset of 
adolescence. 2-arachidonoylglycerol (2-AG) is highest around birth and may fluctuate 
throughout adolescence. N-arachidonoylethanolamine (anandamide; AEA) gradually 
incre ses during early li e and fluctuates dur ng adolescence. Fa ty acid amide hydrolase 
(FAAH) activity fluctuates in reciprocal fashion to AEA during adolescence. Based on data 
from (Berrendero et al., 1999, Ellgren et al., 2008, Fernandez-Ruiz et al., 2000, Heng et al., 
2011, Lee et al., 2013, Rodriguez de Fonseca et al., 1993, Rubino et al., 2015, Wenger et 
al., 2002).
Lee et al. Page 34
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involved in these ligands biosynthesis and degradation (see Figure 4). This is not 
presumed to be the complete system, with other receptors and ligands recognized to 
play some role in the ECS – their mechanisms are still being evaluated, and it is 
assumed more players in the system will be identified.  
2.1 Receptors 
2.1.1 The CB1 receptor, first cloned by Matsuda et al. (1990), is a G-coupled protein 
receptor which retains 97 – 99% amino acid similarity between mice, rats and humans 
(Howlett et al., 2002). CB1 receptors are expressed primarily on preterminal axons 
and presynaptic nerve terminals in the CNS, more commonly on inhibitory rather than 
excitatory synapses although this varies by brain region (Kano et al., 2009). The 
highest densities of the receptor are in the cerebral cortex, basal ganglia, 
hippocampus, striatum and cerebellum (Herkenham et al., 1991; Iversen, 2003; 
Moldrich and Wenger, 2000; Tsou et al., 1998).  
The CB1 receptor may couple with different subtypes of G-proteins depending 
on the activating agonist (Khajehali et al., 2015) but primarily couples with inhibitory 
Gαi/o protein (Howlett et al., 2002). Activation of the CB1 receptor via Gi/o coupling 
results in inhibition of adenylyl cyclase and therefore decreases cyclic AMP, 
inhibition of calcium channels and/or activation of potassium channels – all of which 
can suppress cell firing or neurotransmitter release from the presynaptic neuron 
(Howlett, 2005; Pertwee, 2015). CB1 receptors have recently also been discovered on 
astrocytes but instead increase cell activity through Gq coupled intracellular calcium 
increase (Iannotti et al., 2016; Navarrete and Araque, 2008). Like other receptors 
prolonged exposure to agonists promotes desensitization and reduction of CB1 
receptor expression which subserves tolerance (Howlett et al., 2004). The CB1 
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receptor can also form dimers, either with itself or with other receptors including 
dopamine receptors, although this too may be a product of specific agonist activation 
(Hudson et al., 2010; Kearn et al., 2005; Khajehali et al., 2015; Mackie, 2005). The 
actions of CB1 receptor agonism therefore engender different effects according to 
location, the specific agonist used and G-coupling, making it a flexible player in brain 
signalling.  
2.1.2 The CB2 receptor, first cloned by Munro et al. (1993), is also a G-coupled 
receptor and mouse CB2 receptors have 82% similarity to human CB2 receptors 
(Howlett et al., 2002). The CB2 receptor is expressed primarily on microglia in the 
CNS and receptor expression varies with microglia activation state, with low levels in 
healthy brain states but high levels when there is inflammation or injury (Mecha et al., 
2016). The existence of CB2 receptors on neurons is controversial given the difficulty 
in producing consistent results using immunological techniques (Ashton, 2011; 
Atwood and Mackie, 2010). However recent studies using in situ hybridization and 
electrophysiology have suggested CB2 receptors may be expressed on dopaminergic 
ventral tegmental area (VTA) neurons and pyramidal cells in the hippocampus and 
prefrontal cortex, although at much lower levels than CB1 receptors (den Boon et al., 
2012; Stempel et al., 2016; Zhang et al., 2017). Like CB1, the CB2 receptor primarily 
couples to Gαo and activation of the CB2 receptor inhibits adenylyl cyclase 
(Mallipeddi et al., 2016), although it may differ in its ability to interact with calcium 
and potassium channels (Atwood and Mackie, 2010). This difference might also be 
ligand specific as the CB2 receptor shows biased signalling, with specific ligands 
preferentially activating specific intracellular signalling pathways (Dhopeshwarkar 
and Mackie, 2014, 2016; Mallipeddi et al., 2016). 
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2.1.3 Orphan cannabinoid receptors. A number of putative orphan cannabinoid 
receptors have been identified, although their actions are less well defined than the 
primary receptors. GPR55 (sometimes termed ‘CB3’) has been linked to the ECS 
although there is some debate over whether it should be considered part of the family 
given it is structurally different from both CB1 and CB2 receptors (Petitet et al., 
2006), and its known endogenous ligand, L-α-lysophosphatidylinositol, has little 
activity at CB1 or CB2 receptors (Kano et al., 2009; Kapur et al., 2009; Lauckner et 
al., 2008; Moreno et al., 2014). In addition to GPR55, the receptors GPR119, GPR18 
and GPR35 all have binding affinity with endogenous cannabinoids (Lauckner et al., 
2008; Rajaraman et al., 2016; Syed et al., 2012; Zhao and Abood, 2013). However, 
the functional consequences of activation of these GPRs requires further 
characterization, with research suggesting roles in metabolism, microglial cell 
function, oncogenesis and blood pressure control (McHugh et al., 2012; 
Rajaraman et al., 2016; Syed et al., 2012; Zhao and Abood, 2013). 
2.2 Endocannabinoid ligands and associated enzymes 
A number of endogenous cannabinoid ligands (termed endocannabinoids) act on 
cannabinoid receptors, either orthosterically or allosterically. To date up to 15 have 
been identified (Pertwee, 2015), of which anandamide and 2-AG are the most 
characterised (see Table 1).  
2.2.1 Anandamide. Anandamide was the first endocannabinoid isolated in porcine 
brain (Devane et al., 1992). This endocannabinoid is generated on demand and has a 
primary role in localized cell signalling rather than as a circulating ligand (Pertwee et 
al., 2010). It is a partial agonist of both CB1 and CB2 receptors, with higher affinity 
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and intrinsic activity at CB1 compared to CB2 receptors. It also has agonist activity at 
transient receptor potential vanilloid type 1 (TRPV1) receptors (Pertwee et al., 2010). 
Synthesis is initiated when Ca2+ levels increase, creating precursor N-arachidonoyl-PE 
(NAPE) which is converted into anandamide following hydrolysis by the NAPE-
phospholipase D (NAPE-PLD) enzyme. Intracellular catabolism of anandamide 
occurs via hydrolysis by the fatty acid amide hydrolase (FAAH) enzyme, which 
converts it to arachidonic acid (AA) (Cascio and Marini, 2015; Iannotti et al., 2016). 
It is worth noting however that other enzyme pathways exist, both for biosynthesis 
and breakdown, allowing for compensatory pathways if FAAH activity is disrupted 
(see Figure 4A). It is still debated how endocannabinoids like anandamide traverse 
membranes for intracellular degradation, however an unknown endocannabinoid 
membrane transporter (EMT) is suspected to be involved (Nicolussi and Gertsch, 
2015). Fatty-acid binding proteins (FABPs) also transport endocannabinoids in 
aqueous environments and inhibition of CNS FABP subtypes increases anandamide 
levels in the brain (Kaczocha et al., 2009; Kaczocha et al., 2014; Martin et al., 2016). 
2.2.2 2-AG. 2-AG was first isolated by Sugiura et al. (1995) and is found in much 
higher concentrations in the brain compared to anandamide (Stella et al., 1997). 2-AG 
binds preferentially to the CB1 receptor (see Figure 4B), however has higher 
comparative potency at both CB1 and CB2 receptors compared to anandamide 
(Pertwee et al., 2010). 2-AG is synthetized from precursor 2-arachidonoyl-containing 
diacylglycerols (DAG) via hydrolysis by either DAG-α or DAG-β enzymes (for 
review see Iannotti et al. (2016)). It is predominately broken down by hydrolysis by 
the action of monoacylglycerol lipase (MAGL) into arachidonic acid (Blankman et 
al., 2007), but can also be also catalysed by membrane proteins ABHD6 and 
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ABHD12 (Blankman et al., 2007; Marrs et al., 2010). 2-AG can also bind to 
mammalian brain FABP subtypes, and at higher affinity than anandamide, suggesting 
they may contribute to 2-AG intracellular trafficking (Elmes et al., 2015). 
2.2.3 Endocannabinoid related ligands have also been identified which may play a 
role in the endocannabinoid system (see Table 1), including omega-3 derived 
compounds EPEA and DHEA, which are both orthosteric CB1 and CB2 receptor 
agonists and are possibly metabolized by FAAH (Brown et al., 2010). Other 
compounds such as lipoxin A4 and pregnenolone can interact with allosteric binding 
sites on cannabinoid receptors to positively or negatively alter CB1 agonist efficacy 
(Pamplona et al., 2012; Vallee et al., 2014). 
Although anandamide has cannabinoid receptor affinity, other N-
acylethanolamines like palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) 
have little activity at CB1 and CB2 receptors (Lambert et al., 1999; Rodriguez de 
Fonseca et al., 2001). They do however bind to putative orphan cannabinoid-like 
receptors mentioned above (including GPR199 and GPR55) (Keereetaweep and 
Chapman, 2016; Maccarrone, 2016). Intriguingly, these ligands are thought to be 
‘entourage compounds’ to anandamide. This phenomenon described by Ben-Shabat et 
al. (1998) suggests these compounds, via their co-release with anandamide, potentiate 
anandamide binding and inhibit its inactivation to enhance activity. 2-AG may also be 
subject to the entourage effect although this may be organ-specific, occurring in the 
spleen but not necessarily in the CNS (Murataeva et al., 2016). 
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Table 1: Currently identified endogenous cannabinoids (endocannabinoids) 
Type Name Also known as: 
orthosteric anandamide AEA 
2-arachidonoylglycerol 2-AG
dihomo-γ-linolenylethanolamide dihomo-γ-LEA 
2-arachidonyl glyceryl ether noladin ether 
docosatetraenoylethanolamide DTEA 
N-arachidonoyldopamine NADA 
docosahexaenoylethanolamide DHEA 
eicosapentaenoylethanolamide EPEA 
O-arachidonoylethanolamine virodhamine 
sphingosine - 
oleamide - 
N-oleoyldopamine OLDA 
allosteric pepcan-12 - 
lipoxin A4 LXA4 
pregnenolone - 
2.3 Normal functioning of the endocannabinoid system in the brain 
2.3.1 Maintenance of homeostasis. The majority of neurotransmitters in the brain 
work in a feedforward manner, releasing from presynaptic neurons to cross the 
synapse and activate receptors on the postsynaptic terminal. Endocannabinoids in 
contrast are released from the post-synaptic neuron to active CB1 receptors on the 
presynaptic terminal. This retrograde signalling may ‘fine-tune’ neuronal firing, as 
CB1 receptors through their negative coupling to Ca2+ channels inhibit the release of 
various neurotransmitters including acetylcholine, noradrenaline, dopamine, 
serotonin, GABA and glutamate (Lopez-Moreno et al., 2008). The first example of 
neuromodulatory ECS effects was demonstrated in the hippocampus, where 
depolarized hippocampal neurons released extracellular Ca2+, inducing the release of 
anandamide and 2-AG which activated CB1 receptors on GABA interneurons to 
suppress their firing (Wilson and Nicoll, 2001).  
The brain regions where the CB1 receptor is highly expressed explains the 
functional effects of cannabis, including memory dysfunction (hippocampus), 
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modulation of fear and anxiety (amygdala), increased addictive behaviour (ventral 
striatum), improved sleep and appetite (hypothalamus), and motor impairments  
(cerebellum and basal ganglia) (Jager and Witkamp, 2014; Kluger et al., 2015; Kruk-
Slomka et al., 2016; Lutz et al., 2015; Moreira et al., 2015; Prospero-Garcia et al., 
2016). While this is a simplistic overview of complex neuronal circuitry, it gives an 
indication of the wide number of processes in which the ECS maintains homeostasis. 
Emerging evidence shows CB1 receptor expression on astrocytes also influences 
endocannabinoid signalling by clearing the synaptic space through release of MAGL 
and enhancing post-synaptic hyperpolarisation (Kovacs et al., 2017; Liu et al., 2016). 
CB1 receptors on astrocytes can increase calcium influx through Gq-coupling - this 
has been demonstrated ex vivo to induce glutamate release from astrocytes to activate 
nearby NMDA receptors on pyramidal neurons, indicating endocannabinoids might 
allow for non-synaptic neuronal communication (Navarrete and Araque, 2008).   
2.3.2 Neurodevelopment. The ECS, while present from birth, is not static. It matures 
during neurodevelopment in a complex way from childhood and adolescence until 
adulthood (Fride, 2004). CB1 receptor expression in newborns exists in white matter 
tracts and cell proliferating regions at far higher levels than in adult tissue, 
particularly in the neocortex, corpus callosum and brainstem (Fernandez-Ruiz et al., 
2000; Gaffuri et al., 2012). CB1 receptor expression increases until its highest point 
prior to puberty, a critical period for synaptic pruning and white matter development 
(Lubman et al., 2015), before declining over adolescence to final adult levels (Lee et 
al., 2016). Endocannabinoid concentrations may also shift overtime, as seen in Figure 
4C – anandamide concentration increases from childhood to adulthood in the 
hippocampus, prefrontal cortex and amygdala, while the inverse is seen for FAAH 
(Lee et al., 2013). In contrast, 2-AG has a U-shaped expression pattern, starting high 
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in childhood before decreasing in mid-adolescence and then peaking again in 
adulthood (Dow-Edwards and Silva, 2017).  
The endocannabinoid system may then play an important role in regulating 
normal neurodevelopment. A good example of this is in its role in the maturation of 
the stress response in the HPA axis (Dow-Edwards and Silva, 2017; Lee and 
Gorzalka, 2015; Lee et al., 2016). The endocannabinoids anandamide and 2-AG play 
a vital role in the development of reciprocal receptor connections between the 
prefrontal cortex, amygdala, periventricular nucleus (PVN) and hypothalamus as well 
as in the corticosterone feedback loop (Dow-Edwards and Silva, 2017); disruption 
may create persisting shifts in neuronal functioning causing long-term structural 
changes and behavioural disruptions such as anxiety and depression (Cass et al., 
2014; Gee et al., 2016; Gilbert and Soderstrom, 2014; Shonesy et al., 2014; 
Verdurand et al., 2014). Indeed there is an emerging view that dysregulation of the 
endocannabinoid system contributes to a wide number of brain diseases including 
epilepsy, Alzheimer’s disease, Huntington’s disease, addiction, PTSD, schizophrenia, 
bipolar disorder and major depression (Arnold, 2005; Arnold et al., 2012; Di Iorio et 
al., 2013; Karhson et al., 2016; Karl et al., 2012; Tan et al., 2014). 
2.3.3 Neuroplasticity and neurogenesis. Even after the brain has reached maturity 
the ECS continues to maintain and fine-tune neuronal function. Distinct from its 
tonic, homeostatic action (as per 2.3.1), endocannabinoids may produce long-term 
plasticity through long-term depression (LTD) at both excitatory and inhibitory 
synapses via CB1 receptor activity (Lee et al., 2013). LTD is important to habit 
formation and neuronal circuit adaptation which subserves drug addiction and 
associative learning (Gerdeman et al., 2002; Heifets and Castillo, 2009).  
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Neuronal protection through neurogenesis, or the development of functional 
neurons from precursor cells (Ming and Song, 2011), occurs in the hippocampus and 
sub-ventricular zone (SVZ) as part of normal functioning (sometimes termed ‘adult 
neurogenesis’) (Galve-Roperh et al., 2013). Both CB1 and CB2 receptors may play a 
role in hippocampal neurogenesis (Marchalant et al., 2009), which in particular has 
been linked to prevention of depression and anxiety (Campos et al., 2013c; Fogaca et 
al., 2015; Zhang et al., 2015). CB1 receptor antagonism increases neurogenesis while 
anandamide decreases neurogenesis in the hippocampus, suggesting CB1 receptors 
may maintain homeostatic tone (Rueda et al., 2002). This is apparent with other 
endocannabinoid activity, as DAGL-alpha knockout substantially reduces cell 
proliferation in the hippocampus and SVZ (Gao et al., 2010), while in animal studies 
increased levels of 2-AG or anandamide can restore hippocampal neurogenesis after 
chronic stress and prevent the development of anxiolytic and depressive-like 
behaviours (Campos et al., 2013c; Zhang et al., 2015). As neurogenesis is also 
upregulated following neuronal injury to replace lost cells (Bravo-Ferrer et al., 2017; 
Dyall et al., 2016), the ECS may also play a role in protecting against brain injury. 
The CB2 receptor in particular appears to play a role in increasing progenitor neural 
cell proliferation and migration following stroke and excitotoxicity, as these activities 
are reduced following CB2 receptor antagonism or knockout (Bravo-Ferrer et al., 
2017; Palazuelos et al., 2012). In addition, CB1 receptors in the SVZ protect against 
mortality of progenitor cells following seizure and ischemic stroke in mice (Butti et 
al., 2012). 
2.3.4 Inflammation and immune regulation. Endocannabinoids play an important 
functional role in the immune system in the brain via their interaction with CB2 
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receptors found on microglia (Gong et al., 2006; Maresz et al., 2005; Walter et al., 
2003). The endocannabinoids have neuroprotective effects via the suppression of pro-
inflammatory cytokines and maintaining immune homeostasis (Cabral et al., 2015; De 
Laurentiis et al., 2014). Microglia, the brain’s resident immune cells, can produce up 
to ~20 times the amount of endocannabinoids compared to astrocytes and neurons 
under neuroinflammatory conditions (Walter et al., 2003). CB2 receptor expression is 
low in healthy brain tissue but its expression is induced in response to various 
physiological challenges and disease, with up to 10 times the number expressed on 
microglia than at resting levels (Cabral et al., 2008; Maresz et al., 2005). Activation of 
CB2 receptors on microglia by 2-AG reduces pro-inflammatory cytokines and 
enhances anti-inflammatory microglial migration (Mecha et al., 2016; Stella, 2009). 
Impaired CB2 receptor signalling can also have wide-reaching psychiatric 
implications – for instance, inhibited 2-AG-CB2 receptor binding has been linked to 
increased incidence of depression (Boorman et al., 2016; Lisboa et al., 2016) and 
increased anxiety-like behaviours resulting from uninhibited cytokine activity in the 
HPA axis (Finn et al., 2003; Lisboa et al., 2017). Endocannabinoid disruption of the 
immune system in adolescence has been linked to psychosis vulnerability by 
increasing microglial activation and pro-inflammatory cytokine activity, known as the 
inflammatory hypothesis of schizophrenia (Suarez-Pinilla et al., 2014).  
2.4 Phytocannabinoid pharmacology 
Phytocannabinoids such as THC and CBD produce their effects predominantly by 
modulating the ECS and disrupting normal endocannabinoid function. However these 
molecules, particularly CBD, are promiscuous and interact with non-ECS drug 
targets. The following section overviews the basic pharmacology of THC and CBD. 
Page 21
!!
2.4.1 THC. THC is a partial agonist of CB1 and CB2 receptors (Pertwee, 2008a). 
While THC has approximately equal affinity for CB1 and CB2 receptors (Pertwee et 
al., 2010), the CB1 receptor is thought to play a greater role in THC’s 
neuropharmacological effects given its more substantial expression on neurons 
(Pertwee, 2008a). Single injections of THC in rodents produce a classic ‘tetrad’ of 
symptoms: catalepsy, hypomotility, analgesia and hypothermia (Iversen, 2003; Long 
et al., 2010), which has formed some of the basis for judging whether novel 
molecules, like synthetic cannabinoids, have cannabimimetic activity. CB1 receptor 
antagonist and knockout studies confirm that the majority of THC effects are due to 
activation of CB1 receptors (Jarbe et al., 2010; Monory et al., 2007; Tseng and Craft, 
2004). For instance, CB1 knockout mice do not display THC-induced catalepsy, 
hypolocomotion and hypothermia (Zimmer et al., 1999). Further, CB1 receptor 
antagonists such as SR141716 block THC-induced tetrad effects (Varvel et al., 2005) 
and inhibit subjective psychoactivity and tachycardia from smoked cannabis in 
humans (Huestis et al., 2001). Repeated exposure to THC promotes CB1 receptor 
tolerance, or a reduced drug effect that develops with repeated dosing. This appears to 
be explained by CB1 receptor downregulation and desensitization, although patterns 
vary by brain region in both humans and animals (Lazenka et al., 2013).  
THC interactions with the ECS may be more complex than simple CB1 
receptor ligand binding. CB1 receptors can form heterodimers with other receptors 
including 5-HT through which THC may have indirect effects in the CNS – indeed, 
these heterodimers appear essential for THC-induced memory impairment, anxiety 
and social disturbances (Vinals et al., 2015). THC can also increase circulating levels 
of anandamide and 2-AG by inhibiting transporter fatty acid-binding proteins 
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(FABPs) that traffic these endocannabinoids to their catabolic enzyme (e.g FAAH) 
(Elmes et al., 2015; Thieme et al., 2014; Walter et al., 2013). In addition, THC 
interacts with the immune system where it is generally immunosuppressive, 
suppressing both microglia and Th1 T-cell activity and associated cytokines (IL-2, IL-
10 and TGF-β). This mechanism is thought to be CB2 receptor mediated, although 
other cannabinoid receptor independent mechanisms are suspected to contribute 
(Cabral and Jamerson, 2014; Eisenstein and Meissler, 2015; Stella, 2010). This 
mechanism has attracted interest in harnessing THC to assist in treating autoimmune 
and inflammatory disorders like MS and hepatitis (Nagarkatti et al., 2009).  
2.4.2 CBD. CBD has received much attention recently for its potential therapeutic 
applications and antipsychotic, anti-inflammatory and neuroprotective properties 
(Chen et al., 2016; Martin-Moreno et al., 2011; Seeman, 2016). CBD is non-toxic and 
well tolerated in humans and animals at high doses (Bergamaschi et al., 2011b; 
Devinsky et al., 2017). CBD has anxiolytic and anti-depressant activity as shown in 
animal and small-scale human studies (Long et al., 2010; Shoval et al., 2016). A 
phase II trial showed it to be as effective as the conventional antipsychotic 
amisulpride in reducing positive symptoms of schizophrenia, which suggests CBD 
may be a novel antipsychotic drug (Leweke et al., 2012). More recently, CBD was 
shown to reduce seizures and improve general wellbeing in Dravet syndrome, a 
severe form of childhood epilepsy (Devinsky et al., 2017).  
While CBD was initially thought to be an antagonist of both CB1 and CB2 
receptors this was confounded by its low affinity for both receptors (Pertwee, 2008a; 
Thomas et al., 2007). Recent evidence suggests CBD is a negative allosteric 
modulator of CB1 receptor agonists including THC at low concentrations, whereas 
above 2 µM it behaves as a partial agonist at CB1 receptors (Laprairie et al., 2015). 
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CBD is thought to be an inverse agonist at CB2 receptors, although it may also have 
an indirect mechanism of interaction given its Ki/KB mismatch (McPartland et al., 
2015; Thomas et al., 2007). CBD is however an antagonist at GPR55 (Ryberg et al., 
2007). Further, CBD inhibits anandamide degradative enzyme FAAH and the FABP 
transporter, thereby enhancing and prolonging anandamide’s effects (Bisogno et al., 
2001; Elmes et al., 2015; Fernandez-Ruiz et al., 2012; Leweke et al., 2012). 
Interestingly CBD does not inhibit human FAAH but retains FABP inhibition, 
suggesting species specific activity (Elmes et al., 2015). CBD displays anti-
inflammatory and neuroprotective effects in pathological states, particular through 
inhibiting CB2 receptors on activated microglia to inhibit inflammation (Hassan et al., 
2014; Kaplan et al., 2008; Kozela et al., 2010; Pertwee, 2008a; Srivastava et al., 
1998).  
CBD has activity outside the endocannabinoid system, acting as an agonist at 
TRPV1 and 5-HT1A receptors (Iannotti et al., 2014; Russo et al., 2005). Modulation of 
CB1 receptor agonism by serotonin agonists including CBD increased stimulus 
discrimination and food intake (McMahon, 2016; Scopinho et al., 2011) and it has 
been suggested that CBD’s interaction with 5-HT1A receptors may subserve CBD’s 
anxiolytic and anti-depressant properties (Espejo-Porras et al., 2013; Gomes et al., 
2013; Stern et al., 2015). It is also suggested that CBD’s action at TRPV1 receptors 
may mediate its antipsychotic properties (Long et al., 2006). More recently studies 
have shown that CBD activates Nav1.6 receptors and positively allosterically 
modulates GABAA receptors (Bakas et al., 2017; Patel et al., 2016). 
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3. CBD modulates the effects of THC in human and animal studies
Human and animal research indicates CBD modulates the 
neuropsychopharmacological effects of THC. This is significant as: 1) the increasing 
introduction of medical cannabis requires evidenced-based support for the optimal 
mix of cannabinoids for patients, and 2) in jurisdictions where recreational cannabis 
has been legalized, cannabis balanced in CBD and THC concentrations might pose 
less public health risks than the prevalent THC-rich strains currently available. CBD 
and THC may provide an important “yin and yang” of cannabis producing a more 
favourable symptom profile than the compounds used alone. Both human and animal 
studies have sought to demonstrate and better understand the interactions between 
CBD and THC, however more research is needed to better determine the robustness 
of the interaction and the underlying mechanisms. In the next section, the current state 
of the evidence on the interactions between CBD and THC will be overviewed and 
critically analysed. 
3.1 Naturalistic human studies 
Naturalistic studies have investigated whether the cannabinoid content in the 
preferred cannabis of users can be correlated with specific behavioural or 
neurobiological measures. Cannabinoid concentrations are measured from a provided 
plant sample or via blood, saliva or hair analysis. The results of these studies confirm 
higher potency cannabis is associated with increased risk of psychosis, memory 
impairments, altered decision making, depression, anxiety and risk of dependence (Di 
Forti et al., 2015; Di Forti et al., 2009; Freeman and Winstock, 2015; Hermann et al., 
2009; Morgan et al., 2012). However, the presence of CBD in cannabis seems to 
inhibit schizophrenia-like symptoms, anxiety, attentional bias to drug related stimuli, 
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drug dependence and memory impairment (Brunt et al., 2014; Morgan and Curran, 
2008; Morgan et al., 2010a; Morgan et al., 2010b; Schubart et al., 2011a). CBD 
concentrations did not however impact negative symptoms, depression, or amount of 
cannabis smoked (Freeman et al., 2014; Morgan et al., 2010b; Schubart et al., 2011a).  
The question of whether cannabis affects brain morphology is limited by the 
small number of studies and remains contentious, as changes are not consistently 
reported (Lorenzetti et al., 2016b; Rocchetti et al., 2013). Chronic cannabis use is 
associated with reduced volume of the hippocampus, striatum and amygdala and less 
commonly the orbitofrontal cortex (Lorenzetti et al., 2015; Price et al., 2015; Yucel et 
al., 2008), with heavier and earlier onset users displaying more significant alterations 
(Chye et al., 2017; Jakabek et al., 2016; Mata et al., 2010; Zalesky et al., 2012). 
Additionally, cannabis users also show altered patterns of brain activation and 
connectivity during cognitive tasks involving spatial and working memory (Harding 
et al., 2012; Jager et al., 2006; Kanayama et al., 2004). However, one difficulty for 
these types of studies is controlling for pre-existing brain morphology that may 
predispose to cannabis use (Pagliaccio et al., 2015). Fewer studies have investigated 
the interactive effect of CBD and THC, however chronic cannabis users exposed to 
CBD have less reduction in hippocampal volume compared to those who use 
predominantly THC, suggesting CBD may prevent structural changes (Demirakca et 
al., 2011; Yucel et al., 2016). 
The key problem with naturalistic studies is that they cannot completely 
control for multiple variables, for example the taking of other drugs, socio-economic 
factors, nutrition, consistent dosing of cannabis constituents and heaviness of use, as 
well as underlying abnormalities that may predispose particular individuals to 
cannabis use. It is also difficult to obtain precise cannabinoid measurements, as the 
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accuracy of hair analysis is limited to a three-month period and drug quantity cannot 
be accurately deduced (Skopp et al., 2007; Taylor et al., 2016). Additionally, as 
increases in CBD levels are generally associated with lower THC, these results could 
be attributed to lower overall levels of THC rather than CBD effects specifically.  
3.2 Controlled dosing in humans 
Controlled human studies, administering known doses of CBD and THC under 
laboratory conditions, can be used to overcome some of these limitations, and largely 
concur with the results of the naturalistic studies. CBD in such experiments reduced 
the effects of THC on episodic memory, amotivation, anxiety, time distortion, 
emotion recognition, heart rate and psychosis (Bhattacharyya et al., 2012; Dalton et 
al., 1976; Englund et al., 2013; Hindocha et al., 2015; Karniol et al., 1974; Lawn et 
al., 2016; Zuardi et al., 1982). One benefit of these controlled dosing studies is the use 
of advanced imaging to show real time interaction at a neurobiological level. THC 
and CBD appear to have opposite effects on regional brain function in fMRI imaging 
(Bhattacharyya et al., 2010) indicating potential functional antagonism. Fusar-Poli et 
al. (2009) demonstrated that THC and CBD had distinct effects on the neural 
responses to fearful faces, with THC modulating frontal and parietal areas and CBD 
attenuating signals of the amygdala and posterior cingulate cortex. This was 
associated with increased fear experienced by those taking THC and decreased 
anxiety in the CBD condition. While this supports the hypothesis that CBD has 
opposing actions to THC, no studies have directly examined the interaction of CBD 
and THC when the drugs are simultaneously co-administered. It is also important to 
note that the majority of the effects mentioned above were only observed when CBD 
was administered in doses far greater then THC (Hindocha et al., 2015), which is 
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outside the ratio of general human cannabis consumption. It is therefore difficult to 
draw conclusions from this research. Additionally, neuroimaging studies still have 
issues with reproducibility, and the depth of information is generally regional rather 
than at a cellular level (Batalla et al., 2014a; Lorenzetti et al., 2016b; Weinstein et al., 
2016). 
Human studies while extremely important are limited by ethical restrictions, 
lack of experimental control and an inability to co-administer drugs over an extended 
time-frame with different doses and CBD:THC dose ratios. Controlled long-term use 
and use during adolescence, experiments that would address what harms occur over a 
long period of drug taking, rightfully cannot be tested. As mentioned previously there 
is also difficulty in controlling for specific genetic, socioeconomic or environmental 
factors even in controlled dosing experiments, all of which modulate cannabinoid 
neurobehavioral outcomes (Batalla et al., 2014b; Cooper and Haney, 2014; Konings 
et al., 2012). When this is combined with the potential range of possible CBD:THC 
ratios, the number of participants required is not feasible. Human studies alone are 
therefore inadequate to completely understand what modulating role CBD might play 
in the neurobehavioural effects of THC. Animal studies can efficiently analyse both 
specific factors highlighted by human research that are ethically or practically 
difficult (such as adolescent vulnerability or dose ratio) as well as molecular and 
neurobiological factors out of reach of current technologies used in human 
research. 
3.3 Cannabinoid research in rodents: behaviour 
The logistics of testing different combinations and dosages of cannabinoids in humans 
is difficult given the rigorous ethics required and the time-consuming and expensive 
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nature of human research. Preclinical testing in animal studies provides a more 
efficient and relatively inexpensive means to assess cannabinoid combination 
pharmacology, toxicity and potential medicinal application. Animal studies 
investigating CBD modulation of THC’s behavioural effects have revealed a unique 
and complex range of results (see Table 2, which lists studies of interest). CBD may 
potentiate or reduce the effects of THC depending on which behaviour is assessed or 
what experimental protocol is used. A brief overview of these studies is reviewed 
below.  
The earliest rodent studies on THC and CBD interactions occurred following 
the suggestion that other compounds in the cannabis plant modulated the effects of 
THC (Karniol and Carlini, 1972). Karniol and Carlini (1973) undertook the first 
robust behavioural assay and demonstrated CBD inhibited THC-induced catatonia, 
sleep deprivation-induced aggression and chronic hypolocomotion, but potentiated 
pain relief and motor impairment. However, Fernandes et al. (1974) reported CBD 
potentiated the effects of THC on all measures including hypolocomotion, food intake 
suppression, hypothermia and catalepsy, while another study by Borgen and Davis 
(1974) found CBD inhibited THC-induced hypothermia in rats. In contrast, Ham and 
De Jong (1975) reported CBD did not modulate THC-induced hypothermia or 
aggression. These wide ranging results not only showed CBD could both potentiate 
and inhibit the effects of THC, but also demonstrated the lack of consistency between 
studies. It was proposed CBD actions were the result of CBD inhibiting THC 
metabolism and therefore prolonging its effects (Fernandes et al., 1974; Paton and 
Pertwee, 1972), however increased concentrations of THC in the blood and brain 
following CBD treatment were not consistently reported (Bornheim et al., 1995; Jones 
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and Pertwee, 1972; Levy and McCallum, 1975). This hypothesis was also insufficient 
to explain why CBD could inhibit some of the effects of THC.   
A second wave of CBD and THC interaction studies has occurred in the past 
fifteen years following increased interest in medicinal cannabis and observational 
studies of recreational users suggesting increased CBD content in cannabis may 
mitigate the effects of THC (G.W.Pharma, 2003; Morgan and Curran, 2008; 
Wilkinson et al., 2003). THC-rich cannabis extracts produced spatial and short-term 
memory deficits in rats, while CBD-rich strains did not – however, the combination of 
the extracts was insufficient to reverse deficits, leading to the conclusion that CBD 
could inhibit some but not all of THC’s effects (Fadda et al., 2004). The interaction of 
other constituents could not be excluded in this extract study, and the dose ratio was 
lower than seen in most strains (~1:8 THC:CBD ratio). Varvel et al. (2006) 
investigated the impact of CBD on the effects of THC in the cannabinoid tetrad (that 
is, hypolocomotion, antinociception, catalepsy and hypothermia), and found CBD 
pretreatment only interacted with THC at a 3:10 or 1:100 THC:CBD dose ratio, and 
only for antinociception measures. This led the authors to express doubt over whether 
CBD could have any modulatory effects at dose ratios relevant to street cannabis.  
Later studies also suggested lower dose ratios appeared to be required to 
induce interactions including potentiation of THC-induced hypolocomotion, 
hypothermia and spatial memory deficits at 1:10 – 1:50 THC:CBD dose ratios 
(Hayakawa et al., 2008); hypolocomotion from ~1:10 to ~1:15 THC:CBD dose ratios 
(Britch et al., 2017), and disruption of fear memory at a 1:10 THC:CBD dose ratio 
(Stern et al., 2015). However, CBD at a 1:1 dosage attenuated THC-induced 
amotivation in low responding rats and conditioned place aversion in mice (Silveira et 
al., 2017; Vann et al., 2008) and potentiated hypothermia and anxiety-related 
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behaviour in rats (Klein et al., 2011; Taffe et al., 2015), highlighting interactive 
effects occur for some behaviours at 1:1 dose ratios. Interestingly, some studies 
suggest there may be a dose ratio “sweet spot”. Vann et al. (2008) reported that CBD 
inhibited THC conditioned place aversion at a 1:1 and a 10:1 THC:CBD dose ratio 
but not at a lower 1:3 ratio, while Malone et al. (2009) reported CBD inhibited THC-
induced social deficits at low dose ratios (1:20), but potentiated THC-induced social 
deficits at relatively higher 3:5 and 1:2 THC:CBD dose ratios. Taffe et al. (2015) also 
reported that CBD potentiated THC-induced hypothermia at a 1:1 dose ratio but this 
disappeared when decreasing the THC:CBD dose ratio to 1:3.  
The only study of interactions between CBD and THC following repeated 
dosing was conducted by Klein et al. (2011) who investigated 21 days of escalating 
CBD and THC dosing in adolescent rats at a 1:1 dose ratio. CBD pretreatment 
appeared to potentiate THC effects on weight loss, decreased sociability, 
hypolocomotion and anxiogenesis but did not influence conditioned place preference. 
In terms of mechanisms, no differences were found in CB1 or 5-HT1A receptor 
binding, although THC brain and blood concentrations were elevated in THC/CBD 
treated rats compared to rats treated with THC alone.  
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3.3.1 Considerations from animal studies. There is some concern that treatment of 
CBD prior to THC exposure may bias towards potentiation of outcomes due to CBD 
inhibiting hepatic enzymes involved in the metabolism of THC (Zuardi et al., 2012). 
This hypothesis was drawn from discrepancies in the results of studies that used either 
pretreatment or co-administration, and that increased brain and blood levels of THC 
are more commonly found in pretreatment studies (Bornheim et al., 1995; Klein et al., 
2011; Reid and Bornheim, 2001; Zuardi et al., 2012), although there are instances of 
CBD increasing plasma THC concentrations following acute co-administration (Klein 
et al., 2011). In this thesis we wish to model human drug taking where CBD and THC 
are co-administered in the form of cannabis, and so these cannabinoids will be 
administered in a cocktail in our studies. 
Additionally, CBD and THC interaction outcomes change by the dose ratio, or 
how much larger or smaller the dose of CBD is relative to the THC dose. This raises 
two points that need to be considered in THC and CBD interaction studies. First we 
argue that a 1:1 THC:CBD ratio may better reflect the type of “healthy” cannabis that 
will be administered in a medical context for particular conditions where THC is 
required, which is already seen for formulations such as Sativex® and Bedrocan’s 
Bediol® cannabis flower variety which contain approximate 1:1 THC:CBD dose 
ratios. Further, if ever introduced in a recreational context we believe a 1:1 THC:CBD 
dose ratio would also be favoured as users seek to retain a THC dose which is 
required for psychoactivity. The second consideration is overall dose choice, so we 
have chosen a dose of THC that is both relevant to median human use but also likely 
to produce clear effects of THC in mice. Our lab has previously found that 10 mg/kg 
in mice produces robust neurobehavioural effects of THC (Boucher et al., 2007a; 
Boucher et al., 2007b; Long et al., 2010; Spiro et al., 2012) and following FDA 
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interspecies conversion this dose is equivalent to the median daily cannabis dosage 
for both recreational and medical cannabis users (Harris et al., 2014; Massot-Tarrus 
and McLachlan, 2016; Nair and Jacob, 2016; Zeisser et al., 2012). Therefore in order 
to provide a model consistent with human drug taking, in this thesis we will use co-
administered THC and CBD at a 1:1 dose ratio using 10 mg/kg of each drug.  
Finally, most studies have been restricted to adult mice, hence interactions of 
THC and CBD during adolescence remain under-investigated. THC exposure can 
produce persistent depressive behaviour, social withdrawal and cognitive deficits in 
rodents (Llorente-Berzal et al., 2013; Rubino et al., 2009a; Rubino et al., 2009b; 
Stopponi et al., 2014; Zamberletti et al., 2014), but whether CBD protects against 
such effects is unknown. The repeated dosing study by Klein et al. (2011) represents 
the only study of CBD and THC interaction during adolescence, and indicated that 
CBD potentiated the effects of THC on weight loss, anxiety, hypolocomotion and 
social withdrawal using an escalating dosing regimen which reached a maximal dose 
of 10 mg/kg in rats. However, this study used a pretreatment schedule, which as 
mentioned previously may not necessarily produce the same effects as co-
administration; in addition, it was not assessed whether these changes persisted into 
adulthood following drug cessation. 
3.4 Cannabinoid research in rodents: neurobiology 
CNS interactions between CBD and THC require further investigation, particularly 
given the interest in maximizing therapeutic effects and minimizing the adverse 
effects of THC. Current human and animal studies have not adequately addressed this 
interaction on a brain region or circuitry scale. Human studies have examined each 
cannabinoid in isolation, indicating CBD activates regions distinct to THC or shows 
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opposite patterns of activity in the same regions, however the effects of brain 
activation have not been examined when the drugs are administered simultaneously 
(Bhattacharyya et al., 2015; Bhattacharyya et al., 2010; Borgwardt et al., 2008; Fusar-
Poli et al., 2009; Winton-Brown et al., 2011). The effects of CBD and THC co-
administration on brain activity in animals has similarly not been examined, 
although some studies have assessed the impact at a receptor level with the studies 
often specifically analysing CB1 receptor expression levels in a limited number 
of brain regions (Hayakawa et al., 2008; Klein et al., 2011; Silveira et al., 2017). 
These studies again have provided mixed results with one study reporting 
CBD and THC acutely interacted to increase CB1 receptor expression in 
the hippocampus of mice (Hayakawa et al., 2008), whereas another study in 
rats which utilised repeated adolescent dosing could not discern any such 
interaction on CB1 receptor expression  (Klein et al., 2011). While there were 
many experimental differences in protocol between these studies it does raise the 
question of whether acute effects might differ from repeated dosing effects. Further, 
given the wide but inconsistent CB1 receptor expression in the brain, it is probable 
that CBD and THC may interact in some brain regions but not others suggesting 
whole brain region examination may be more illuminating.   
There are several methods to investigate neurobiology in rodents at a region 
level. The expression of the transcriptional factor c-Fos is used as a marker of acute 
neuronal activation (Sagar et al., 1988) and is reliably induced in nuclei of neurons by 
exposure to novel stimuli. This includes drugs of addiction such as THC, which 
induces c-Fos in a brain region specific manner (Boucher et al., 2007b; McGregor et 
al., 1998). THC treatment induces c-Fos in brain regions including the striatum, bed 
nucleus of the stria terminalis (BNST), paraventricular hypothalamus, amygdala, and 
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lateral septum but not the hippocampus or caudate putamen (Boucher et al., 2007b; 
McGregor et al., 1998; Miyamoto et al., 1996). In contrast, there has been no reported 
effects of CBD on c-Fos except at high doses where an increase in expression was 
found in the nucleus accumbens (Guimaraes et al., 2004). CBD alone did not induce 
c-Fos, but inhibited haloperidol-induced c-Fos expression in the dorsolateral striatum
(Sonego et al., 2016). No studies have yet examined whether CBD modulates THC-
induced c-Fos expression, which will be addressed in Chapter 2. 
In contrast to the multiple acute CBD and THC dosing experiments described 
in section 3.3, very few studies have assessed their interaction using repeated dosing 
schedules, and none have analysed whether CBD can influence the long-term 
neuroadaptive changes that occur following repeated pharmacological treatment with 
THC. ΔFosB, a related transcription factor to c-Fos, is used as a marker of 
neuroadaptive changes as it has a long half-life and accumulates in the mesolimbic 
circuit in response to repeated exposure to drugs of abuse, stress and natural 
reinforcers such as food (McClung et al., 2004; Perrotti et al., 2008). The mesolimbic 
dopaminergic circuit consists of the ventral tegmental area and its projection to the 
nucleus accumbens and is implicated in attributing salience to novel stimuli, whether 
rewarding or aversive in nature, and is implicated in the pathophysiology of 
schizophrenia and drug addiction (Brisch et al., 2014; Koob and Volkow, 2010; 
Pierce and Kumaresan, 2006; Richter et al., 2015). Repeated THC exposure induces 
ΔFosB expression in the nucleus accumbens at relatively high doses (Lazenka et al., 
2014b; Lobo et al., 2013; Perrotti et al., 2008). The effect of CBD in modulating this 
response has not been examined and is of great interest given CBD has strong 
modulatory effects on this circuit and can inhibit the mesolimbic sensitization induced 
by morphine and heroin (Ren et al., 2009; Renard et al., 2016; Renard et al., 2017). 
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Another mechanism that may subserve neuroadaptive alterations is epigenetic 
modification, which like activation of transcription factors, influences gene 
expression and ultimately protein expression (Kenny, 2014). This can result from 
remodelling of chromatin, the complex that stores DNA with histones in the cell, 
which occurs when histones are acetylated such as from increased levels of acetyl-
CoA (Lu and Thompson, 2012). This addition of an acetyl group to histone proteins 
results in looser DNA-histone complexes, increasing access for transcription and 
upregulation of gene expression (Graff and Tsai, 2013). Chromatin remodelling in 
specific brain regions may be involved in addiction, cognition issues, maladaptive 
responses to stress and predisposition to depressive behaviours (Heller et al., 2014; 
McCann et al., 2017; Sprow et al., 2014; Zhong et al., 2015). The immunohistological 
labelling of antigens associated with histone acetylation has demonstrated chromatin 
remodelling occurs in the VTA and/or nucleus accumbens following cocaine, alcohol 
and methamphetamine treatment (Schmidt et al., 2012; Shibasaki et al., 2011; Sprow 
et al., 2014), but cannabinoids have yet to be investigated in detail (Szutorisz and 
Hurd, 2016). Measuring c-Fos, ΔFosB and histone acetylation expression may 
then provide insight into the neuroadaptive changes occurring following acute 
and chronic drug treatment schedules and then be exploited to examine 
interactions between CBD and THC. 
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4. Aims
The research presented in this thesis aims to examine neurobehavioural effects of 
CBD and THC treatment, alone and combined, at a 1:1 ratio in mice. The protocols 
chosen aimed to model both dose and dose ratio of recreational users and medicinal 
cannabis users in order to examine behaviour and neurobiological changes; from this 
we hope to expand the knowledge base of cannabis and cannabinoid-based medicines. 
We will undertake this by: 
1) Examining the acute neurobehavioral interactions between a 1:1 acute dose of 
THC and CBD in adult mice (Chapter 2). Naturalistic studies of cannabis suggest 
CBD might decrease the negative effects of THC. This implies cannabis might be 
more safely administered when CBD and THC are balanced in the plant. Animal 
studies indicate this interaction is complex and requires further clarification. Further, 
the interaction between CBD and THC within neuronal circuits is unknown.  In 
Chapter 2 we will determine the acute effects of CBD alone and combined with THC 
on locomotion, anxiety and body temperature, as well as brain activity as measured by 
c-Fos immunohistochemistry. THC when given alone induces hypolocomotion, 
anxiety and hypothermia as well as inducing c-Fos expression in multiple brain 
regions. We hypothesize CBD alone will have no impact but will ameliorate the 
brain-activating effects of THC when co-administered.  
2) Examining the neurobehavioral effects of repeated exposure to CBD and THC 
in adult mice (Chapter 3). Few animal studies of CBD and THC interaction have 
used repeated dosing schedules, and questions remain over what degree CBD can 
mediate the development of tolerance to the effects of THC. The effects of CBD and 
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THC on the mesolimbic pathway in particular has not been investigated, a circuit of 
relevance given its role in the development of addiction and schizophrenia. Chapter 3 
will extend upon the findings of Chapter 2 by examining the impact of CBD on 
repeated THC exposure in adulthood and specifically the development of tolerance to 
locomotion, anxiety, body temperature, PPI and social interaction. We will also 
examine neuroadaptive changes in the mesolimbic pathway by measuring ΔFosB 
expression and histone acetylation. We predict that CBD may inhibit THC effects but 
alter the development of tolerance, and that this will be associated with decreased 
transcriptional activity and epigenetic changes. 
3) Examining the impact of CBD on persistent behavioural deficits promoted by
adolescent THC exposure (Chapter 4). The development of cannabis-related 
deficits, which persist after drug taking has ceased, is associated most commonly with 
adolescent exposure. This is concerning given both the high use of cannabis by 
adolescents but also the increasing use of cannabinoid-based medicines in this 
population. In particular, CBD has recently been shown to be effective in treating 
childhood epilepsy, but no investigation of any long-term impacts on the developing 
brain has been undertaken. In Chapter 4 we will examine whether CBD modulates 
long-term disturbances promoted by repeated THC treatment during adolescence: 
specifically locomotion, anxiety, object recognition memory, sociability and 
depression-related behaviour will be examined 3 weeks after the final cannabinoid 
exposure. Adolescent THC treatment has been demonstrated to induce long-term 
deficits on such behavioural parameters and we hypothesise that CBD may reduce 
these THC-induced deficits.  
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BACKGROUND AND PURPOSE
It has been proposed that medicinal strains of cannabis and therapeutic preparations would be safer with a more balanced
concentration ratio of Δ9-tetrahydrocannabinol (THC) to cannabidiol (CBD), as CBD reduces the adverse psychotropic effects of
THC. However, our understanding of CBD and THC interactions is limited and the brain circuitry mediating interactions between
CBD and THC are unknown. The aim of this study was to investigate whether CBD modulated the functional effects and c-Fos
expression induced by THC, using a 1:1 dose ratio that approximates therapeutic strains of cannabis and nabiximols.
EXPERIMENTAL APPROACH
Male C57BL/6mice were treated with vehicle, CBD, THC or a combination of CBD and THC (10mg·kg!1 i.p. for both cannabinoids)
to examine effects on locomotor activity, anxiety-related behaviour, body temperature and brain c-Fos expression (a marker of
neuronal activation).
KEY RESULTS
CBD potentiated THC-induced locomotor suppression but reduced the hypothermic and anxiogenic effects of THC. CBD alone
had no effect on these measures. THC increased brain activation as measured by c-Fos expression in 11 of the 35 brain regions
studied. CBD co-administration suppressed THC-induced c-Fos expression in six of these brain regions. This effect was most
pronounced in the medial preoptic nucleus and lateral periaqueductal gray. Treatment with CBD alone diminished c-Fos ex-
pression only in the central nucleus of the amygdala compared with vehicle.
CONCLUSIONS AND IMPLICATIONS
These data conﬁrm that CBD modulated the pharmacological actions of THC and provide new information regarding brain
regions involved in the interaction between CBD and THC.
Abbreviations
BNST, bed nucleus of the stria terminalis; CBD, cannabidiol; PAG, periaqueductal gray; PVH, paraventricular hypothalamic
nucleus; THC, Δ9-tetrahydrocannabinol
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Introduction
Cannabis is a complex mixture of approximately 100 different
cannabinoids that may modulate the effects of Δ9-tetrahydro-
cannabinol (THC), the main psychoactive constituent of the
plant (Elsohly and Slade, 2005; Radwan et al., 2008). A number
of studies now support the view that cannabidiol (CBD)may re-
duce the negative psychotropic effects of THC while enhancing
its positive therapeutic actions (Russo, 2011; Niesink and van
Laar, 2013). In naturalistic human studies where cannabinoid
content in smoked material or the user’s hair is compared with
the subjective effects of cannabis, it has been inferred that
CBD attenuates some effects of THC, such as memory impair-
ment, attentional bias to drug-related stimuli, appetite stimula-
tion, anxiety and psychotic-like states (Morgan and Curran,
2008; Niesink and van Laar, 2013). Controlled human labora-
tory studies administering knowndoses ofCBD and THC largely
agree with the results of the naturalistic studies, with CBD de-
creasing the psychoactive and physiological effects of THC. Spe-
ciﬁcally, CBDwas shown to reduce the effects of THCon anxiety
(Zuardi et al., 1982), hippocampus-dependent episodicmemory,
psychotic-like symptoms (Englund et al., 2013) and emotional
processing (Hindocha et al., 2014).
Theseﬁndings havemajor therapeutic and public health im-
plications. For recreational use, they suggest that thewidespread
consumption of cannabis strains high in THC but low in CBD
may endanger users by shifting the balance toward the more
detrimental psychotropic effects of THC (Swift et al., 2013).
BreedingCBDback into the plantmay therefore be awise public
health strategy in locations where recreational cannabis is now
legal. Further, for medicinal cannabis, this opens the possibility
of utilizing plant strains with balanced CBD to THC concentra-
tions that maximize therapeutic endpoints while minimizing
side effects. The near 1:1 ratio of CBD and THC in nabiximols
is thought to explain this preparation’s favourable therapeutic
and side-effect proﬁle (Robson, 2014; Allsop et al., 2014a). Like-
wise, companies and regulatory bodies such as the Ofﬁce of Me-
dicinal Cannabis in the Netherlands have made available
cannabis strains that contain near equal amounts of CBD and
THC. It is for this reason that the current study will focus on
the interactive effects of CBD and THC in a 1:1 ratio.
Animal studies provide better experimental control in ad-
vancing our understanding of any neuropharmacological in-
teractions between CBD and THC. These studies have
revealed great complexity in the nature of these interactions
with factors such as dose, the dose ratio of CBD to THC and
the interval between CBD and THC injection, all inﬂuencing
the experimental outcome (Zuardi et al., 2012). While animal
studies reproduce the effects observed in human research,
where CBD inhibited the actions of THC, in many instances
CBD also potentiated the effects of THC (see Arnold et al.
(2012)). The mechanism of interaction between CBD and
THC requires clariﬁcation, and no human or animal studies
have addressed the question of which brain circuits are acti-
vated during such an interaction. In rodents, the expression
of the transcriptional factor c-Fos is used as amarker of neuro-
nal activation and is reliably induced by exposure to THC
(McGregor et al., 1998; Boucher et al., 2007). Therefore, the
aims of this study were to investigate in mice whether CBD
was able tomodulate the acute behavioural and physiological
effects of THC, at a 1:1 THC/CBD dose ratio, and to observe
whether CBD affected the characteristic brain activation pat-
tern promoted by THC using the well-validated marker c-Fos.
Methods
Animals
All animal care and experimental procedures complied with
the Australian Code of Practice for the Care and Use of Ani-
mals for Scientiﬁc Purposes and was approved by University
of Sydney’s Animal Ethics Committee. This study was re-
ported in accordance with ARRIVE guidelines for experi-
ments involving animals (Kilkenny et al., 2010; McGrath
et al., 2010). A total of 51 animals were used in the experi-
ments described here.
Male C57BL/6 wild-type mice were provided by the
Animal Resources Centre (Perth, Australia) and kept in the
animal facility of the Brain and Mind Centre (Sydney,
Australia). The animals were housed in standard cages of six
under a reversed 12h light : dark cycle with food and water
freely available. Mice were provided with an enriched envi-
ronment including mouse house igloo, tissue bedding, paper
roll, climbing ring and sunﬂower seeds. Mice aged 14weeks
(N = 24, wt 24–30 g) were used for behavioural tests and
immunohistochemistry, while mice aged 12weeks were used
for body temperature measurements (N = 27, wt 26–32 g).
Experimental procedures
All drugs were administered i.p. in a volume of 10mL·kg!1, at a
dose of 10mg·kg!1 (1mg·mL!1 ﬁnal drug concentration). A
Tables of Links
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Ion Channelsb Transportersd
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dose of 10mg·kg!1 THC was chosen as we have previously
shown it to be a threshold dose for the induction of hypother-
mia, locomotor suppression and anxiety-related behaviour in
C57BL/6mice (Long et al., 2010). Moreover, it is a dose that reli-
ably induces signiﬁcant c-Fos expression (Boucher et al., 2007).
Animals were injected with vehicle, CBD, THC or THC/
CBD in combination (n = 6 per group, N = 24) from 9AM to
2 PM. Thirty minutes after injection, mice were tested for loco-
motor activity in the open ﬁeld for 45min. Animals were habit-
uated to the open ﬁeld for 3min the day prior to experiment.
Locomotor activity was measured in red plexiglass open-ﬁeld
chambers (43 cm × 43 cm × 25 cm)with the horizontal distance
travelled (m) recorded with video tracking software (Motion
Mensura, Cooks Hill, NSW, Australia) (Spencer et al., 2012).
Data from the ﬁrst 10min were used for the analysis of
anxiety-related behaviour. Anxiety was additionally measured
in this test using a distance ratio measure, as rodents tend to
avoid exploration of the central zone of the open-ﬁeld test in
favour of peripheral areas. Distance travelled in the centre in-
ner 50% of the arena compared with the distance travelled in
the total area was calculated into a distance ratio percentage,
with a lower distance ratio percentage indicating higher
anxiety (Denenberg, 1969; Long et al., 2010). The comparative
distance, rather than time, travelled in these regions was used
in order to distinguish from any THC-induced locomotor sup-
pression. The open-ﬁeld data of three animals for locomotion
were excluded due to computer recording failure (one each
for vehicle, CBD and THC/CBD groups for locomotion).
A separate cohort was used tomeasure rectal body temper-
ature (n = 7 for vehicle, CBD and THC groups; n = 6 for the
THC/CBD group; N = 27) with injections occurring between
9 and 11 AM. Following injection with vehicle, CBD, THC or
the THC/CBD mixture, body temperature was measured
30min, 90min and 6 h after cannabinoid administration.
Body temperature was measured using a mouse rectal temper-
ature probe (ADInstruments, Sydney, Australia) attached to a
thermocouple as previously described (Boucher et al., 2011).
Temperature readings were excluded from analysis if output
was below 28°C as evidence of probe error (one from vehicle
at 90min; one from THC/CBD at 6 h).
Immunohistochemistry
c-Fos immunohistochemistry was used to assess changes in
neuronal activity following acute cannabinoid exposure in
mice that underwent the open-ﬁeld test (N = 24). A detailed
overview of the Fos immunohistochemistry protocol can be
found in Boucher et al. (2007). Brieﬂy, 2 h following injection,
mice were euthanized with isoﬂurane and then transcardially
perfused with 4% paraformaldehyde. This time of 2 h after
the THC injection coincides with the period of maximal
THC-induced c-Fos expression (Miyamoto et al., 1996).
Following 24 h post-ﬁxing, the extracted brains were
preserved in a sucrose and phosphate buffer solution, ﬁrst at
15% concentration over 24 h and then 30% over 72 h. Brains
were sliced using a cryostat at 40 μm and incubated with c-Fos
antibody (1:10 000, Santa Cruz Biotechnology, Santa Cruz,
USA) for 72 h. After 1 h incubation with a biotinylated anti-
rabbit IgG secondary antibody (1:500, Vector Laboratories,
Burlingame, USA), a peroxidase reaction was visualized with
10min incubation with diaminobenzidine and glucose
oxidase (all Sigma, Australia). Brain slices were mounted on
gelatinized glass slides before they were dehydrated with eth-
anol, cleared with xylene and coverslipped.
Cell quantification
An observer, unaware of the treatment conditions, quantiﬁed
cells with black or brown staining under a light microscope at
20× magniﬁcation according to the mouse brain atlas of
Paxinos and Keith (2001). A 0.5mm square graticule was po-
sitioned over each structure and counted by eye for absolute
counts. The following brain regions were analyzed: the cingu-
late and prelimbic cortices at plate 14 (Bregma 1.98mm); the
infralimbic cortex at plate 16 (Bregma 1.78mm); the lateral
septum (ventral and dorsal), nucleus accumbens shell and
core, piriform cortex, caudate putamen (central, dorsal and
dorsomedial) and anterior cingulate cortex at plate 23
(Bregma 0.98mm); the bed nucleus of the stria terminalis
(BNST), medial preoptic nucleus and preoptic area (lateral
and medial) at plate 30 (Bregma 0.14mm); the anterior
paraventricular thalamic nucleus at plate 35 (Bregma
!0.46mm); the paraventricular thalamic nucleus and
paraventricular hypothalamic nucleus (PVH) at plate 39
(Bregma !0.94mm); the medial amygdala (posteroventral
and posterodorsal), basolateral amygdala, central nucleus of
the amygdala and the lateral, dorsomedial and ventromedial
hypothalamus at plate 44 (Bregma !1.58mm); the CA1 and
CA3 regions of the hippocampus and the dentate gyrus at
plate 45 (Bregma !1.70mm); the ventral tegmental area at
plate 59 (Bregma !3.40mm); the Edinger–Westphal nucleus
at plate 62 (Bregma !3.80mm); and the periaqueductal gray
(PAG) (dorsomedial, dorsolateral, lateral and ventrolateral)
at plate 69 (Bregma !4.60mm). For a diagrammatic represen-
tation of the quantiﬁcation locations used, see Figure 1.
Data analysis
All statistical tests were undertaken in PASW 21.0 for Macin-
tosh (SPSS Inc., Chicago, USA). A one-way ANOVAwas used
for all comparisons with Student–Newman–Keuls test for post
hoc analysis. If data failed to pass homogeneity of variance, it
was transformed logarithmically; if this also failed homoge-
neity, non-parametric tests were used (Kruskal-Wallis, with
Mann–Whitney plus Bonferroni correction as post hoc). A sig-
niﬁcance level of P < 0.05 was used for all analyses.
Materials
THC and CBD (THC Pharm, Frankfurt, Germany) were dis-
solved in a mixture of ethanol, Tween 80 and saline (1:1:18)
(Spiro et al., 2012; Long et al., 2013; Spencer et al., 2013). In
the case of the co-administration of THC and CBD, CBD pow-
der was ﬁrst dissolved in THC stock ethanol solution.
Results
CBD transiently inhibited THC-induced
hypothermia
A one-way ANOVA showed a signiﬁcant difference between
groups on body temperature at 30min (F3,23 = 73.96, P <
0.001) and 90min (F3,22 = 106.77, P < 0.001) following
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injection (Figure 2). CBD on its own had no effect on body
temperature at any time point. THC caused signiﬁcant
hypothermia compared with vehicle control mice at 30min
(P < 0.001). Although mice in the THC/CBD group still
displayed signiﬁcant hypothermia (P < 0.001 compared with
vehicle), the THC/CBD group had signiﬁcantly less hypother-
mia than the THC-alone group at 30min (P < 0.05). At
90min, however, the CBD/THC group was not different from
the THC group, with both groups inducing equivalent
hypothermia (P< 0.001). By 6 h after injection, no signiﬁcant
differences were found between groups.
CBD potentiated THC-induced
hypolocomotion
A one-way ANOVA indicated signiﬁcant differences between the
groups on total locomotor activity (F3,17 = 51.23, P < 0.001)
(Figure 3A). Post hoc analysis showed no signiﬁcant effects of
CBD on locomotor activity compared with vehicle, while THC
signiﬁcantly suppressed locomotion in mice (P < 0.001). CBD
potentiated the locomotor suppressant effects of THC as the
THC/CBD group showed signiﬁcantly less locomotor activity
compared with THC alone (P < 0.05).
We additionally analyzed locomotion over the 45min
testing period in the open ﬁeld (Figure 3B). A signiﬁcant dif-
ference in locomotion between groups was found in all time
bins measured: 0–5min (F3,17 = 5.39, P < 0.01), 5–10min
(F3,17 = 39.28, P < 0.001), 10–15min (χ
2(3) = 16.13, P <
0.01), 15–20min (χ2(3) = 16.87, P < 0.01), 20–25min (χ2(3)
= 16.30, P < 0.01), 25–30min (χ2(3) = 17.25, P < 0.01),
30–35min (χ2(3) = 16.90, P < 0.01), 35–40min (χ2(3) = 9.07,
P < 0.05) and 40–45min (χ2(3) = 9.89, P < 0.05). Effects of
CBD were not signiﬁcantly different to those of vehicle at
any time point. Locomotion in the THC group was
Figure 1
Bregma locations of coronal sections in mouse brain (adapted from Paxinos and Keith, 2001). c-Fos positive cells were counted within labelled
regions and correspond to those listed in Table 1.
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signiﬁcantly lower than that in the vehicle controls in the 5–10
(P< 0.001) and all 5min bins thereafter up to and including the
30–35min time bin (Ps < 0.05). THC/CBD was signiﬁcantly
lower than vehicle in the ﬁrst 5min (P < 0.01), at 5–10min
(P < 0.001) and at all remaining time bins (Ps < 0.05). The
THC/CBD mixture group had signiﬁcantly lower locomotor
activity than THC alone at the 5–10min bin (P < 0.05).
CBD inhibited THC-induced anxiety-related
behaviour
A one-way ANOVA demonstrated a signiﬁcant difference be-
tween groups (F3,20 = 6.98, P< 0.01) (Figure 4) on the percent-
age ratio of distance travelled in the central region to total
distance travelled (distance ratio). Student–Newman–Keuls
post hoc analysis indicated that THC signiﬁcantly decreased
the distance ratio compared with the vehicle control group
(P < 0.05). However, treatment with CBD abolished this
THC-induced reduction in distance ratio, with the
THC/CBD co-administration group displaying an equivalent
distance ratio to the vehicle control group and a signiﬁcantly
higher distance ratio than the THC-alone group (P < 0.05).
CBD reversed THC-induced c-Fos expression in
regions involved in the cognitive impairing,
anxiogenic and hypothermic actions of THC
The effects of THC and CBD alone and in combination on
c-Fos expression are displayed in Table 1 along with the asso-
ciated ANOVA F-values or Kruskal–Wallis chi-square values.
CBD alone did not affect c-Fos expression, except in the cen-
tral nucleus of the amygdala where it decreased expression
compared with the vehicle control group (P < 0.05). THC sig-
niﬁcantly increased c-Fos expression compared with vehicle
in 11 of the 35 brain regions examined, that is, in the
ventrolateral septum (P < 0.05), BNST (P < 0.001),
paraventricular thalamic nucleus (P < 0.01), anterior
paraventricular thalamic nucleus (P < 0.05), ventromedial
hypothalamus (P < 0.001), medial preoptic nucleus and me-
dial preoptic area (both P < 0.001), PVH (P < 0.01), medial
dorsolateral and central nucleus of the amygdala (P < 0.05;
P < 0.001) and the lateral PAG (P < 0.05).
CBD co-administration tended to suppress THC-induced
c-Fos expression in six of the 11 brain regions. The effects of
CBD on THC-induced c-Fos expression were most
pronounced in the medial preoptic nucleus and lateral PAG
(Ps < 0.05). Additionally, in the dentate gyrus, CBD co-
administered with THC signiﬁcantly reduced c-Fos expres-
sion compared with THC alone. However, this was in the
absence of THC signiﬁcantly increasing c-Fos compared with
vehicle in this region. This may be a false negative due to a
lack of power, as earlier studies have found THC to increase
c-Fos in this brain region in mice at a lower dose of 5mg·kg!1
(Valjent et al., 2002). Representative photomicrographs of
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CBD reduced THC-induced hypothermia at 30min following injec-
tion but was not different from THC at 90min after injection (n = 7
for vehicle, CBD and THC; n = 6 for THC/CBD;N = 27). No signiﬁcant
cannabinoid-induced hypothermia remained 6 h after injection.
VEH, vehicle control group; CBD, cannabidiol alone; THC, Δ9-tetra-
hydrocannabinol alone; and THC/CBD = THC + CBD combination
dose in a 1:1 ratio. CBD and THC were all administered at
10mg·kg!1 i.p. in mice. Data represent means + SEM. analyses, *P
< 0.05, **P < 0.01, ***P < 0.001; signiﬁcantly different as indicated;
one-way ANOVA with post hoc Student–Newman–Keuls test.
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(A) CBD potentiated the locomotor suppressant effects of THC in the
open-ﬁeld test. (B) Locomotion in 5min bins in the 45min open-ﬁeld
test (n = 6 for THC group; n = 5 for vehicle, CBD and THC/CBD
groups;N = 23). VEH, vehicle control group; CBD, cannabidiol alone;
THC, Δ9-tetrahydrocannabinol alone; and THC/CBD, THC + CBD
combination dose in a 1:1 ratio. CBD and THC were all administered
at 10mg·kg!1 i.p. in mice. Data represent means + SEM. *P < 0.05,
**P < 0.01, ***P < 0.001; signiﬁcantly different as indicated. #P <
0.05; THC signiﬁcantly different from THC/CBD. one-way ANOVA
with post hoc Student–Newman–Keuls test.
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these regions are displayed in Figures 5–7. While THC signif-
icantly increased c-Fos expression in the ventrolateral
septum, the anterior part of the paraventricular thalamic
nucleus and the PVH, results from the THC/CBD group failed
to reach signiﬁcance compared with the vehicle group with
lower mean c-Fos positive neurons in these areas.
Discussion
This study reports for the ﬁrst time the brain regions
involved in CBD’s modulation of the pharmacological
actions of THC, using a 1:1 mixture, approximating that
found in medicinal cannabis strains and nabiximols. Our
results also demonstrate CBD may potentiate or hinder the
effects of THC, depending on the effect being examined.
We found that CBD enhanced the locomotor suppressant
effects of THC, while reducing its hypothermic and
anxiogenic actions. This was associated with CBD reversing
THC-induced c-Fos expression in the medial preoptic nu-
cleus, the lateral PAG and the dentate gyrus, the areas of
the brain implicated in the hypothermic, anxiogenic and
memory-impairing effects of THC. Our observations that
CBD diminished the actions of THC could not be explained
by physiological antagonism, as CBD alone was largely inef-
fective and there were no instances of CBD or THC alone
promoting opposing actions on our measures.
We demonstrated here that CBD alone did not alter loco-
motor activity, anxiety-related behaviour and body tempera-
ture. However, CBD did decrease the number of c-Fos
positive neurons in the central nucleus of the amygdala.
The central nucleus of the amygdala is thought to have a role
in the expression of fear and anxiety (Tye et al., 2011; Penzo
et al., 2014), and direct CBD injection into the central nucleus
of the amygdala can reduce anxiety behaviours (Hsiao et al.,
2012). We did not observe any effect of CBD on baseline
anxiety-related behaviour, although it may be that the anxio-
lytic effects of CBD require application of an explicit stressor.
While our results showed that CBD alone had a limited effect
on the brain and behaviour of mice at 10mg·kg!1, this does
not preclude effects at higher doses. For example,
120mg·kg!1 CBD in rats increased c-Fos expression in the nu-
cleus accumbens (Guimaraes et al., 2004). We did however
show that acute THC administration promoted robust
hypolocomotion, anxiogenesis and hypothermia. Further,
THC increased c-Fos expression in 11 of the 35 brain regions
examined. This conﬁrmed earlier ﬁndings that THC and its
synthetic analogues increased c-Fos expression in various
brain regions (Miyamoto et al., 1996; McGregor et al., 1998;
Arnold et al., 2001; Boucher et al., 2007). These results pro-
vide a clear background to discern modulatory effects of
CBD on THC.
Our study showed that CBD inhibited THC-induced
hypothermia in mice. The effect of CBD was modest, only
reversing the profound hypothermic effects of 10mg·kg!1
THC by about 24%. This inhibition of THC-induced hypo-
thermia was also transient in nature, as although the effect
was observed at 30min, it disappeared by 90min. This inhi-
bition is consistent with the results of Borgen and Davis
(1974), where rats were pretreated with 25mg·kg!1 CBD
1h before a 10mg·kg!1 THC challenge injection. As in our
study, repeated rectal probe measures were taken, and CBD
reduced THC-induced hypothermia by 47% and decreased
the duration of the hypothermia. However, other studies
have been unable to replicate this effect or have found
potentiation (Varvel et al., 2006; Hayakawa et al., 2008; Taffe
et al., 2015). In particular, Taffe et al. (2015) used a 1:1
THC/CBD dose ratio in rats at a higher dose of 30mg·kg!1
and found CBD potentiated the hypothermic effects of
THC. This study utilized biotelemetry, raising the possibility
that the method of body temperature sampling might inﬂu-
ence the result observed. However, Hayakawa et al. (2008)
found that 50mg·kg!1 CBD potentiated the hypothermic ef-
fects of 1mg·kg!1 THC i.p. in mice using the same rectal
probe methodology as we have used. It may be that it is
impossible for CBD to modulate saturating doses of THC
(e.g. 30mg·kg!1 in a rat) and that only threshold doses of
THC, as was used here, may be sensitive to modulation.
More studies are needed to reconcile the diverse ﬁndings of
the interactions between CBD and THC on body tempera-
ture, with species, mode of drug delivery, the endpoint being
measured and dose ratio and speciﬁc doses all needing to be
considered.
Our ﬁndings suggested that CBD inhibition of THC actions
involved the medial preoptic nucleus, a structure that ex-
presses CB1 receptors and is known tomediate the temperature
regulatory actions of THC (Fitton and Pertwee, 1982;
Hrabovszky et al., 2012). Body temperature is regulated by ther-
mogenesis controlled by reciprocal connections between the
brain and brown fat tissue. THC induces c-Fos expression in
the medial preoptic nucleus, medial preoptic area, PVH and
lateral PAG, all of which are key brain regions involved in the
innervation of brown fat tissue (Ryu et al., 2015). It is of interest
then that CBD also signiﬁcantly lowered THC-induced c-Fos
expression in the lateral PAG and tended to do so in the PVH.
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Figure 4
CBD reversed THC-induced avoidance of the centre region of the
open ﬁeld as measured by distance ratio (n = 6, N = 24). VEH, vehicle
control group; CBD, cannabidiol alone; THC, Δ9-tetrahydrocannab-
inol alone; and THC/CBD = THC + CBD combination dose in a 1:1 ra-
tio. CBD and THC were all administered at 10mg·kg!1 i.p. in mice.
Data represent means + SEM. *P < 0.05, **P < 0.01, ***P < 0.001;
signiﬁcantly different as indicated; one-way ANOVA with post hoc
Student–Newman–Keuls test.
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The PVH receives projections from the preoptic hypothalamus
(Nakamura, 2011), and CB1 receptors are critical to PVH-
mediated thermogenesis in brown fat (Monge-Roffarello
et al., 2014). Taken together, our results suggest that the medial
preoptic nucleus, PVH and lateral PAG could be further ex-
plored in studies examining the molecular mechanisms of
the inhibition by CBD of THC-induced hypothermia.
We found that CBD potentiated THC’s locomotor suppres-
sant effects, as has been documented previously in mice and
rats at both high and low CBD: THC dose ratios (Hayakawa
et al., 2008; Malone et al., 2009; Klein et al., 2011; Taffe et al.,
2015). Taken together with our ﬁndings on body temperature
and anxiety-related behaviour, this reinforces the premise that
both inhibiting and potentiating interactions between THC
and CBD may be simultaneously observed. This is promising
as it provides potential for therapeutic outcomes to be maxi-
mized while minimizing deleterious effects of THC. It could
be that enhanced motor suppression explains the beneﬁcial
therapeutic effects of nabiximols in treating movement dys-
function such as spasticity in multiple sclerosis and
Table 1
Mean number (±SEM) of Fos-labelled cells in mouse brain following drug treatment and behavioural testing in the open ﬁeld (n = 6 per condition)
Regions Bregma
Groups
Vehicle CBD
(10mg·kg!1)
THC
(10mg·kg!1)
THC + CBD
(10mg·kg!1)
Statistics
(F/X, P)
Frontal
1. Cingulate cortex +1.98 2.0 ± 0.7 1.8 ± 0.8 1.5 ± 0.6 1.7 ± 0.5 0.10, >0.05
2. Prelimbic cortex +1.98 1.5 ± 0.3 2.2 ± 0.8 2.3 ± 1.0 2.2 ± 0.7 0.25, >0.05
3. Infralimbic cortex +1.78 1.2 ± 0.5 1.2 ± 0.6 1.8 ± 1.1 2.0 ± 0.8 0.33, >0.05
4. Ventrolateral septum +0.98 7.3 ± 3.3 11.8 ± 3.3 31.8 ± 6.4# 27.0 ± 9.0 4.42, <0.05
5. Dorsolateral septum +0.98 1.2 ± 0.7 1.0 ± 0.5 10.0 ± 4.8 10.40 ± 3.5# 5.16, <0.01
6. Anterior cingulate cortex +0.98 1.8 ± 0.9 3.3 ± 1.8 2.2 ± 0.7 2.6 ± 1.1 0.30, >0.05
7. Piriform cortex +0.98 5.7 ± 2.6 5.7 ± 1.9 5.2 ± 1.5 5.2 ± 1.2 0.02, >0.05
8. BNST +0.14 1.2 ± 0.4 2.7 ± 1.1 54.7 ± 9.8### 40.3 ± 9.4### 60.01, <0.001
Striatum
9. Central caudate putamen +0.98 1.3 ± 0.4 1.5 ± 0.6 2.3 ± 0.8 1.8 ± 0.7 0.48, >0.05
10. Dorsal caudate putamen +0.98 1.3 ± 0.5 0.7 ± 0.2 2.2 ± 0.3 1.3 ± 0.5 2.40, >0.05
11. Dorsomedial caudate putamen +0.98 4.8 ± 1.8 4.5 ± 1.4 8.3 ± 1.9 7.5 ± 2.2 1.10, >0.05
12. Nucleus accumbens, shell +0.98 3.5 ± 1.4 1.0 ± 0.4 5.0 ± 2.3 3.7 ± 1.4 1.02, >0.05
13. Nucleus accumbens, core +0.98 0.8 ± 0.7 0.5 ± 0.3 1.0 ± 0.4 0.3 ± 0.2 0.51, >0.05
Thalamus
14. Paraventricular thalamic nucleus, anterior !0.46 18.0 ± 2.9 16.0 ± 5.4 60.0 ± 10.0# 39.0 ± 10.6 6.69, <0.01
15. Paraventricular thalamic nucleus !0.94 4.8 ± 1.9 8.0 ± 3.2 18.5 ± 3.6# 18.3 ± 2.4# 6.05, <0.01
Hypothalamus/preoptic
16. Lateral !1.58 2.7 ± 1.1 3.0 ± 0.7 6.3 ± 2.0 5.8 ± 2.3 1.16, >0.05
17. Dorsomedial !1.58 5.2 ± 2.3 6.7 ± 1.9 15.3 ± 3.0 12.3 ± 4.4 2.40, >0.05
18. Ventromedial !1.58 1.2 ± 0.7 2.7 ± 1.1 28.0 ± 5.6### 29.8 ± 7.8### 25.98, <0.001
19. Medial preoptic nucleus +0.14 0.7 ± 0.3 1.0 ± 0.8 10.8 ± 1.7### 5.8 ± 2.0## $ 16.30, <0.001
20. Medial preoptic area +0.14 1.2 ± 0.5 1.8 ± 0.6 8.0 ± 1.1### 5.8 ± 1.5# 10.42, <0.001
21. Lateral preoptic area +0.14 0.8 ± 0.3 1.0 ± 0.4 1.5 ± 0.4 1.0 ± 0.3 0.70, >0.05
22. Paraventricular hypothalamic nucleus !0.94 5.3 ± 4.5 2.2 ± 1.6 26.3 ± 5.1## 16.0 ± 4.0 7.33, <0.01
Hippocampus
23. CA1 !1.70 0.3 ± 0.2 0.3 ± 0.3 0.8 ± 0.4 0.3 ± 0.2 0.69, >0.05
24. CA3 !1.70 0.8 ± 0.3 0.8 ± 0.5 1.0 ± 0.5 0.0 ± 0.0 [4.72, >0.05]
25. Dentate gyrus !1.70 4.0 ± 1.1 5.0 ± 1.6 8.5 ± 1.8 2.5 ± 1.2$ 3.08, 0.051
Amygdala
26. Medial, posteroventral !1.58 2.3 ± 1.2 1.0 ± 0.5 5.8 ± 2.1 4.3 ± 1.2 2.45, >0.05
27. Medial, posterodorsal !1.58 0.8 ± 0.3 0.2 ± 0.2 3.5 ± 0.9# 6.7 ± 2.2 [14.30, <0.01]
28. Central nucleus !1.58 3.3 ± 1.8 0.3 ± 0.2# 44.0 ± 5.8### 37.8 ± 6.6### 51.35, <0.001
29. Basolateral !1.58 1.3 ± 0.5 2.2 ± 1.0 3.7 ± 1.0 1.7 ± 0.7 1.54, >0.05
Midbrain
30. Ventral tegmental area !3.40 1.0 ± 0.5 0.2 ± 0.2 1.5 ± 0.4 0.3 ± 0.2 2.96, >0.05
31. Edinger–Westphal nucleus !3.80 5.3 ± 3.2 3.3 ± 1.3 10.0 ± 2.7 10.8 ± 4.4 1.52, >0.05
Periaqueductal gray
32. Dorsomedial !4.60 0.3 ± 0.2 1.3 ± 0.8 3.5 ± 1.0 2.0 ± 1.2 2.35, >0.05
33. Dorsolateral !4.60 0.2 ± 0.2 0.5 ± 0.5 1.7 ± 0.3 0.7 ± 0.5 2.63, >0.05
34. Lateral !4.60 1.2 ± 0.5 1.0 ± 0.5 4.7 ± 1.4# 1.7 ± 0.7$ 4.35, <0.05
35. Ventrolateral !4.60 1.7 ± 0.7 3.7 ± 2.0 6.8 ± 1.2 6.7 ± 2.2 2.36, >0.05
All ANOVA F-values represent (3,20) d.f. [Kruskal-Wallis Test, d.f. = 3]. Post hoc Student–Newman–Keuls. #P< 0.05, ##P< 0.01, ###P< 0.001;
signiﬁcantly different from vehicle. $P < 0.05 signiﬁcantly different from THC.
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hyperkinesis in Huntington’s disorder (Sagredo et al., 2012;
Moreno Torres et al., 2014). Unfortunately, we could not dem-
onstrate a neural correlate of CBD and THC interaction on lo-
comotor activity. Cannabinoids affect a number of regions
involved in locomotion including the prefrontal cortex, nu-
cleus accumbens, caudate putamen, substantia nigra and
globus pallidus. However, THC did not increase c-Fos expres-
sion in any of these brain regions, as c-Fos is a poor marker
for cannabinoid action on motor function (McGregor et al.,
1998; Arnold et al., 2001; Boucher et al., 2007)
CBD reversed the anxiogenic effects of THC in the open-
ﬁeld test. We used a ratio of distance travelled in the centre
(anxiety-related behaviour) to the total distance travelled
(locomotor activity) to control for the locomotor suppressant
effects of THC. However, we cannot completely rule out the
confounding inﬂuence of locomotor suppression and our
results on anxiety should be interpreted with caution.
Arguing in favour of a selective effect on anxiety is that our
results replicate numerous ﬁndings that CBD reduced the
anxiogenic and aversive effects of THC in rodents and
humans. CBD reversed THC-induced conditioned emotional
responses in rats (10mg·kg!1 CBD and 2mg·kg!1 THC)
(Zuardi and Karniol, 1983), social withdrawal in rats
(20mg·kg!1 CBD and 1mg·kg!1 CBD) (Malone et al., 2009)
and conditioned place aversion in mice (Vann et al., 2008).
It is of note that the latter ﬁnding also used a 1:1 THC/CBD
dose ratio at 10mg·kg!1 of both drugs. Moreover, in humans,
CBD reduced the anxiety-provoking effects of THC (Zuardi
et al., 1982; Bergamaschi et al., 2011). Further arguing in fa-
vour of a selective effect of CBD on THC-induced anxiety is
that CBD reduced c-Fos expression induced by THC, in
anxiety-related regions of the brain.
THC exposure robustly increased c-Fos expression in
the lateral septum, the BNST, the PVH, the paraventricular
thalamic nucleus, the central nucleus of the amygdala
and the lateral PAG, regions all involved in stress and
anxiety circuits (Luthi and Luscher, 2014; Allsop et al.,
2014b). CBD signiﬁcantly reduced THC-induced c-Fos in
the dentate gyrus and lateral PAG and tended to reduce it
in the ventrolateral septum, the anterior part of the
paraventricular thalamic nucleus and the PVH. Electrical
stimulation of the dorsolateral and lateral PAG elicits defen-
sive behaviours characterized by vigilance, freezing and es-
cape (Borelli et al., 2004). Direct infusion of synthetic
cannabinoid agonists such as HU210 into the dorsal PAG
is anxiolytic, which is surprising given that cannabinoids
have been shown to exert anxiogenic effects in rodents
(Finn et al., 2003; Arnold et al., 2010). However, the con-
centrations infused into the PAG may reﬂect that found
in low systemic doses that are anxiolytic (Moreira and
Figure 5
Representative photomicrographs of c-Fos positive neurons in the medial preoptic nucleus at +0.14 Bregma in (A) vehicle, (B) THC and (C) THC/
CBD groups. The anterior commissure (aca) is also indicated. Scale bar = 150 μm. Mean c-Fos counts across groups are displayed in (D). VEH,
vehicle control group; CBD, cannabidiol; THC, Δ9-tetrahydrocannabinol; and THC/CBD, THC + CBD combination dose in a 1:1 ratio. CBD and
THC were all administered at 10mg·kg!1 i.p. in mice (n = 6 per group, N = 24). Data represent means + SEM. *P < 0.05, **P < 0.01, ***P < 0.001;
signiﬁcantly different as indicated; one-way ANOVA with post hoc Student–Newman–Keuls test.
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Wotjak, 2010). CBD administered into the PAG also pro-
moted anxiolytic effects (Campos et al., 2013). It would
be of interest to examine if the reversal by CBD of THC
anxiogenesis, as observed here, could be reproduced via a
direct infusion of these drugs into the lateral PAG. The abil-
ity of CBD to reduce the effects of THC on brain regions
that mediate anxiety supports the viewpoint that the psy-
chotropic effects of 1:1 THC/CBD medicinal cannabis
strains may be better tolerated than those of street canna-
bis, which contains high THC but low CBD concentrations
(Swift et al., 2013).
The molecular mechanisms responsible for the interac-
tion of CBD and THC in discrete brain regions need to be
elucidated. CBD has a multimodal pharmacology affecting
numerous drug targets that might interfere with the
actions of THC including the orphan GPCR GPR55,
5-HT1A receptors, voltage-dependent anion-selective chan-
nel protein 1 and glycine receptors (Devinsky et al.,
2014). In the absence of physiological antagonism, our
results accord with the view that CBD might modulate
the effects of THC at cannabinoid receptors. This could be
achieved through indirect competition, where CBD in-
hibits FAAH, which increases anandamide concentrations
that then compete with THC for CB1 receptor binding
(Pertwee, 2008; McPartland et al., 2015). Alternatively, a
new ﬁnding suggests that CBD inhibits the effects of THC
through allosteric modulation. In cultured cells heterolo-
gously and endogenously expressing CB1 receptors, CBD
behaved as a negative allosteric modulator of the CB1
receptor and decreased the effects of THC at the orthosteric
binding site (Laprairie et al., 2015). However, neither
theory can explain why CBD inhibited THC-induced c-Fos
expression in a restricted set of brain regions.
One explanation for the anatomical speciﬁcity of CBD–
THC interactions involves TRPV1 receptors, as CBD acti-
vates TRPV1 receptors (Iannotti et al., 2014). The regional
localization of TRPV1 receptors in the brain is still a matter
of debate and appears to be restricted to some of the brain
regions where we observed CBD to reduce THC-induced c-
Fos expression, that is, the medial preoptic nucleus of the
hypothalamus, the dentate gyrus of the hippocampus and
the periaqueductal gray (Karlsson et al., 2005; Chavez
et al., 2010; Cavanaugh et al., 2011; Fan-xin et al., 2012;
Tsurugizawa et al., 2013; Puente et al., 2015). CB1 and
TRPVI receptors colocalize (Cristino et al., 2006), and
TRPV1 receptors oppose the effects of CB1 receptor activa-
tion in brain circuits (Xing and Li, 2007; Lisboa and
Guimaraes, 2012). For example, elevation of anandamide
in the PAG may simultaneously inhibit or excite gluta-
matergic synaptic transmission mediated by CB1 and
Figure 6
Representative photomicrographs of c-Fos positive neurons in the dentate gyrus at !1.70 Bregma in (A) vehicle, (B) THC and (C) THC/CBD
groups. Scale bar = 150 μm. Mean c-Fos counts across groups are also displayed (D). VEH, vehicle control group; CBD, cannabidiol alone;
THC, Δ9-tetrahydrocannabinol alone; and THC/CBD, THC + CBD combination dose in a 1:1 ratio. CBD and THC were all administered at
10mg·kg!1 i.p. in mice (n = 6 per group, N = 24). Data represent means + SEM. *P < 0.05; signiﬁcantly different as indicated; one-way ANOVA
with post hoc Student–Newman–Keuls test.
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TRPV1 receptors respectively (Kawahara et al., 2011). In ad-
dition, CB1 and TRPVI receptor activation in the PAG has
opposing effects on panic-like responses (Casarotto et al.,
2012). Therefore, it may be that CBD only inhibits the
effects of THC in brain regions that co-express both CB1
and TRPV1 receptors.
The mechanism responsible for CBD potentiation of THC
effects also requires clariﬁcation. Pharmacokinetic mecha-
nisms may play a role as CBD treatment increased brain con-
centrations of THC (Klein et al., 2011). One proposed
mechanism for this involves ABC transporters, which regu-
late the brain uptake of drugs due to their localization at the
blood brain barrier (Arnold et al., 2012). CBD inhibits these
transporters, and THC is an ABC transporter substrate (Zhu
et al., 2006; Holland et al., 2007; Spiro et al., 2012); therefore,
it is possible that CBD reduces THC efﬂux from the brain,
thereby enhancing its brain concentration.
This study showed that the behavioural and physiological
interactions of 1:1 ratios of THC and CBD were associated
with CBD inhibiting THC-induced c-Fos expression in vari-
ous regions, with robust inhibition in the hypothalamus
and the PAG. This suggests that the mechanism of
THC/CBD interactions is complex, as CBD simultaneously
potentiated the locomotor suppressant effects of THC while
inhibiting its anxiogenic and hypothermic actions. Our
results are consistent with the notion that cannabis plant
strains that contain THC and CBD at 1:1 ratios may be prefer-
able to street cannabis for medicinal applications because
they maximize therapeutic efﬁcacy while minimizing the
adverse effects of THC.
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Abstract
The evidence base for the use of medical cannabis preparations containing speciﬁc ratios of
cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) is limited. While there is abundant data
on acute interactions between CBD and THC, few studies have assessed the impact of their
repeated co-administration. We previously reported that CBD inhibited or potentiated the
acute effects of THC dependent on the measure being examined at a 1:1 CBD:THC dose ratio.
Further, CBD decreased THC effects on brain regions involved in memory, anxiety and body
temperature regulation. Here we extend on these ﬁnding by examining over 15 days of
treatment whether CBD modulated the repeated effects of THC on behaviour and neuroadap-
tion markers in the mesolimbic dopamine pathway. After acute locomotor suppression,
repeated THC caused rebound locomotor hyperactivity that was modestly inhibited by CBD.
CBD also slightly reduced the acute effects of THC on sensorimotor gating. These subtle effects
were found at a 1:1 CBD:THC dose ratio but were not accentuated by a 5:1 dose ratio. CBD did
not alter the trajectory of enduring THC-induced anxiety nor tolerance to the pharmacological
effects of THC. There was no evidence of CBD potentiating the behavioural effects of THC.
However we demonstrated for the ﬁrst time that repeated co-administration of CBD and THC
increased histone 3 acetylation (H3K9/14ac) in the VTA and ΔFosB expression in the nucleus
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accumbens. These changes suggest that while CBD may have protective effects acutely, its
long-term molecular actions on the brain are more complex and may be supradditive.
& 2016 Elsevier B.V. and ECNP. All rights reserved.
1. Introduction
The legalisation of cannabis for medical purposes is being
adopted by a growing number of countries. There is there-
fore an urgent need to expand the evidence base of medical
cannabis so that it is used optimally for the treatment of
medical conditions (Filloux, 2015; Koliani-Pace and Siegel,
2016). Cannabis contains more than 100 cannabinoids with
various strains providing a unique array of compounds
(Radwan et al., 2015). Use of street cannabis is associated
with adverse effects such as anxiety, addiction and, in rare
instances, psychosis (Kedzior and Laeber, 2014; Marconi
et al., 2016; Winton-Brown et al., 2015). These adverse
effects have been attributed to the predominance of the
main psychoactive constituent Δ9-tetrahydrocannabinol
(THC) over other cannabinoids such as cannabidiol (CBD),
which is virtually absent in street cannabis (ElSohly et al.,
2016; Swift et al., 2013). This may have major health
implications as CBD has anxiolytic and antipsychotic proper-
ties that could improve the safety and tolerability of
cannabis (Blessing et al., 2015; Iseger and Bossong, 2015).
Indeed, medical cannabis strains and pharmaceutical pre-
parations like the nabiximols have been developed contain-
ing close to 1:1 CBD to THC ratios (Robson, 2014; Russo and
Guy, 2006).
More research is needed to justify the use of medical
cannabis and cannabinoid preparations containing speciﬁc
CBD:THC ratios. Human studies suggest CBD protects against
the adverse effects of THC on brain structure and function
(Morgan et al., 2010a, 2010b; Yucel et al., 2016). However
human studies are limited as they lack experimental control
and may be confounded by concomitant drug use (Schoeler
et al., 2016). Animal studies can assist in developing the
evidence base by enabling increased control over variables
and in-depth investigation into underlying mechanisms. We
have recently shown that CBD reduces the brain activating
effects of THC at a 1:1 CBD:THC concentration ratio (Todd
and Arnold, 2016). This is consistent with CBD behaving as a
negative allosteric modulator (NAM) of THC actions on the
CB1 receptor (Laprairie et al., 2015). However, interactions
between CBD and THC are complicated by the fact that
there are also many instances of CBD potentiating the
actions of THC (Karniol and Carlini, 1973; Klein et al.,
2011). Our recent study showed while CBD predominately
diminished the neuropharmacological effects of THC, CBD
simultaneously potentiated the locomotor suppressant
effects of THC in the same animals (Todd and Arnold,
2016). Both pharmacodynamic and pharmacokinetic
mechanisms have been proposed for such potentiating
effects (Arnold et al., 2012; Todd and Arnold, 2016).
A major limitation of existing animal studies is they almost
exclusively focus on acute interactions between CBD and THC
(Arnold et al., 2012). No studies have addressed whether CBD
modulates development of tolerance to the pharmacological
effects of THC. Additionally no studies have examined
whether CBD modulates long-term neuroadaptive effects of
THC on the mesolimbic dopamine pathway, a pathway
implicated in the pathophysiology of addiction and schizo-
phrenia (Volman et al., 2013). More speciﬁcally, THC induces
the transcription factor ΔFosB in the nucleus accumbens
(Lazenka et al., 2014a; Perrotti et al., 2008), which plays a
key role in orchestrating transcriptional events that subserve
enduring changes in neuronal structure and function
(McClung et al., 2004; Nestler, 2001). Epigenetic modiﬁca-
tions may also contribute to molecular changes in the
mesolimbic pathway through activation or repression of
various downstream genes. For example, histone 3 acetyla-
tion in the mesolimbic pathway contributes to the addictive
properties of drugs of abuse, however this has not yet been
investigated for cannabinoids (Kumar et al., 2005; Schmidt
et al., 2012; Shibasaki et al., 2011). Hyperacetylation of H3
at lysine 9/14 (H3K9/14) is of particular interest as it occurs
in the nucleus accumbens and VTA following repeated
exposure to psychostimulants and opioids (Kumar et al.,
2005; Schmidt et al., 2012; Shibasaki et al., 2011).
The aim of this study is to investigate whether CBD
modulates the acute and long-term behavioural, physiolo-
gical and neurobiological effects of THC in adult mice. We
will examine anxiety-related behaviour and sensorimotor
gating which are sensitive to the effects of cannabinoids
(Boucher et al., 2007a, 2011; Leweke et al., 2012; Long
et al., 2010). We will also examine whether CBD modulates
the actions of THC on epigenetic and neuroadaption mar-
kers in the mesolimbic dopamine pathway as demarcated by
histone 3 acetylation and ΔFosB induction.
2. Experimental procedures
2.1. Animals
75 male C57Bl6 mice (provided by ARC Perth) were used in this
study: 27 (aged 11–13 weeks) for the ﬁrst experiment, and 48 (aged
16 weeks) for a follow up study examining the effects of a higher
CBD dose on the neurobehavioural effects of THC. Mice were housed
in an enriched environment under a reverse 12 h light:dark cycle
with food and water available ad libitum. All experimental
procedures were approved by the University of Sydney's Animal
Ethics Committee.
2.2. Cannabinoid dosing
Four different treatment groups were used: vehicle, CBD, THC, and
a cocktail of THC and CBD. THC and CBD (THC Pharm, Frankfurt,
Germany) were prepared as previously described and administered
i.p. (Long et al., 2010; Todd and Arnold, 2016). A 1:1 dose ratio of
10 mg/kg of both CBD and THC was chosen for the initial experi-
ment as we have recently shown that CBD acutely modulates THC
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effects using this dosing regimen (Todd and Arnold, 2016). In the
follow up study a higher dose of CBD was used (50 mg/kg) in both
the CBD and CBD+THC groups.
2.3. Experimental design and testing sequence
A diagram of the experimental timeline is displayed in Table 1.
Animals were treated daily with vehicle (n=7), CBD (n=6), THC
(n=7) or CBD + THC at 10 mg/kg (CBD10|THC10; n=7) for 15 days
at approximately the same time each day (8–10 am). Every other
day mice were tested for body temperature at 30, 90 and 360 min
post-injection, and for locomotor activity in the open ﬁeld (OF)
(10 min duration) just after the ﬁrst body temperature measure-
ment (Boucher et al., 2007a; Todd and Arnold, 2016). On days 1 and
15 following OF testing, mice were also tested in the light dark (LD)
test followed by the prepulse inhibition of startle (PPI) paradigm.
On day 16, approximately 24 hours after the ﬁnal injection, mice
were euthanized with isoﬂurane and the brain extracted for ΔFosB
analysis, a marker of long-term neuroadaptive changes in the brain.
The following mice were removed from statistical analysis for
the 1st cohort experiment: one mouse (CBD10|THC10) from all
measures on day one due to body temperature measures and
behaviour suggesting incomplete injection; one mouse (VEH) from
PPI on day 1 due to low baseline startle readings of o10 arbitrary
units (Chang et al., 2010); one mouse (THC group) from the LD test
on day 1 due to video recording failure.
For the second cohort (N=48), CBD was administered at 50 mg/
kg and the four groups (n=12) underwent similar conditions to the
previous cohort, with the only differences being body temperature
was not recorded and a social interaction paradigm replaced the LD
test. Two mice were removed from analysis of PPI (both THC10
group) on day 1 due to exceeding 2 standard deviations from the
mean for multiple prepulse intensities (Powers and Chester, 2014).
Following testing on day 3, a subset of the animals were euthanized
with isoﬂurane at 2 hours post drug injection and tissue taken for
analysis of histone 3 acetylation, an epigenetic marker that is
induced with repeated exposure to drugs of abuse (Kumar et al.,
2005; Schmidt et al., 2012; Shibasaki et al., 2011) (n=6). Brain
tissue was examined at this timepoint to match the peak in
observed THC-induced locomotor hyperactivity.
2.4. Behavioural tests
2.4.1. Open ﬁeld (OF)
Locomotor activity was measured in the open ﬁeld activity test
chamber with video tracking software (Motion Mensura, NSW,
Australia) quantifying the horizontal movement (mm) of mice over
10 min (Boucher et al., 2011). Distance ratio [(distance travelled in
central 50% zone/distance travelled total)! 100] was also recorded
as a measure of anxiety (Todd and Arnold, 2016).
2.4.2. Light dark (LD) test
The light–dark test was used to measure anxiety-like behaviour as
previously described (Boucher et al., 2007a, 2011). In this paradigm
a hide box with exit hole was placed in the centre of the open ﬁeld.
Time spent in, entries into and latency to leave hide box were
measured over 10 min.
2.4.3. Social interaction (SI) test
The SI test was used to measure social and anxiety-like behaviour
against a cage mate opponent (Boucher et al., 2011; Silverman
et al., 2010). Behaviours measured were total interaction time and
frequency of social behaviours (anogenital snifﬁng, nosing, follow-
ing, and allogrooming) over 10 min (Silverman et al., 2010).
2.4.4. Prepulse inhibition of startle (PPI)
PPI was measured in startle chambers (SR-Lab; San Diego Instru-
ments, USA) using a protocol sensitive to the effects of cannabinoids
(Boucher et al., 2011; Long et al., 2010). Animals were habituated for
5 min and then presented a series of trials with multiple prepulses
(74 dB, 78 dB, 86 dB) followed by a pulse (120 dB startle). The
interstimulus interval (ISI) varied between trials (32 ms, 64 ms,
128 ms, 256 ms, 512 ms). %PPI was calculated as [((startle response
120 dB)"(prepulse+pulse response)*100)/startle response 120 dB].
2.5. ΔFosB and histone 3 acetylation
immunohistochemistry
A detailed overview of the immunohistochemistry protocol can be
found in Boucher et al. (2011) and Boucher et al. (2007b).
Paraformaldehyde-ﬁxed brain sections (40 mm thickness) were
incubated with either a FosB/ΔFosB antibody (Santa Cruz Biotech-
nology USA, 1:2000) or acetyl-histone 3 (lysine 9/14) antibody
(H3K9/14ac) (Cell Signalling Technology, USA, 1:4000) for 24 h,
followed by a biotinylated anti-rabbit IgG secondary antibody
(1:500, Vector Laboratories USA) over 1 h. A peroxidase reaction
was visualised with diaminobenzidine (all Sigma, Australia). A
control study was done in which the H3K9/14ac antibody was
preincubated with an antigen blocking peptide, resulting in no
immunostaining. The FosB antibody is a widely used antibody for
staining and has known speciﬁcity (Chocyk et al., 2006).
Table 1 Testing sequence for the experiment examining the effects of the repeated administration of CBD and THC alone
and in combination at a 1:1 CBD:THC dose (10 mg/kg of each dose).
Treatment day
Time Procedure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0 INJ X X X X X X X X X X X X X X X –
30 TEMP30 X – X – X – X – X – X – X – X –
30 OF X – X – X – X – X – X – X – X –
45 LD X – – – – – – – – – – – – – X –
60 PPI X – – – – – – – – – – – – – X –
90 TEMP90 X – X – X – X – X – X – X – X –
360 TEMP360 X – X – X – X – X – X – X – X –
+24 h PERF (ΔFosB) – – – – – – – – – – – – – – – X
INJ= injection of either VEH, CBD10, THC10, CBD10|THC10; TEMP=body temperature measured; OF=open ﬁeld; LD= light–dark test;
PPI=prepulse inhibition of startle test; PERF (ΔFosB)=mice euthanised with isoﬂurane followed by paraformaldehyde perfusion for
ΔFosB immunohistochemistry.
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For ΔFosB staining, an observer blind to treatment condition
quantiﬁed absolute counts of cells as previously described (Boucher
et al., 2007b, 2011; Todd and Arnold, 2016). For H3K9/14ac labelling,
images were taken with an Olympus BX51 microscope at 20x
magniﬁcation with Olympus DP2-BSW imaging software and counted
by a semi-automated method using ImageJ software – 16-bit grey-
scale images of equal dimension were manually thresholded to
create a binary image of cells of interest with background sub-
tracted. Cell counts were produced blind to experimental condition
following watersheding and deﬁning cell pixel size and circularity
manually for each brain region.
2.6. Statistical analysis
All statistical tests were undertaken in PASW 21.0 (SPSS Inc.; Chicago,
USA). We ﬁrst conducted higher level factorial ANOVA where appro-
priate. Most of the data were examined with three factor ANOVA
(with factors of CBD treatment, THC treatment and time). For PPI
data four factor ANOVA (with factors of CBD treatment, THC
treatment, prepulse intensity and time) was applied. Further two-
way ANOVA (with factors of THC treatment and CBD treatment) was
used for all individual time point comparisons followed by Student-
Newman-Kuels (SNK) post-hoc analysis. If data failed to pass normal-
ity and/or homogeneity of variance it was transformed logarithmi-
cally; if this failed, non-parametric tests were used (Kruskall Wallis
followed by Mann–Whitney tests with Bonferroni correction).
3. Results
3.1. CBD promoted subtle reductions in THC-induced
rebound hyperlocomotion following repeated
administration
Locomotor activity data from mice repeatedly dosed with
cannabinoids violated assumptions of ANOVA and so
non-parametric tests were employed. Signiﬁcant group
differences in total distance travelled (Figure 1A) were
found from day 1 to 11 [Kruskall Wallis tests – day 1: χ2(3)
=18.33, Po0.001; day 3 χ2(3)=11.03, Po0.05; day 5 χ2(3)
=13.35, Po0.01; day 7 χ2(3)=13.34, Po0.01; day 9 χ2(3)
=8.30, Po0.05; day 11 χ2(3)=9.65, Po0.05], but no
signiﬁcant differences were found on day 13 or 15. On
day 1, mice that received THC alone or CBD10|THC10
demonstrated signiﬁcantly decreased activity compared
to the vehicle control group (Mann Whitney U test, P
reported in Figure 1A). Surprisingly on subsequent testing
days THC treatment increased locomotion compared to
vehicle treatment – this hyperlocomotor effect disap-
peared by day 13 (Mann Whitney U tests, Ps reported in
Figure 1A). Unlike THC alone, the CBD10|THC10 group was
not signiﬁcantly higher than vehicle at any time-point,
implying that CBD inhibited the hyperlocomotor effects of
THC. However, this effect was subtle as the CBD10|THC10
was not signiﬁcantly lower than the THC alone group.
Treatment with CBD alone was not different to vehicle at
any time point.
To further assess the modest blunting effect of CBD on THC-
induced hyperlocomotion we analysed the time-course on days
3, 5 and 7 minute by minute. Similar ﬁndings were observed on
days 3 (see Figure 1B) and 5 (data not shown), that is THC
alone signiﬁcantly increased locomotor activity while the
CBD10|THC10 group failed to be signiﬁcantly higher than
vehicle (Mann Whitney U tests, see Ps in Figure 1B). However,
on day 7 there was a signiﬁcant interaction between CBD and
THC [F(1,23)=4.50, Po0.05, data were parametric on this
day] at the 5th minute bin. CBD signiﬁcantly reduced THC-
induced hyperlocomotion, suggesting a faster return to base-
line in the CBD10|THC10 combination group than the THC
alone group (SNK post-hoc, P values reported in Figure 1C).
Figure 1 CBD promoted a modest reduction in THC-induced hyperlocomotion following repeated administration. (A) Total travelled
distance over the 15 days of administration. Locomotion minute by minute on (B) day 3 and (C) day 7 at a 1:1 CBD:THC dosage.
(D) Total travelled distance over ten minute period on day 1 and day 3 following a 5:1 CBD:THC dosage. Data represent means7SEM
with either ANOVAs with SNK post-hocs or Kruskall–Wallis and Mann–Whitney with Bonferroni correction post-hocs. *Po0.05,
**Po0.01, ***Po0.001 VEH vs THC; #Po0.05, ##Po0.01, ###Po0.001 VEH vs CBD|THC; $Po0.05, THC vs CBD|THC.
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We additionally examined whether a higher CBD dose
(50 mg/kg) might promote greater inhibition of THC-
induced rebound hyperactivity, assessing effects over
3 days of dosing (see Figure 1D). In this experiment, three
factor ANOVA indicated a signiﬁcant effect of time and a
THC treatment by time interaction [F(1,44)=8.68,
Po0.001; F(1,44)=56.25, Po0.001 respectively]. We
replicated our initial ﬁndings with THC, that is 10 mg/kg
THC signiﬁcantly reduced locomotor activity on day 1 but
by the 3rd day of exposure this switched to increased
locomotor activity (SNK post-hocs, see Figure 1D). CBD
(50 mg/kg) appeared to subtly reduce this hyperactivity
as, unlike THC alone, the CBD50|THC10 combination failed
to be signiﬁcantly higher than vehicle on day 3, although
the combination group was not signiﬁcantly lower than the
THC group (SNK post-hocs, Ps reported in Figure 1D). There
were no signiﬁcant CBD by THC interactions on either day
1 or day 3. The administration of 50 mg/kg CBD alone did
not affect locomotion.
3.2. CBD did not modulate the acute or repeated
effects of THC on anxiety-related behaviour
A ratio comparison of distance travelled in the central zone
of the open ﬁeld to total area was calculated to assess
anxiety-related behaviour (see Figure 2A). Three-factor
ANOVA with time, THC and CBD drug treatments as factors
found a signiﬁcant effect of time [F(7,161)=14.49,
Po0.001]. Two-factor ANOVA of each day showed signiﬁcant
main effects of THC on all days of testing [day 1: F(1,23)
=13.53, Po0.01; day 3: F(1,23)=18.14, Po0.001; day 5: F
(1,23)=19.65, Po0.001; day 7: F(1,23)=27.60, Po0.001;
day 9: F(1,23)=11.60, Po0.01; day 11: F(1,23)=33.50,
Po0.001; day 13: F(1,23)=16.39, Po0.001; day 15: F(1,23)
=26.89, Po0.001]. No main effect of CBD or any interaction
effects were found on any day. THC alone and the CBD10|
THC10 combination equivalently reduced distance travelled
in the central part of the open ﬁeld in a generally consistent
manner throughout testing (SNK post-hoc tests, Ps displayed
Figure 2 CBD did not modulate the acute or repeated effects of THC on anxiety-related behaviour. (A) Distance ratio data from the
OF test, and for LD test (B) time in the hide box, (C) entries into hide box, and (D) latency to exit the hide box at a 1:1 CBD:THC
dosage. For SI test (E) total social interaction time and (F) frequency of social interactions at a 5:1 CBD:THC dose ratio. Data
represent means7SEM with two-way ANOVAs and SNK post-hocs or Kruskall–Wallis and Mann–Whitney with Bonferroni correction
post-hocs. *Po0.05, **Po0.01, ***Po0.001 VEH vs THC; #Po0.05, ##Po0.01, ###Po0.001 VEH vs CBD|THC. XPo0.05, VEH vs CBD.
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in Figure 2A). There were no signiﬁcant differences between
CBD and vehicle apart from one instance on day 7, where the
vehicle group had a ﬂeeting increase in distance ratio
compared to all other groups.
We conducted the LD test to provide another measure of
anxiety-related behaviour. On day 1, although no signiﬁcant
overall difference was seen between groups in time spent in
hide chamber (Figure 2B), differences were observed in
entries [Kruskall Wallis test – χ2(3)=20.32, Po0.001] and
latency to leave hide box [χ2(3)=16.93, Po0.01] (Figure 2C
and D). THC alone and in combination with CBD (CBD10|
THC10 group) equivalently reduced entries and increased
latency to leave the hide box (Mann–Whitney U tests, Ps
displayed in Figure 2C and D). By day 15 no other effects
were observed except that both THC and the CBD10|THC10
combination continued to equivalently reduce the number
of entries into the hide box [χ2(3)=17.12, Po0.01] com-
pared to vehicle (Mann–Whitney U tests, Ps displayed
Figure 2C). No differences were found between the vehicle
and CBD treatment groups on any measure on any day.
The social interaction test was used to assess social
behaviour. Three-factor ANOVA indicated a signiﬁcant time
and THC treatment by time effect for both total interaction
time [F(1,43)=7.11, Po0.05; F(1,43)=41.29, Po0.001] and
frequency of social behaviours [F(1,43)=10.81, Po0.01; F
(1,43)=43.92, Po0.001]. Further two-way analysis found a
signiﬁcant main effect of THC for total interaction time and
frequency of social behaviours on day 1 [F(1,43)=76.52,
Po0.001; F(1,43)=104.81, Po0.001 respectively], with
SNK post-hocs indicating THC decreased both of these
behaviours equivalently in both the THC10 and the CBD50|
THC10 groups (Ps displayed in Figure 2E and F). However, as
this was concurrent with decreases in locomotor behaviour
(see Figure 1A), these differences were likely a product of
sedation rather than decreased sociability. By day 3, there
were no differences in total interaction time; while a main
Figure 3 CBD acutely promoted a subtle reduction in THC-induced PPI facilitation. (A) %PPI across different prepulse intensities on
day 1, (B) %PPI for trials at the 86 dB – ISI 256 ms combination on day 1 and 15, (C) %PPI across different prepulse intensities on day
15 and (D) Startle response on day 1 and day 15 at a 1:1 CBD:THC dose ratio. As displayed are (E) %PPI across different prepulse
intensities on day 1 and (F) day 3 at a 5:1 CBD:THC dose ratio. Data represent means7SEM with either two-way ANOVAs with SNK
post-hocs or Kruskall–Wallis and Mann–Whitney with Bonferroni correction post-hocs. *Po0.05, ***Po0.001 VEH vs THC; #Po0.05,
###Po0.001 VEH vs CBD|THC; XXXPo0.001, VEH vs CBD; $Po0.05, THC vs CBD|THC.
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effect of THC was found for frequency of social behaviours
[F(1,44)=5.61, Po0.05], analysis of post-hocs indicated no
speciﬁc differences.
3.3. CBD acutely reduced THC-induced
hypothermia but did not alter the trajectory of THC
tolerance
Acute CBD co-administration partially inhibited THC-
induced hypothermia at 30 min but not at 90 min or beyond
as previously described in (Todd and Arnold, 2016) (data not
shown). The mice rapidly developed tolerance to the
hypothermic effects of all cannabinoid treatment groups
(THC alone and CBD10|THC10 groups) by day 3 of dosing.
There was no evidence of CBD modulating tolerance to the
hypothermic effects of THC and no differences were
observed between all 4 groups from day 3 to 15 of the
dosing period (data not shown).
3.4. CBD modestly reduced THC-induced PPI
facilitation following acute but not repeated
exposure
We then examined whether CBD might modulate the effects
of THC on PPI (Boucher et al., 2007a; Leweke et al., 2012;
Long et al., 2012). A four factor ANOVA with day, prepulse
intensity, THC treatment and CBD treatment factors indi-
cated a signiﬁcant interaction of THC treatment, prepulse
intensity and day [F(2,42)=4.24, Po0.05], suggesting THC
treatment altered PPI dependent on prepulse intensity and
that this changed over days. On day 1, while no signiﬁcant
differences between groups were found at 74 dB, there were
main effects of THC and CBD at 82 dB [F(1,21)=11.70,
Po0.01; F(1,21)=5.18 Po0.05 respectively] and a main
effect of THC at 86 dB [F(1,21)=9.35, Po0.01]. SNK
post-hoc analysis conﬁrmed THC alone signiﬁcantly facili-
tated PPI compared to the vehicle group at 82 dB and 86 dB.
While CBD alone was without effect on PPI, it tended to
reduce THC-induced PPI facilitation, as the CBD10|THC10
group was not signiﬁcantly higher than the vehicle group
(although it was not signiﬁcantly lower than the THC alone
treatment group; Ps displayed Figure 3A). Further analysis of
speciﬁc prepulse intensity and interstimulus interval data
combinations showed a signiﬁcant main effect of both THC
and CBD at the 86 db-256 ISI [F(1,21)=10.60, Po0.01; F
(1,21)=8.53, Po0.01 respectively], however there was no
signiﬁcant CBD by THC interactions. CBD signiﬁcantly reduced
THC-induced PPI facilitation as SNK post-hoc analysis showed
THC signiﬁcantly increased %PPI compared to vehicle, and
this was reversed with the co-administration of 10 mg/kg CBD
(Ps displayed Figure 3B). By day 15 however mice became
completely tolerant to the effects of THC on PPI (Figure 3C).
When examining the startle response, a signiﬁcant effect
of time was found in three-way ANOVA analysis [F(1,21)=4.6,
Po0.05]. Signiﬁcant THC and CBD main effects were found
on day 1 [F(1,21)=27.21 Po0.001; F(1,21)=5.51, Po0.05],
with CBD, THC and CBD10|THC10 displaying signiﬁcantly
lower startle compared to vehicle (SNK post-hocs, Ps dis-
played Figure 3D). By day 15 all animals became completely
tolerant to cannabinoid-induced startle impairments.
We then examined whether a higher CBD 50 mg/kg dose
would have a more pronounced effect than 10 mg/kg CBD
on THC-induced PPI facilitation. Four-way ANOVA indicated
a signiﬁcant THC by prepulse intensity by day interaction [F
(2, 84=4.57, Po0.05] and a CBD treatment by prepulse
intensity interaction [F(2,84)=4.14, Po0.05]. Two-way
ANOVA on day 1 showed a main effect of CBD at 74 dB [F
(1,42)=5.57, Po0.05], while THC again facilitated PPI at
82 dB [F(1,42)=12.22, Po0.01] and 86 dB [F(1,42)=10.23,
Po0.01] (SNK post-hocs, Ps reported Figure 3E). However
50 mg/kg CBD did not signiﬁcantly reduce THC-induced PPI
Figure 4 The combination of CBD and THC synergistically enhanced expression of H3K9/14ac in the mesolimbic pathway following
3 days of treatment. Mean H3K9/14ac+ neurons in the (A) nucleus accumbens shell, (B) nucleus accumbens core and (C) VTA. Also
displayed is (D) an exemplar of H3K9/14ac+ positive neuron staining at 40x magniﬁcation and representative photomicrographs of
staining in the VTA for (E) vehicle, (F) CBD50, (G) THC10 and (H) CBD50|THC10 at 20x magniﬁcation. Data represent means + SEM.
Two-way ANOVA with SNK post-hocs. ##Po0.01 VEH vs CBD|THC. AcbSh, nucleus accumbens shell; AcbC, nucleus accumbens core;
VTA, ventral tegmental area; PN, paranigral nucleus; ml, medial lemniscus. Scale bar 50 mm.
S.M. Todd et al.138
Page 61
facilitation, even at the 86 dB-256 ISI combination (data not
shown). We predicted that, given the strong THC-induced
hyperlocomotor effect on day 3, we might see a correspond-
ing switch in the THC-treated animals to displaying a PPI
deﬁcit on this day. This was not observed and THC-induced
PPI facilitation was absent by day 3 (Figure 3F). There was
no effect of CBD alone or the CBD50|THC10 combination on
%PPI on day 3.
3.5. The combination of CBD and THC
synergistically enhanced expression of H3K9/14ac
and ΔFosB in the mesolimbic pathway
Given that THC-induced a behavioural sensitisation-like
locomotor hyperactivity phenotype (Figure 1A), and CBD
modestly blunted this effect over repeated dosing time
(Figure 1A and D), we performed some exploratory studies
to examine whether CBD might reduce the effects of THC on
epigenetic and long-term neuroadaption markers in the
mesolimbic pathway.
First we analysed H3K9/14ac expression following the
administration of CBD, THC and CBD50|THC10 following 3 days
of administration. No effects were observed in the nucleus
accumbens core or shell, the outputs of the mesolimbic
pathway [Figure 4A and B]. Two-way ANOVA showed main
effects of THC and CBD on H3K9/14ac expression in the VTA
[F(1,20)=8.82, Po0.01 and F(1,20)=4.74, Po0.05 respec-
tively], with SNK post-hoc analysis showing only the CBD50|
THC10 group signiﬁcantly increased the number of neurons
labelled positive for H3K9/14ac compared to vehicle (Ps
displayed Figure 4C; representative micrographs are dis-
played in Figure 4D–H).
We also analysed ΔFosB expression in brain tissue of mice
exposed to the cannabinoids for 15 days. While no effects on
ΔFosB expression were seen in the VTA, a signiﬁcant main
effect of THC was seen in the nucleus accumbens shell
[ANOVA: F(1,23)=5.52, Po0.05] and both THC and CBD in
the nucleus accumbens core [F(1,23)=6.79, Po0.05; F
(1,23)=5.53, Po0.05 respectively] [Figure 5A–C]. SNK
post-hoc analysis showed THC10 and CBD10 alone were no
different to vehicle but when combined signiﬁcantly
increased the number of neurons labelled positive for ΔFosB
compared to vehicle in both the shell and core (Ps displayed
Figure 5A and B; representative micrographs of the NA shell
are shown Figure 5D–H).
4. Discussion
We report a novel phenomenon where following classic
acute THC-induced locomotor suppression, repeated THC
dosing surprisingly caused rebound locomotor hyperactivity
that endured until the 11th day of dosing. CBD partially
inhibited this rebound hyperactivity and also promoted a
reduction in acute THC-induced PPI facilitation. The modest
inhibitory action of CBD on THC-induced rebound hyperac-
tivity and PPI found at a 1:1 CBD:THC ratio (10 mg/kg of
each compound) was not accentuated by a 5:1 CBD:THC
ratio (50 mg/kg CBD/10 mg/kg THC). CBD did not impact on
the trajectory of tolerance to the effects of THC on body
temperature, anxiety or PPI. While there was limited
evidence of potentiating effects of combined CBD and THC
dosing on the physiological and behavioural endpoints
examined here, there was on the induction of epigenetic
and neuroadaptive changes in the mesolimbic pathway. The
5:1 CBD:THC dose ratio signiﬁcantly increased H3K9/14ac in
the VTA following three days of dosing. Moreover, the 1:1
CBD:THC ratio signiﬁcantly increased ΔFosB expression in
the nucleus accumbens following 15 days of dosing. Both of
these effects were observed in the absence of THC or CBD
effects alone, suggesting a synergistic interaction.
Figure 5 The combination of CBD and THC synergistically enhanced expression of ΔFosB expression in the mesolimbic pathway
following 15 days of treatment. Mean ΔFosB+ counts of neurons in the (A) nucleus accumbens shell, (B) nucleus accumbens core and
(C) VTA. Also displayed is (D) an exemplar of Δ FosB positive neuron staining at 40x magniﬁcation, and representative
photomicrographs of staining in the NA shell for (D) vehicle, (E) CBD10, (F) THC10 and (G) CBD10|THC10 at 20! magniﬁcation.
Data represent means7SEM with two-way ANOVAs and SNK post-hocs. #Po0.05 VEH vs CBD|THC. aca, anterior commissure; AcbSh,
nucleus accumbens shell; AcbC, nucleus accumbens core; VTA, ventral tegmental area; ICjM= islands of Calleja. Scale bar 50 mm.
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On day 1 acute THC administration profoundly reduced
locomotor activity. We then expected to observe classic
cannabinoid tolerance (for review see Maldonado and
Rodriguez de Fonseca (2002)), which has been reported in
the vast majority of studies conducted, where initial robust
locomotor suppression progressively diminishes over time
until cannabinoid-treated animals behave no differently to
control animals (Boucher et al., 2009, 2011; Castane et al.,
2003; Ghozland et al., 2002; Long et al., 2010; Puighermanal
et al., 2013; Valverde et al., 2000). However much to our
surprise continual THC treatment instead induced a rebound
shift from hypoactivity to hyperactivity that endured up to
the 11th day of THC exposure. Supporting the robustness of
our anomalous ﬁnding, we replicated the phenomenon twice,
once in the present manuscript (see Figure 1D) and on
another occasion (data not shown). Closer inspection of the
literature revealed that an early study reported a similar
phenomenon in rats repeatedly administered THC daily for 34
days (Aulakh et al., 1980). That is, THC exposure promoted
initial hypolocomotion before transitioning to hyperlococo-
motion which was close to double that of control locomotor
activity, before diminishing again to control activity levels by
day 15 of THC exposure.
We ﬁrst hypothesised stress may be a factor in explaining
the rebound hyperactivity, as the ﬁrst demonstration of the
phenomenon occurred in a cohort of animals that received a
rectal temperature probe just prior to locomotor activity
testing. However, we replicated the effect in mice that had
not been subjected to body temperature recordings
(Figure 1D), disproving the role of rectal probe stress. Other
potential explanations for the rebound hyperactivity are not
as readily apparent. The mouse strain used does not appear
to explain this effect as previous studies have shown that
repeated THC exposure in C57Bl6 mice, the strain used
here, can promote typical cannabinoid tolerance to the
locomotor suppressant effects of THC (Boucher et al., 2009;
Ghozland et al., 2002; Long et al., 2010; Puighermanal
et al., 2013; Tai et al., 2015). Another potential explanation
is that the present study was conducted in the dark, active
phase of the light–dark cycle, whereas other similar studies
were conducted in the light phase when rodents sleep
(Boucher et al., 2011; Castane et al., 2003; Ghozland
et al., 2002; Long et al., 2010; Tai et al., 2015; Valverde
et al., 2000). Unfortunately, Aulakh et al. (1980) who
reported a similar rebound hyperactivity phenotype did
not specify under which phase of the light/dark cycle the
rats were tested. Brain endocannabinoid concentrations
vary according to circadian rhythm, so it may be that the
impact of repeated THC exposure on this system produces
different effects dependent on the time of exposure (Glaser
and Kaczocha, 2009; Liedhegner et al., 2014). Future
studies are required to determine whether THC produces
distinct effects on locomotor activity dependent on the
phase of the awake/sleep cycle it was administered in.
It is also important to note that rebound locomotor
hyperactivity has been frequently demonstrated using other
classes of drugs. For example, D2 and D3 dopamine receptor
agonists such as bromocriptine, 7-OH DPAT and quinpirole
suppress locomotor activity acutely but with repeated
administration produce hyperactivity (Hoffman and Wise,
1992; Mattingly et al., 1996; Rowlett et al., 1995). THC
increases dopamine concentrations in the nucleus
accumbens, which may then impact upon D2 and D3
receptors in this structure (Chen et al., 1990; Fadda
et al., 2006). Interestingly, THC-induced dopamine release
is dependent on CB1 receptors and may be less subject to
tolerance, as unlike other brain regions such as the pre-
frontal cortex, amygdala and hippocampus, repeated THC
exposure did not desensitise or downregulate CB1 receptors
in the striatum (Lazenka et al., 2013, 2014b). Therefore
repeated THC exposure may cause prolonged dopamine
release in the nucleus accumbens and sensitise dopamine
receptors. Indeed cannabis consumption alters striatal D2
and D3 receptor availability, and repeated THC exposure in
rodents sensitises D2 and D3 receptors in the mesoaccum-
bens dopamine system (Albrecht et al., 2013; Ginovart
et al., 2012). Future studies could examine whether
repeated THC-induced rebound hyperactivity is subserved
by dopamine interaction with D2 and D3 receptors in the
nucleus accumbens.
THC-induced rebound hyperactivity resembles behavioural
sensitisation to psychostimulants such as cocaine and amphe-
tamine – a phenomenon used to model addiction and schizo-
phrenia in rodents. However, behavioural sensitisation
normally sees an incremental and long-lasting hyperactivity
with repeated administration of psychostimulants (Arnold
et al., 1998; Pierce and Kalivas, 1997), whereas the THC-
induced rebound hyperactivity observed here was transient in
nature, peaking on day 3 and then progressively dissipating,
so that by day 12 locomotor activity was equivalent to vehicle
controls. Robust behavioural sensitisation to cannabinoids has
not been validly demonstrated (see Arnold et al. (2012) and
Varvel et al. (2007) for reviews on this topic), and our ﬁndings
here are the best demonstration to date of an unconventional
form of behavioural sensitisation to these compounds.
Repeated co-administration of CBD mitigated THC-
induced rebound hyperactivity, as the trend for hyperactiv-
ity in mice administered a 1:1 CBD:THC dose ratio failed to
reach signiﬁcance and was not of the same magnitude as
that observed in mice treated with THC alone. Increasing
the CBD dose, yielding a 5:1 CBD:THC dosing ratio, failed to
more markedly reduce THC-induced hyperactivity. This is
not really surprising given the literature is replete with
examples of CBD's pharmacological actions lacking dose-
dependence (Arnold et al., 2012; Long et al., 2010, 2012;
O'Brien et al., 2013). CBD pretreatment inhibits hyperloco-
motion induced by acute amphetamine, so CBD might
inhibit THC-induced rebound hyperactivity via a common
mechanism that could be explored in future studies (Long
et al., 2010; Moreira and Guimaraes, 2005). Here we failed
to replicate the ﬁnding that CBD acutely potentiated the
locomotor suppressant effects of THC at a 1:1 CBD:THC dose
ratio (Hayakawa et al., 2008; Todd and Arnold, 2016).
However this is explained by the shorter duration of testing
used here than in our earlier study (10 min versus 45 min).
Indeed, much of the potentiating effect of CBD on THC-
induced locomotor suppression is accounted for by CBD
prolonging the locomotor suppressant effects of THC.
CBD acutely promoted subtle reductions in THC-induced
facilitation of PPI providing further evidence of CBD's ability
to reduce the acute pharmacological effects of THC (Arnold
et al., 2012; Todd and Arnold, 2016). CBD modestly reduced
THC-induced PPI facilitation at a 1:1 CBD:THC dosing ratio,
and this was not accentuated by increasing the CBD dose to
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the 5:1 CBD:THC dose ratio. CBD and THC co-administration
did not interact to affect the expression of PPI reassessed
after 15 days of exposure. The mice became tolerant to the
effects of THC on PPI upon the third day of daily exposure
which continued up until day 15. Conﬁrming our prior work,
CBD alone was without effect on PPI at both 10 and 50 mg/
kg (Long et al., 2010).
The most compelling mechanism for CBD reducing the
actions of THC is via CBD being a negative allosteric
modulator (NAM) of cannabinoid CB1 receptors (Laprairie
et al., 2015), although other mechanisms may be involved
(Arnold et al., 2012; Todd and Arnold, 2016). It is note-
worthy that CBD can also reduce the effects of other
propsychotic agents on PPI, such as MK-801 and ampheta-
mine (Long et al., 2006; Pedrazzi et al., 2015). THC
facilitated PPI which replicates our prior work (Long
et al., 2010). Interestingly, like for other psychotomimetic
drugs acute cannabinoid exposure has also been shown to
promote PPI deﬁcits – the opposing ﬁndings may be
explained by various factors including drug, dose, strain
or the speciﬁc PPI paradigm used (Boucher et al., 2007a;
Malone and Taylor, 2006; Spencer et al., 2013). Given
atypical antipsychotic drugs facilitate PPI and normalise
PPI deﬁcits observed in chronic schizophrenia patients
(Oranje et al., 2002; Quednow et al., 2006), one straight-
forward interpretation of our ﬁndings is that THC has a
beneﬁcial, antipsychotic effect. However, this viewpoint is
likely oversimplistic as schizophrenia patients during the
prodromal period show PPI facilitation that can be exa-
cerbated by cannabis use (Cadenhead, 2011). It is there-
fore possible that PPI facilitation heralds the early
development of underlying pathology in the brain circuitry
of schizophrenia patients, which is sensitive to the effects
of cannabis. The PPI facilitation produced by THC in mice
observed here may then reﬂect some perturbation of PPI
circuitry.
THC increased anxiety-related behaviour in the light
dark, open ﬁeld and social interaction tests, which was not
modulated by CBD co-administration. These ﬁndings are
inconsistent with our previous results where CBD reversed
avoidance of the central zone in the open ﬁeld test (Todd
and Arnold, 2016). The use of a body temperature rectal
probe in the present study may explain this. This proce-
dure was not implemented in our prior study, and so it is
possible the stress of this procedure may have undermined
the ability to discern CBD actions on THC-induced anxiety
here. THC elicited consistent anxiety-related behaviour
throughout the drug administration period in the open ﬁeld
and light dark tests, but not in the social interaction test.
This enduring anxiety can’t be confounded by suppressed
locomotion on days 13 and 15 when the locomotor activity
of THC-treated animals was no different to vehicle con-
trols. In addition, CBD alone was without effect on
anxiety-related parameters in the light dark test and open
ﬁeld consistent with prior ﬁndings (Long et al., 2010, 2012;
O'Brien et al., 2013; Todd and Arnold, 2016).
We further explored whether CBD might reduce THC-
induced epigenetic and neuroadaptive changes in the meso-
limbic pathway. Surprisingly we observed that the repeated
co-administration of CBD and THC interacted to increase
both H3K9/14ac in the VTA and ΔFosB in the nucleus
accumbens following 3 and 15 days of repeated exposure
respectively. Following repeated exposure psychostimulants
induce behavioural sensitisation and hyperacetylate H3K9/14
in the nucleus accumbens and VTA (Kumar et al., 2005;
Schmidt et al., 2012; Shibasaki et al., 2011). We explored
whether H3K9/14ac was increased on day 3 given the
observed behavioural sensitisation-like hyperlocomotion to
THC was maximal at this time-point. Here we could not
demonstrate any effect of CBD and THC alone on H3K9/14ac,
however the combined administration of the cannabinoids at
a 5:1 CBD:THC ratio hyperacetylated H3K9/14 in the VTA.
Similarly the repeated co-administration of CBD and THC at a
1:1 dosing ratio increased expression of ΔFosB in the nucleus
accumbens, an effect observed in the absence of CBD or THC
effects alone on this transcription factor.
The interaction of CBD and THC on H3K9/14ac and ΔFosB
in the mesolimbic pathway is likely explained by CBD
altering the pharmacokinetics of THC, as it is well estab-
lished that CBD increases maximal THC concentrations and
prolongs THC disposition in the CNS (Bornheim et al., 1995;
Klein et al., 2011; Varvel et al., 2006). This effect is likely
mediated by CYP450 enzymes and/or ABC transporters
(Arnold et al., 2012; Holland et al., 2007; Spiro et al.,
2012). Thus a compelling mechanism for our ﬁndings is that
CBD increased THC brain disposition to the extent necessary
to trigger H3K9/14 acetylation and ΔFosB induction in the
mesolimbic pathway. Extended, high dose exposure of the
brain to THC appears a likely requirement for ΔFosB
induction. While here we could not demonstrate induction
of ΔFosB with single, daily exposure of mice to 10 mg/kg
THC for 15 days, twice daily administration of the same dose
increased ΔFosB expression in the nucleus accumbens of
mice (Lazenka et al., 2014b; Perrotti et al., 2008). Further,
Perrotti et al. (2008) reported robust accumbal ΔFosB
induction following 15 days of twice daily escalating doses
of THC, reaching a maximum dose of 160 mg/kg.
No previous studies have examined the impact of CBD or
THC treatment in adulthood on epigenetic markers in the
brain, with prior studies showing altered H3K9 methylation in
the nucleus accumbens of adult rodents following in utero
and adolescent THC exposure (DiNieri et al., 2011;
Tomasiewicz et al., 2012). THC was without effect here on
H3K9/14ac, however a future more comprehensive study is
required to rule this out. It is possible we missed the window
of THC effects on this epigenetic marker, as we only sampled
once at 2 h post-dose. CBD's propensity to enhance THC brain
disposition may have cast a broader temporal net to detect
H3K9/14 hyperacetylation in the CBD:THC co-administration
group. However, arguments of missed sampling windows are
not compelling with the ΔFosB marker, as this transcription
factor has a long-half life, and so if there were any effects of
repeated THC exposure alone, it should have been evident as
we sampled 24 h post-dose.
Chromatin remodelling mediated by H3K9/14 hyperacety-
lation and ΔFosB induction in the mesolimbic pathway is
likely to affect the transcription of various genes that
subserve neuroadaptive changes in this system (Kurdistani
et al., 2004; Strahl and Allis, 2000). Future studies are
therefore needed to identify the speciﬁc target genes
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promoted by CBD and THC co-administration. Possible candi-
dates include the D2 dopamine receptor and brain-derived
neurotrophic factor genes which are inﬂuenced by histone
3 modiﬁcations induced by cannabinoids or psychostimulants
(DiNieri et al., 2011; Schmidt et al., 2012). In addition, the
target genes of ΔFosB might be explored such as GluR2, a
subunit of AMPA glutamate receptors, cyclin dependent
kinase 5 (Cdk5) and nuclear factor-kB (NFkB) (Rufﬂe, 2014).
The functional signiﬁcance of the epigenetic and neuroa-
daptive changes associated with CBD and THC co-
administration requires clariﬁcation. None of our beha-
vioural measures provided robust evidence of potentiation,
but these readouts may not be sensitive to changes in the
mesolimbic pathway. Given the role of the mesolimbic
system in addiction, future studies might address whether
the co-administration of CBD and THC increases the pro-
pensity for cannabinoid reward using the voluntary self-
administration paradigm in rodents. Interestingly, we pre-
viously reported a strong trend towards combined CBD and
THC at a 1:1 CBD:THC dosing ratio promoting a conditioned
place preference reﬂecting a rewarding effect (Klein et al.,
2011), although another study in adult mice showed that
CBD reduced the aversive effects of THC in this model (Vann
et al., 2008) consistent with the view that CBD improves the
subjective tolerability of THC. In humans, administration of
high CBD:THC strains of cannabis reduced attentional bias
and liking of drug related stimuli (Morgan et al., 2010a).
CBD has also been shown to reduce the rewarding effects of
other drugs of abuse in human and rodent studies (Morgan
et al., 2010b; Ren et al., 2009), conﬂicting with the idea
that 1:1 CBD:THC dosing ratios may engender greater
addictive properties.
In conclusion, this study reinforces the view that the
neuropsychopharmacology of CBD and THC interactions is
complex. Consistent with prior work we showed that CBD
tended to reduce some of the acute and subchronic effects
of THC, such as rebound hyperactivity and PPI facilitation.
Further, CBD did not appear to alter the trajectory of
enduring THC-induced anxiety-related behaviour nor toler-
ance to the pharmacological effects of THC. There was no
evidence of CBD potentiating the behavioural effects of
THC, although for the ﬁrst time we report co-administration
of CBD and THC induced synergistic epigenetic and neuroa-
daptive changes in the mesolimbic pathway.
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Chapter 4 
Resilience of adult mice against long-term 
behavioural disturbances induced by adolescent 
THC treatment and enduring antidepressant 
actions of adolescent CBD exposure  
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Introduction 
 
Whether cannabis use can cause long-term detrimental effects, even after drug taking 
has ceased, has been the subject of intense debate. Cannabis use represents the highest 
proportion of illicit drug use worldwide, and heavy use has been linked to anxiety 
disorders, depression, and psychosis, as well as cognitive deficits (Degenhardt and 
Hall, 2012; Degenhardt et al., 2016; Rubino et al., 2012). There is evidence to suggest 
persistent psychiatric morbidity and cognitive deficits exist in abstinent cannabis 
users, particularly in those who commenced use during early adolescence (Broyd et 
al., 2016a; Broyd et al., 2016b; Chadwick et al., 2013; Meier et al., 2012) however 
others have not been able to demonstrate such outcomes (Bechtold et al., 2015; Fried 
et al., 2005; Mokrysz et al., 2016).  
It has been argued that adolescent cannabis users are particularly sensitive to 
the detrimental effects of cannabis due to Δ9-tetrahydrocannabinol (THC), the 
primary psychoactive constituent of cannabis, disrupting a critical period of 
neurodevelopment governed by the endocannabinoid system (Lubman et al., 2015). 
The severity of effect appears dose-dependent, which is concerning given selective 
breeding has increased THC plant concentrations worldwide at the expense of the 
non-psychoactive cannabinoid component cannabidiol (CBD) (Dujourdy and 
Besacier, 2017; ElSohly et al., 2016; Jacobus and Tapert, 2014; Swift et al., 2013). 
CBD in contrast appears to ameliorate some of the long-term effects of cannabis on 
mood, psychosis and cognition in chronic adult users, suggesting some protective 
effects, although the full extent of this requires further characterisation (Broyd et al., 
2016b; Morgan et al., 2012; Morgan et al., 2010b). Only one observational study in 
adolescents has been undertaken which reported that the THC/CBD ratio was not a 
predictor of psychotic symptoms in adolescents – however, CBD levels were less than 
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10% of those of THC (Morgan et al., 2016). It is therefore unknown whether the 
proposed protective effects of CBD against THC may also extend to adolescent users.  
Given the ethical constraints of controlled studies of cannabinoids in human 
adolescents, animal studies provide a vital source of neurobehavioural information 
otherwise impossible to obtain. Although developmental trajectories differ somewhat 
between humans and rodents (Long et al., 2012; Rubino et al., 2015), the 
endocannabinoid system plays a central role in neuronal maturation and synaptic 
pruning during adolescence for both humans and rodents, and it is this system with 
which THC and CBD are thought to primarily interact (Dow-Edwards and Silva, 
2017; Lee et al., 2016). Replicating human studies, rodent studies indicate 
cannabinoid-induced cognitive and neuronal disturbances are more pronounced if 
treatment occurs in adolescence compared to adulthood (Abboussi et al., 2014; Quinn 
et al., 2008; Silva et al., 2016). Wide-ranging residual behavioural abnormalities have 
been reported long after adolescent exposure to THC or its synthetic analogues has 
ceased, including: altered anxiety and startle responses, inhibited social interaction, 
increased depression-related behaviour, reduced exploratory behaviour, and cognitive 
deficits (Abboussi et al., 2014; Biscaia et al., 2003; Bortolato et al., 2014; Macri and 
Laviola, 2004; O'Shea et al., 2006; Quinn et al., 2008; Rubino et al., 2009a; Silva et 
al., 2016; Zamberletti et al., 2014). However, no previous human or rodent study has 
assessed whether 1:1 CBD co-administration protects against persisting behavioural 
effects of adolescent THC exposure. Adult animal studies indicate that CBD may both 
potentiate and inhibit THC’s behavioural effects, even in the same animal (Hayakawa 
et al., 2008; Stern et al., 2015; Taffe et al., 2015; Todd and Arnold, 2016; Zuardi and 
Karniol, 1983b). We demonstrated in Chapter 2 and Chapter 3 that CBD potentiated 
the acute locomotor suppressant effects of THC but inhibited THC-induced 
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hypothermia, anxiety and facilitation of sensorimotor gating (Todd and Arnold, 2016; 
Todd et al., 2017). We also found repeated co-administration of CBD and THC to 
adult mice induced long-term transcriptional and epigenetic modifications in the 
mesolimbic dopamine pathway - effects that were not observed with THC or CBD 
administration alone (Todd et al., 2017). The present chapter aims to extend this 
research by assessing whether CBD co-administration modulates the long-term effects 
of adolescent THC exposure on behaviour in mice.  
In addition to this line of research, CBD is being developed as a novel 
treatment for a myriad of medical conditions due to its anti-inflammatory, anxiolytic, 
antidepressant, anticonvulsant and antipsychotic properties (Amminger et al., 2017; 
Leweke et al., 2012; Pisanti et al., 2017). It is likely that CBD will soon be approved 
as a therapeutic agent in the treatment of intractable childhood epilepsy due to the 
success of open-label and phase III clinical trials (Devinsky et al., 2017; Geffrey et 
al., 2015; O'Connell et al., 2017). The emerging use of CBD in child and adolescent 
populations then prompts the question of whether CBD has any long-term impact on 
the developing brain and behaviour. Existing clinical trials suggest CBD has minimal 
toxicity, however more research is needed (Devinsky et al., 2016). There is some 
cause for concern as CBD may also modulate endocannabinoid transmission during 
adolescent neurodevelopment (Dow-Edwards and Silva, 2017). Therefore in this 
present chapter we aimed to examine not only whether CBD could reverse persisting 
behavioural effects in adult mice after repeated THC treatment during adolescence 
(specifically locomotion, object memory, social interaction, sensorimotor gating and 
behavioural despair), expanding upon our previous work, but also whether adolescent 
CBD exposure alone has any long-term impact on any of these behaviours.  
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Methods
Animals 
31 hemizygous Thy1-YFP mice and 15 WT cage mates (C57BL/6 background) 
were used in the cannabinoid dosing experiment. Mice were stratified by genotype to 
the 4 experimental groups and no statistical differences in behaviour between 
Thy1-YFP and WT mice were seen. 8 age-matched male A/J mice were used as social 
interaction opponents (provided by Animal Resources Centre, Perth). Mice were 
housed in standard cages of 3 - 6 per cage with food and water available ad libitum 
and weight measured daily. During injection animals were under a normalised 12 
h light:dark cycle, and following treatment they were transferred to a reversed 12 
h light:dark for the abstinence period and behavioural tests. The University of 
Sydney’s Animal Ethics Committee approved all experimental procedures. 
Pharmacological treatment 
Four different treatment groups were used: vehicle, CBD, THC, and a cocktail of 
THC and CBD. THC and CBD (THCPharm, Frankfurt, Germany) were dissolved in 
ethanol, Tween 80, and saline (1:1:18) as previously described (Todd and Arnold, 
2016; Todd et al., 2017). For combined THC and CBD dosages CBD powder was 
dissolved in THC stock ethanol solution. All drugs were administered by 
intraperitoneal (i.p) injection at 10 mg/kg with a 10 mL/kg volume of injection. A 10 
mg/kg THC dose was used as we have previously found it robustly produces 
acute cannabinoid effects (Todd and Arnold, 2016; Todd et al., 2017). 
Additionally, according to FDA interspecies calculations this equates to a human 
dose of ~0.80 mg/kg a day, or approximately ~70 mg for an 85 kg adult male. This 
approximates the median daily cannabis dosage for both recreational and 
medical cannabis users 
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(Harris et al., 2014; Massot-Tarrus and McLachlan, 2016; Nair and Jacob, 2016; 
Zeisser et al., 2012). This was matched by a 10 mg/kg CBD dose to reflect a 1:1 dose 
ratio as used in medicinal cannabis preparation Sativex (Fernandez, 2016; Syed et al., 
2014) and medical cannabis cultivars (ElSohly et al., 2017; Swift et al., 2013).  
Experimental procedures 
Starting from PND 27—29 (~PND 28, adolescence), mice were treated daily with 
vehicle (n = 11), CBD (10 mg/kg; n = 11), THC (10 mg/kg, n = 12), or THC + CBD 
(10 mg/kg, n = 12) for 14 days at approximately the same time each day (8 am – 10 
am, +/- 30 min) (Figure 1). Body weight was recorded every day during the drug 
treatment period and following a three-week washout period to assess if any weight 
differences persisted. After the washout, commencing PND 62 - 64 (~PND 63, 
adulthood), mice underwent testing in the open field, novel object recognition test 
(NORT), social interaction paradigm, prepulse inhibition of startle (PPI) model and 
the forced swim test, with all tests separated by 24 h.  
To assess whether any residual CBD remained in brain tissue, on PND 68 
CBD treated mice (n = 4) were euthanized with isoflurane and brain tissue extracted 
and the frontal cortex was dissected. Tissue was snap frozen in liquid nitrogen and 
stored at –80 °C. 
Figure 1. Testing sequence for examining the long-term effects of adolescent exposure to CBD and 
THC, alone and in combination, at a 1:1 CBD:THC dose (10 mg/kg of each dose) following a period of 
washout. OF = open field; NORT = novel object recognition test; SI = social interaction; PPI = 
prepulse inhibition of startle test; FST = forced swim test. 
~PND28' ~PND63'~PND41'
Injec1on''
+'weight'
Abs1nence' Behavioural''
tes1ng'
~PND67'
OF' NORT' SI' PPI' FST'
Adolescence) Adulthood)
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1. Locomotor activity was measured by placing mice into a red plexiglass open field
activity test chamber (43 cm x 43 cm x 25 cm) and recording horizontal movement 
(mm) using video tracking software over a 10 minute period (Motion Mensura, NSW,
Australia) (Boucher et al., 2011a; Spencer et al., 2012). Distance ratio [distance 
travelled in the central 50% of arena space (÷) total travelled distance] was measured 
as an indirect measure of anxiety, with distance rather than time used to control for 
any differences in baseline locomotion (Todd and Arnold, 2016). 
2. The novel object recognition test is a measure of cognition in rodents distinct
from spatial or episodic memory (Dere et al., 2007). The locomotor activity test, 
undertaken on the previous day (PND 62—64, ~PND 63), was used as the habituation 
phase of this test. On the test day (PND 63—65, ~PND 64) mice were placed in the 
open field with two identical objects for ten minutes (familiarization phase), and after 
a 30 min inter-trial interval returned back into the open field with one novel and one 
familiar object (test phase – objects counterbalanced to the familiarization phase). The 
objects used were: 6.5 cm x 6.5 cm x 3 cm clear square containers with bright pink 
lids (familiar object) and 5.5 cm diameter, 2.5 cm dark blue circular jar tops (novel 
object). Objects and open field were cleaned with ethanol between each testing phase. 
Time spent investigating the novel object (< 2cm distance away) was measured using 
Trackmate quad 2.1 software. The discrimination index (DI) was calculated as [(novel 
object exploration – familiar object exploration) / (time exploring total) * 100], with 
DI = 0 indicating equal preference or two objects and DI ≥ 25 indicating preference 
for the novel object (Vogel-Ciernia and Wood, 2014). 
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3. Social interaction was measured in the open field over 10 minutes. Test animals
were placed in the opposite corner to an age-matched A/J opponent and behaviour 
measured by observer blind to treatment condition (Boucher et al., 2007a). 
Behaviours measured were total time spent interacting and frequency of social 
behaviours (i.e anogenital sniffing, nosing, following – see Silverman et al. (2010)). 
4. Prepulse inhibition of startle (PPI) was used to measure sensorimotor gating.
Disruptions in this measure are seen in chronic cannabis users and schizophrenia 
patients (Cadenhead, 2011; Scholes-Balog and Martin-Iverson, 2011). PPI was 
measured in startle chambers (SR-Lab; San Diego Instruments, USA) with a protocol 
sensitive to the effects of cannabinoids (Boucher et al., 2011b; Todd et al., 2017). 
Animals were habituated to the test chambers and background noise (70 dB) for 10 
minutes the day prior to testing. %PPI was calculated as [((startle response 120 dB) – 
(prepulse + pulse response)*100)/(startle response 120 dB)], while acoustic startle 
response was averaged from responses to 120 dB single acoustic stimulus alone trials. 
5. The forced swim test was used as a measure of behavioural despair (Boucher et
al., 2011a). Mice were placed in a clear Perspex cylinder (41 cm height; 17 cm 
diameter) filled with 22°C degree water. Immobility time (or time spent passively 
floating) was recorded by Trackmate quad 2.1 software (standardized to human 
observation) over 6 minutes.  
Quantification of CBD in brain samples 
CBD was analysed following a method previously described and used by our research 
group (Brzozowska et al., 2016). Briefly, deuterated CBD-D3 internal standard 
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solution was added to every prefrontal tissue sample, and compared to calibration 
standards (brain homogenates with added linear concentrations CBD from 10 – 400 
ng/g). The standards were vortexed and treated identically to other samples. All 
quantification was performed using a Shimadzu 8030 triple quadrupole mass 
spectrometer. The limit of quantification (LOQ) was 11.5 ng/g for brain analysis. 
Statistical analysis 
PASW 21.0 (SPSS Inc.; Chicago, USA) was used for statistical analysis. We 
conducted a repeated measures factorial ANOVA (THC treatment and CBD treatment 
as factors and either selection time points or day as the repeated factor) for weight 
over the injection period; for all other measures we used two-way ANOVA (THC 
treatment and CBD treatment as factors) followed by Student-Neuman-Kuels (SNK) 
post-hoc analysis. Data was transformed either logarithmically or cubically if it failed 
normality and/or homogeneity assumptions. 
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Results
1. Weight
Body weight at ~PND 28 (baseline), ~PND 41 (post—dosing) and ~PND 63 
(washout) are reported in Figure 2A. There was an overall effect of day [F(2,84) = 
1651.61, P < 0.001] and a THC treatment by day interaction [F(2,84) = 10.63, P < 
0.01]. No significant differences were seen before treatment at baseline (~PND 28), 
however a main effect of THC was found at ~PND 41 after 14 days of injections 
[F(1,42) = 20.48, P < 0.001] indicating reduced body weight in the mice. SNK post-
hocs showed that both THC and THC + CBD treated mice both had equivalently 
lower body weight than vehicle mice at ~PND 41 (Ps displayed in Figure 2A). By 
~PND 63 there were no longer any significant differences between groups, indicating 
mice returned to normal weight following THC washout.  
Daily weight was then examined over the dosing period to see if there were 
any difference in rate of weight loss (see Figure 2B). A significant effect of day 
[F(13, 546) = 693.67, P < 0.001] and a THC treatment by day interaction was found 
[F(13, 546) = 19.25, P < 0.001]. Further individual day analyses indicated that from 
day 7 onwards there were significant group differences with THC decreasing body 
weight [day 6: F(3,42) = 5.29, P < 0.05; day 7: F(3,42) = 8.43, P < 0.01; day 8: 
F(3,42) = 11.56, P < 0.01; day 9: F(3,42) = 13.58, P < 0.01; day 10: F(3,42) = 16.31, 
P < 0.001; day 11: F(3,42) = 20.35, P < 0.001; day 12: F(3,42) = 22.10, P < 0.001; 
day 13: F(3,42) = 21.20, P < 0.001; day 14: F(3,42) = 20.48, P < 0.001]. SNK post-
hocs indicated that both THC and THC + CBD treated mice had significantly lower 
body weight than vehicle mice from day 7 onwards (Ps displayed in Figure 2B). 
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Figure 2. Average weight at A) baseline (~PND 28), after 14 days of cannabinoid post-dosing (~PND 
41) and after a 21 day drug washout period (~PND 63). Also displayed is B) weight over 14 days of
cannabinoid injection from ~PND 28 to ~PND 41. VEH, vehicle control group (n = 11); CBD,
cannabidiol alone (n = 11); THC, Δ9-tetrahydrocannabinol alone (n = 12); and THC + CBD, combined
dose in a 1:1 ratio (n = 12), all at 10 mg/kg i.p. Data represent means ± SEM with two-way ANOVAs
and SNK post-hocs. *P < 0.05, **P < 0.01 VEH vs THC; #P < 0.05, ##P < 0.01 VEH vs THC + CBD.
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2. Open field
Following 14 days of injection and 21 days of THC washout, animals were tested for 
locomotor activity and distance ratio in the open field over 10 minutes. Factorial 
ANOVA of overall locomotor activity (Figure 3A) and distance ratio (Figure 3B) 
indicated no significant differences between groups.  
Figure 3. Locomotion and anxiety-related behaviour in the open field. A) Distance travelled in the 
open field and B) distance ratio in the open field. VEH, vehicle control group (n = 11); CBD, 
cannabidiol alone (n = 11); THC, Δ9-tetrahydrocannabinol alone (n = 12); and THC + CBD, combined 
dose in a 1:1 ratio (n = 12), all at 10 mg/kg i.p. Data represent means ± SEM with two-way ANOVAs 
and SNK post-hocs.  
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3. Novel object recognition
The mice displayed novel object recognition as they showed a preference to explore 
the novel object as measured by increased exploration time in the test phase compared 
to the familiarization phase [F(1,45) = 105.53, P < 0.001] (Figure 4A). However 
there was no difference between conditions in exploration time and discrimination 
index, indicating that prior treatment with THC, CBD or their combination did not 
influence novel object recognition in the test phase (Figure 4B). 
Figure 4. Recognition memory in the novel object recognition test (NORT). Displayed are A) average 
time exploring objects in the familiarization and test phase and B) discrimination index of objects 
during test phase. VEH, vehicle control group (n = 11); CBD, cannabidiol alone (n = 11); THC, Δ9-
tetrahydrocannabinol alone (n = 12); and THC + CBD, combined dose in a 1:1 ratio (n = 12), all at 10 
mg/kg i.p. Data represent means ± SEM with two-way ANOVAs and SNK post-hocs.  
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4. Social interaction
No significant main or interaction effects were found in total interaction time (Figure 
5A) or frequency of social interactions (Figure 5B).   
Figure 5. Social behaviour in the social interaction test. Displayed are A) total time spend socially 
interacting and B) frequency of social interactions over a 10 minute period. VEH, vehicle control group 
(n = 11); CBD, cannabidiol alone (n = 11); THC, Δ9-tetrahydrocannabinol alone (n = 12); and THC + 
CBD, combined dose in a 1:1 ratio (n = 12), all at 10 mg/kg i.p. Data represent means ± SEM with 
two-way ANOVAs and SNK post-hocs.  
Additional analysis of specific behaviours in the social interaction test revealed no 
significant main or interaction effects, indicating that there were no observable 
differences in particular types of social behavior between groups (see Table 1).  
Table 1. Reported means of social behaviours in the social interaction test (mean ± 
SEM) 
Behaviour 
VEH 
(n = 11) 
CBD  
(n = 11) 
THC  
(n = 12) 
THC + CBD  
(n = 12) 
Social 
   Nosing 19.0 ± 1.8 20.8 ± 1.5 22.4 ± 1.6 22.7 ± 1.7 
   Anogenital sniffing 11.5 ± 1.2 10.9 ± 1.3 9.0 ± 1.4 12.2 ± 1.6 
   Following 4.1 ± 0.9 5.0 ± 1.5 4.3 ± 1.1 5.8 ± 1.0 
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5. Prepulse inhibition of startle
Repeated factorial ANOVA (between factors of THC treatment, CBD treatment, and 
a repeated factor of prepulse intensity) indicated a significant effect of prepulse 
intensity [F(3,126) = 29.34, P < 0.001] but no main effects of CBD or THC nor any 
interaction effects. Likewise, no significant main effects or interactions were found 
when applying individual ANOVAs at specific prepulse intensities (Figure 6A). 
Adolescent cannabinoid treatment also did not alter average startle between groups 
(Figure 6B). 
Figure 6. Sensorimotor gating in the PPI test. Displayed are A) %PPI across different prepulse 
intensities and B) startle response to a 120 dB stimulus (au = arbitrary units). VEH, vehicle control 
group (n = 11); CBD, cannabidiol alone (n = 11); THC, Δ9-tetrahydrocannabinol alone (n = 12); and 
THC + CBD, combined dose in a 1:1 ratio (n = 12), all at 10 mg/kg i.p. Data represent means ± SEM 
with two-way ANOVAs and SNK post-hocs. 
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6. Forced swim test
Repeated factorial ANOVA minute-by-minute indicated increased immobility over 
time [main effect of time: F(5,210) = 93.23, P < 0.001]. CBD treatment overall also 
decreased immobility time [main effect of CBD: F(1,42) = 6.51, P < 0.05] but did not 
produce a time by CBD effect, indicating this effect was consistent across testing 
time. There was no main effect of THC or THC-related interaction effects. Further 
analysis minute-by-minute indicated a main effect for CBD to reduce immobility at 
minute 3 [F(1,42) = 4.52, P < 0.05] but no specific between group differences were 
found in post-hoc analysis (Figure 7A).  
For clarity of exposition we have reproduced the VEH and CBD data alone in 
Figure 7B. This also allows analysis without any potential contaminating influence of 
THC. Again immobility increased with time [F(5,100) = 53.30, P < 0.001] and CBD 
overall decreased immobility [F(1,20) = 6.73, P < 0.05]. Individual t-tests indicated 
that mice treated with CBD had significantly lower immobility than vehicle mice at 
minutes 2, 3, and 4 [t(20) = 2.88, P < 0.01; t(20) = 2.32, P < 0.05; t(20) = 2.22]. 
These results indicate that adolescent CBD exposure decreased immobility in the 
FST.!! !!
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Figure 7. Depression-like behaviour as measured by immobility in the FST over 6 minutes. Displayed 
are A) immobility in the FST with all conditions per minute and B) immobility with vehicle and CBD 
group only per minute. VEH, vehicle control group (n = 11); CBD, cannabidiol alone (n = 11); THC, 
Δ9-tetrahydrocannabinol alone (n = 12); and THC + CBD, combined dose in a 1:1 ratio (n = 12), all at 
10 mg/kg i.p. Data represent means ± SEM with two-way ANOVAs and SNK post-hocs.  
7. CBD brain concentrations
Concentrations of CBD were not detected in the prefrontal cortex tissue, indicating 
complete drug washout following the adolescent CBD treatment (data not shown). 
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Discussion 
Investigating the potential protective effect of CBD against residual behavioural 
deficits of adolescent THC administration is important given the widespread 
recreational use of cannabis by adolescents and increasing medical use in younger 
populations. In this study we were unable to demonstrate any enduring behavioural 
deficits of adolescent THC exposure to begin with, which is at odds with previous 
studies reporting long-lasting behavioural alterations following adolescent 
cannabinoid exposure (Biscaia et al., 2003; O'Shea et al., 2006; Quinn et al., 2008; 
Schneider and Koch, 2003; Zamberletti et al., 2014). Faulty drug administration 
cannot explain our negative findings as our adolescent THC dosing regimen produced 
clear reductions in body weight (Wong et al., 2012; Wong et al., 2014). Surprisingly, 
we found adolescent CBD exposure alone reduced depression-like behaviour in 
adulthood, 3 weeks following the final exposure to CBD, an effect that occurred 
independent of detectable residual brain CBD concentrations. While CBD exposure 
has been previously shown to promote an acute antidepressant profile (El-Alfy et al., 
2010; Reus et al., 2011; Zanelati et al., 2010), this study represents the first 
demonstration of an enduring antidepressant action of CBD and reinforces the notion 
that CBD might be useful in the treatment of mood disorders. 
Our negative results are surprising as we had a reasonable expectation that 
deficits would occur based on the abundance of rodent studies that have reported 
behavioural disturbances following adolescent cannabinoid treatment (Abboussi et al., 
2014; Quinn et al., 2008; Silva et al., 2016). However, further investigation of the 
literature indicates wide variation in the experimental methods that have been 
implemented to achieve deficits. First, in many cases the cannabinoid used in 
adolescent dosing studies was a synthetic cannabinoid receptor agonist and not the 
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phytocannabinoid THC. Adolescent exposure to synthetic CB1 receptor agonists 
including WIN 55212-2 and CP 55,940 produced social withdrawal, depression-like 
behaviour, sensorimotor gating deficits, decreased object recognition and anxiety 
disturbances (Bambico et al., 2010; Biscaia et al., 2003; O'Shea et al., 2006; 
Schneider and Koch, 2003). However, these synthetic cannabinoids are full CB1 
receptor agonists, unlike THC which is a partial agonist at CB1 receptors (Khajehali 
et al., 2015; Luk et al., 2004; Tai and Fantegrossi, 2016). While this would create an 
difference in the maximal effect of the drug attained, it may also produce variation in 
cannabinoid tolerance as THC produces less desensitization of the CB1 receptor than 
synthetic cannabinoids (Luk et al., 2004; Lundberg et al., 2005; Wu et al., 2008). The 
CB1 receptor also displays biased agonism to orthosteric ligands (Diez-Alarcia et al., 
2016; Khajehali et al., 2015), with agonists differently affecting specific G-protein 
signalling pathways (Laprairie et al., 2014). Such variances in pharmacology indicate 
synthetic cannabinoids may not be necessarily equivalent (or substitutable) with THC 
in in vivo studies and therefore, while relevant to understanding the rising recreational 
use of synthetic cannabinoids, are irrelevant to modelling the pharmacological effects 
of the phytocannabinoids found in the cannabis plant (Tai and Fantegrossi, 2016). 
When restricting analysis to THC studies alone, a further consideration emerges 
regarding dose strength. Most rat studies have used high THC doses: in one widely 
used protocol, a 10 day escalating dosing regimen (from 5 to 20 mg/kg) during 
adolescence induced impairments in spatial and object recognition memory, social 
withdrawal and depression-like behaviour in adulthood (Llorente-Berzal et al., 2013; 
Rubino et al., 2009a; Rubino et al., 2009b; Stopponi et al., 2014; Zamberletti et al., 
2014). The 20 mg/kg final dose used in these studies equates to ~275 mg of THC per 
day in a human, or the monthly consumption of 55 g of 15% strength cannabis (Cha et 
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al., 2007; Nair and Jacob, 2016; Quinn et al., 2008; Rosenkrantz, 1976; Shen et al., 
2011; Swift et al., 2013). Considering the median monthly recreational and medicinal 
cannabis user consumes ~15 g, and that even heavy users on average use ~23 g of 
cannabis, these doses are well beyond that consumed by the majority of cannabis 
users (Allsop et al., 2014a; Harris et al., 2014; Massot-Tarrus and McLachlan, 2016; 
Nair and Jacob, 2016; Zeisser et al., 2012). The dose used in the present study is 
consistent with median consumption of cannabis by recreational or medicinal users, 
and may therefore, at least based on the behavioural measures selected here, imply 
that adolescent THC exposure at modest doses will not promote lasting alterations to 
behaviour, mood and cognition (Jacobus and Tapert, 2014). 
Rodent studies modelling the average cannabis user have reported fewer deficits 
following adolescent THC administration. Rat studies with an equivalent THC dose to 
our study (~5 mg/kg according to FDA interspecies conversions) found no persisting 
disturbances in locomotion, motor control, exploratory behaviour or spatial memory 
(Cha et al., 2007; Keeley et al., 2015; Shen et al., 2011). However, object recognition 
deficits and decreased social interaction were reported after two-week washout 
(Quinn et al., 2008), although a separate study with a 10 day washout found no 
differences in social behaviour (Shen et al., 2011). This discrepancy may be strain 
related, as Quinn et al (2008) used Wistar rats which appear particularly sensitive to 
the neuropharmacological effects of THC (Arnold et al., 2001; Cadoni et al., 2015; 
Quinn et al., 2008). Only a couple of studies have assessed the residual behavioural 
effects of adolescent THC exposure in mice; these studies used a THC dose of ~8 
mg/kg in C57BL/6 strain mice, the same as used here, and reported no lasting effects 
on locomotor activity, anxiety, fear conditioning, and spatial and novel object 
recognition memory after drug washout (Ballinger et al., 2015; O'Tuathaigh et al., 
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2010). However, in both studies deficits were seen in “vulnerable” genetic mutant 
mouse lines, for instance Comt knockout mice displayed worse spatial memory than 
WT mice (Ballinger et al., 2015; O'Tuathaigh et al., 2010). This mirrors human 
research indicating the severity of the adverse effects of cannabis is modulated by 
gene polymorphisms in COMT (Morgan et al., 2016; Nieman et al., 2016; Tunbridge 
et al., 2015) and together suggest that at recreational doses, chronic adolescent THC 
treatment alone may not necessarily be sufficient to produce persisting behavioural 
deficits.  
As we could not demonstrate long-lasting deficits of adolescent THC exposure, it 
still remains an open question whether CBD modulates the behavioural effects of 
THC exposure during adolescence. Some of the results of Chapters 2 and 3, which 
used the same CBD/THC dosing regimen as in the present chapter, suggested that 
CBD might potentiate the effects of THC at least in adult mice (Todd and Arnold, 
2016; Todd et al., 2017). However, we did not observe any evidence of a synergistic 
interaction of adolescent CBD and THC co-administration on behaviour long after 
final exposure to these drugs. A major finding of Todd et al. (2017) was that 
combined THC and CBD administration produced more pronounced alterations than 
THC alone in markers of long-term neuroadaptation and epigenetic modification in 
the mesolimbic pathway. As we did not assess molecular changes in this chapter, it is 
possible that underlying neuroadaptive and epigenetic alterations might remain long 
after repeated adolescent exposure to THC and CBD. Further, the behaviours we 
examined here may not be sensitive to detecting changes subserved by the 
mesolimbic pathway. Molecular and neuronal alterations could have occurred in this 
study without behavioural disturbance as has been demonstrated in human MRI 
studies of both adults and adolescent cannabis users (Bossong et al., 2012; Chang et 
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al., 2006; Eldreth et al., 2004; Gilman et al., 2016; Harding et al., 2012; Jager et al., 
2010; Lorenzetti et al., 2016a). As a final note, animal modelling of developmental 
impacts during adolescence may not be perfectly translatable to humans given 
somewhat distinctive developmental trajectories, which should also be considered in 
the interpretation of our results. 
A major serendipitous finding of the present study is the discovery that repeated 
exposure of adolescent mice to CBD promoted persistent improved stress coping 
behaviour in the FST, an animal model of depression. Mice treated for 14 days with 
CBD during adolescence showed less immobility than control mice when tested in 
adulthood, 3 weeks after their final CBD exposure. The brain tissue of these mice had 
lower than detectable concentrations of CBD, suggesting that adolescent CBD 
exposure engendered reduced depression-like behaviour via its beneficial effects on 
adolescent brain development. Alternatively, the enhanced stress-tolerability of 
adolescent CBD-treated mice might also be explained by CBD limiting the long-term 
adverse effects of injection stress on depression-like behaviour, as adolescent stress 
increases depression-like behaviour (McCormick and Green, 2013; Yohn and Blendy, 
2017) and CBD is known to have acute anxiolytic, antidepressant and anti-stressor 
effects (Linge et al., 2016; Rock et al., 2017; Soares Vde et al., 2010). Future studies 
could address this specifically using non-stressful modes of drug delivery, such as 
providing CBD orally in the lab chow of the mice, to test whether the enduring 
antidepressant effects of CBD can be replicated in the absence of an explicit stressor. 
This is the first demonstration of adolescent CBD exposure having enduring anti-
depressant effects in the absence of the drug being present in the brain. Prior studies 
have shown that acute and chronic CBD in adult animals decreased immobility in the 
FST (El-Alfy et al., 2010; Reus et al., 2011; Zanelati et al., 2010). These studies 
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showed that CBD reduced immobility, but only at 30 mg/kg in mice (Zanelati et al., 
2010) and at 200 mg/kg in rats (El-Alfy et al., 2010). Daily CBD dosing for 14 days 
in rats also decreased immobility at 30 mg/kg (Reus et al., 2011). In light of all these 
findings our result is surprising since it occurred at a much lower dose of 10 mg/kg of 
CBD. In mice 10 mg/kg is equivalent to a human dose of ~0.8 mg/kg (Nair and Jacob, 
2016), and current CBD human therapeutic doses range between 1 – 30 mg/kg with 
an average of 5 mg/kg (Gofshteyn et al., 2016; Hussain et al., 2015; Porter and 
Jacobson, 2013; Tzadok et al., 2016). This indicates our dose represents the lower end 
of human dosing and so such a beneficial effect might be relevant to medicinal users, 
particularly children with childhood epilepsy. CBD has recently been shown to reduce 
seizures in childhood epilepsy in a phase 3 clinical trial (Devinsky et al., 2017; 
Devinsky et al., 2016; Gofshteyn et al., 2017). It is likely then that soon children and 
adolescents with childhood epilepsy will increasingly be exposed to CBD, and our 
results suggest this exposure may be beneficial and reduce the risk of developing 
depression later in life. Such studies in humans need to be conducted however to 
confirm this outcome.  
Future studies might address the molecular and neurobiological basis for the 
enduring antidepressant effect of adolescent CBD exposure. CBD exposure in adult 
animals increased expression of BDNF in the amygdala (Reus et al., 2011), which is 
promising given that antidepressant drugs appear to normalize the lower BDNF 
concentrations observed in depressed patients (Caviedes et al., 2017; Jiang et al., 
2017; Zhou et al., 2017). Future studies examining the brain concentrations of BDNF 
in mice exposed to CBD in adolescence may therefore be informative towards 
understanding its mechanism of action. CBD also increases anandamide 
concentrations through inhibition of FAAH and/or FABPs (Bisogno and Di Marzo, 
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2010; Elmes et al., 2015), which may confer resilience to depression-like behaviour 
and have prohedonic actions (Gobbi et al., 2005; Karhson et al., 2016; Shoval et al., 
2016; Zlebnik and Cheer, 2016). Future studies might then also examine whether 
adolescent CBD exposure altered the developmental course of the endocannabinoid 
system in the brain, and whether the effects of adolescent CBD exposure extend to 
other animal models of depression such the sucrose preference or tail suspension tests. 
Conclusion
In our hands repeated adolescent THC treatment was unable to induce long-term 
behavioural alterations in adult mice. It still therefore remains an open question 
whether CBD can protect against the adverse effects of THC in the adolescent brain 
and on behaviour. Serendipitously, we discovered that adolescent CBD exposure 
alone reduced depression-like behaviour long after the final administration of the 
drug, laying the platform for future more detailed investigations into this 
phenomenon.  
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5. General Discussion
This thesis expanded our knowledge of CBD modulation of the neurobehavioural 
effects of THC following acute, repeated and adolescent treatment. In Chapter 2 we 
demonstrated for the first time that acutely co-administered CBD suppressed THC-
induced brain activation patterns at a 1:1 CBD:THC dosage as measured by c-Fos 
expression. In Chapter 3 we determined that a 1:1 CBD:THC dosage ratio CBD 
subtly suppressed the effects of THC on several behavioural measures, but a 1:5 
dosage ratio did not enhance this inhibition any further. We additionally reported in 
Chapter 3 that CBD did not alter the trajectory of tolerance to the behavioural and 
physiological effects of THC. However, the combination of CBD and THC increased 
histone acetylation in the VTA and ΔFosB expression in the nucleus accumbens, 
outcomes not seen with either cannabinoid alone. These results were surprising, and 
imply combined CBD and THC exposure may sensitize mesolimbic dopamine 
circuitry. Finally in Chapter 4 we examined whether CBD could ameliorate persistent 
behavioural deficits promoted by adolescent THC treatment. However, the expected 
THC-induced deficits were not found on any measure, and therefore no CBD 
inhibiting effects could be assessed. These results suggest persistent deficits may 
require very high THC doses modelling abuse rather than normative use. 
Serendipitously we discovered adolescent CBD exposure reduced depression-like 
behaviour in adulthood, three weeks after the final CBD dose. This suggests 
adolescent CBD exposure may have enduring beneficial effects on mood.  
The possibility of CBD suppressing THC’s adverse psychoactive properties to 
make cannabis a safer drug remains an area of great interest and significance given 
increasing acceptance of cannabis use for recreational and medicinal purposes. The 
optimal balance of CBD and THC may render cannabis “healthier” either by reducing 
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the adverse effects of THC or by magnifying the plants’ therapeutic efficacy. 
However, there has been limited research addressing the important question of 
whether the major cannabinoid constituents CBD and THC interact in the brain, and 
before this thesis it was unknown whether CBD could modulate the acute brain-
activating effects of THC. Chapter 2 demonstrated CBD suppressed acute THC-
induced c-Fos expression, a marker of neuronal activation, in multiple brain regions at 
a 1:1 CBD:THC ratio relevant to medicinal cannabis consumption. Specifically, CBD 
reduced THC-induced c-Fos expression in the medial preoptic nucleus of the 
hypothalamus, the lateral PAG and the dentate gyrus, regions implicated in the 
hypothermic, anxiogenic and memory-impairing effects of THC respectively. While 
CBD acutely reduced the effects of THC on the brain in Chapter 2, a different picture 
emerged following repeated co-administration of CBD and THC in Chapter 3. There 
was no evidence of CBD reducing the neuroadaptive effects of THC on the brain as 
measured by ΔFosB, a transcription factor with a relatively long half-life implicated 
in the development of drug dependence (Nestler, 2013; Robison and Nestler, 2011; 
Ruffle, 2014). In fact, the combination of CBD and THC triggered ΔFosB expression 
in the mesolimbic dopamine pathway. This underscores that the impact of CBD and 
THC combinations on the brain may change with repeated exposure.  
The complexity of the interaction between CBD and THC is highlighted by 
the results of Chapter 2 where, in the same set of mice, CBD simultaneously inhibited 
THC-induced hypothermia and anxiety-related behaviour, while potentiating the 
locomotor suppressant effects of THC. To tease out the specific roles of brain regions 
in such effects, microcannulation studies might be conducted. That is, CBD and THC 
could be directly infused into either the medial preoptic nucleus of the hypothalamus, 
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the lateral PAG or the dentate gyrus of the hippocampus to observe whether CBD 
offsets the hypothermic, anxiogenic and memory-impairing effects of THC.  
We demonstrated in Chapter 2 that CBD suppressed c-Fos expression, with 
the magnitude of effect varying by brain region. However, c-Fos is limited in its 
ability to inform on changes in neural circuitry, as it only shows changes in discrete 
brain regions. This could be addressed by connectomics, which aims to describe and 
analyse the global network of the brain by using mathematical modelling of regional 
co-variation to identify neural hubs or networks (Shibata et al., 2015). Wheeler et al. 
(2013) used such a technique to analyse long-term memory development in mice by 
examining interregional correlations between 84 brain regions. Groups of co-varying 
regions were identified according to strength and stability of correlations. This 
revealed eight distinct clusters involved in long-term memory processing, but also 
showed hippocampal and medial prefrontal cortical nuclei were hubs in this network, 
and so were most likely to affect the entire system. The ability to identify networks 
and hubs would provide valuable information on CBD and THC interactions.  
For instance, human imaging studies have shown CBD disruption of 
connectivity from the amygdala may underpin its suppression of fear responses 
(Fusar-Poli et al., 2010), while CBD may have opposite effects to THC in the 
hippocampal-cortex circuit in attention tasks (Bhattacharyya et al., 2010). Combining 
c-Fos with connectomics could be an inexpensive route to identify brain circuits of
interest for more elaborate techniques such as live imaging. We performed a 
preliminary network analysis of the regional co-variation in our c-Fos data, which 
suggested networks differed between treatment groups (see Figure 1). Interestingly, 
compared to the vehicle group, CBD treatment appeared to uncouple the central 
amygdala from previous connections, which could explain our finding in Chapter 2 
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that CBD treatment decreased c-Fos expression in this region. Analysis with a greater 
test sample number might provide further information on the connective networks 
following co-administration of CBD and THC.  
Figure 1. Network graphs generated by analysing region co-variation of c-Fos expression in A) vehicle 
and B) CBD treated mice as per Chapter 2. Bar thickness represents correlation strength, while colour 
represents direction of correlation (green = positive, red = negative). 
Identifying the phenotype of specific neuronal populations involved in CBD’s 
suppression of THC-induced c-Fos expression is a logical next step for future 
research. This could be easily addressed in immunofluorescence colocalisation studies 
using antibodies for distinct cell populations to identify which neurons specifically 
express c-Fos (Diano et al., 2011). For example, the 5-HT1A receptor might contribute 
to CBD’s modulatory effects as it is expressed in the dentate gyrus of the 
hippocampus, the medial preoptic nucleus and periaqueductal grey (Clements et al., 
1985; de Paula Soares and Zangrossi, 2009; Kia et al., 1996; Marvin et al., 2010). 
Moreover, 5-HT1A has modest affinity with CBD (Russo et al., 2005) and has been 
shown to mediate the anxiolytic behavioural effects of CBD (Campos et al., 2012; 
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Campos and Guimaraes, 2008; Soares Vde et al., 2010). We would hypothesise that in 
a co-localization study, regions where CBD most suppressed THC-induced c-Fos, 
such as the lateral PAG or preoptic nucleus, would show a higher degree of 5-
HT1A+/c-Fos+ double labelled cells, and areas that were not modulated by CBD such as 
the BNST would show low 5-HT1A+/c-Fos+ overlap. This technique could also be 
extended to other receptors that have affinity with CBD such as GPR55 or GABAA 
receptors (Bakas et al., 2017; Ryberg et al., 2007).  
The rules of dose-response relationships do not appear to readily apply to 
CBD and THC interactions as highlighted by the results of Chapter 3. The ability of 
CBD to inhibit THC behavioural effects at a 1:1 CBD:THC dosing ratio was not 
enhanced by increasing the dose ratio. That is, although PPI and rebound 
hyperactivity were subtly suppressed by a 1:1 dose, increasing the dose ratio from 1:1 
to 5:1 (CBD:THC) did not produce any substantial difference in results. This suggests 
CBD’s modulation of THC might not be dose-dependent. As reviewed in the 
introductory chapter, animal studies have shown CBD can potentiate, suppress, or 
have no effect on the actions of THC. CBD produces inverted U-shaped dose-
response curves in its antidepressant, anxiolytic and anti-inflammatory effects 
(Campos and Guimaraes, 2009; Jamontt et al., 2010; Zanelati et al., 2010), so it may 
be there exists a ‘sweet spot’ for CBD to modulate the effects of THC. It may also 
mean a 1:1 CBD:THC dose ratio may not produce the same interaction at different 
relative dose strengths, for instance at 1 mg/kg versus 100 mg/kg of each drug. 
Whether the neurobiological suppression we saw here is consistent across other dose 
ranges could be investigated in future studies.  
This thought can be extended further when considering that THC sometimes 
produces unusual dose-response relationships. THC has demonstrated biphasic effects 
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on anxiety, feeding, and locomotor responses, with low doses being anxiolytic, 
hyperphagic and locomotor stimulant, whereas high doses produce anxiogenesis, 
hypophagia and locomotor suppression (Bellocchio et al., 2010; Fokos and Panagis, 
2010; Katsidoni et al., 2013).!Even triphasic effects for have been reported, with both 
THC and CBD suppressing nerve pain in rats within two separate dose ranges, 
suggesting multiple mechanisms of action (King et al., 2017). Bellocchio et al. (2010) 
suggested biphasic responses might be the result of THC interacting with different 
CB1 receptor subpopulations, each subserving opposite regulatory effects of a 
particular response. For instance, cortical glutamatergic CB1 receptor agonism 
increases food intake, while ventrostriatal GABAergic CB1 receptor agonism 
suppresses feeding (Bellocchio et al., 2010). A similar divergence has been found 
with the CB1 receptor agonist CP 55,940 and anxiety, with low doses producing 
glutamatergic driven anxiolysis and high doses producing GABAergic mediated 
anxiogenesis (Rey et al., 2012). CBD might then bias THC to activate neuronal 
pathways favouring stimulatory as opposed to inhibitory effects, particularly in 
GABAergic or glutamatergic neurons. The relative contributions of these two 
subpopulations in CBD and THC interactions should be considered in future 
experiments. 
An additional route of inquiry to expand on the results of this thesis involves 
pharmacokinetic mechanisms. The ability of CBD to potentiate the behavioural 
effects of THC and synergistically enhance neuroadaptive changes in the mesolimbic 
pathway, as shown in Chapters 2 and 3, may be explained by CBD elevating brain 
and plasma THC concentrations. This has been demonstrated in numerous rodent 
studies (Bornheim et al., 1995; Fernandes et al., 1974; Jones and Pertwee, 1972; Reid 
and Bornheim, 2001; Varvel et al., 2006), and is evident with both acute and repeated 
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dosing (Klein et al., 2011). CBD’s ability to increase brain and plasma THC levels 
might be explained via interactions with cytochrome P450 enzymes or ABC 
transporters. For instance, CBD inhibits cytochrome P450 (CYP) 2C9 and CYP3A4 
enzymes involved in the metabolism of THC (Bland et al., 2005; Bornheim et al., 
1992; Stout and Cimino, 2014; Watanabe et al., 2007; Yamaori et al., 2011). In 
addition, CBD inhibits P-gp and Bcrp, two efflux transporters that regulate the brain 
accumulation of THC (Brzozowska et al., 2016; Holland et al., 2007; Holland et al., 
2006; Spiro et al., 2012; Zhu et al., 2006). Future experiments may provide more 
definitive proof for mechanisms subserving pharmacokinetic interactions between 
CBD and THC. Analysing whether CBD disrupts THC metabolism in liver 
microsomes or hepatocytes selectively expressing CYP2C9 or CYP3A4 would help 
address the issue. Similarly, transwell assays of cells overexpressing P-gp or Bcrp 
may assess whether the transport of THC is impaired by CBD co-administration. 
The majority of cannabis users (both recreationally and medicinally) will use 
the drug over a period of time, so in Chapter 3 we aimed to investigate the 
neurobehavioural outcomes of repeated co-administration of CBD and THC. We 
hypothesized that CBD may alter the development of tolerance to the 
pharmacological effects of THC, as well as inhibit the induction of the transcription 
factor ΔFosB, a marker of long-term neuroadaptive changes, and acetylation of 
histone H3K9, an epigenetic marker. We found that despite subtle inhibition of acute 
THC responses, continued CBD dosing did not change the trajectory of tolerance to 
THC for most measures. Surprisingly, immunohistochemical analysis indicated an 
additive and possibly synergistic effect of combined CBD and THC administration on 
mesolimbic circuitry, with the combination increasing ΔFosB expression in the 
nucleus accumbens and histone H3K9 acetylation in the VTA. The apparent 
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sensitization of the mesolimbic circuit following the co-administration of CBD and 
THC is surprising given our Chapter 2 results showing CBD suppressed the acute 
brain-activating effects of THC. The apparent switch from acute inhibition to chronic 
sensitization is concerning given mesolimbic pathway sensitization is considered a 
sign of addictive potential of drugs of abuse, and this needs to be further explored in 
future investigations (van Huijstee and Mansvelder, 2014; Weidenauer et al., 2017).  
This thesis represents the first investigation of the interactive effects of CBD 
and THC on epigenetic modification through chromatin remodelling. DNA is 
wrapped around histone proteins forming chromatin, which packages DNA in the cell 
nucleus. Chromatin structure can be altered to either permit or suppress access to 
DNA by transcriptase enzymes, altering gene expression. Histone acetylation relaxes 
chromatin structure, allowing for greater protein transcription (Graff and Tsai, 2013). 
In Chapter 3 we hypothesised that THC might acetylate H3K9, as this epigenetic 
modification in the mesolimbic pathway has been demonstrated following dosing 
with drugs of abuse such as alcohol, cocaine, morphine and methamphetamine 
(Ciccarelli et al., 2013; Godino et al., 2015; Sartor et al., 2015; Sprow et al., 2014). 
We also co-administered CBD in order to investigate whether it modulates the 
anticipated effects of THC on H3K9 acetylation. Surprisingly, we found the 
combination of THC and CBD at a 1:5 THC:CBD dose ratio induced H3K9 
acetylation in the VTA following three days of treatment, which was not seen when 
each drug was given alone.  
Future studies could attempt to isolate which genes are affected by this 
increase in histone acetylation. Microarray screening of mRNA changes in VTA 
tissue could be performed to address this. Better still, chromatin immunoprecipitation 
(ChIP) would allow genome wide identification of highly histone modified promoter 
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regions within the VTA of animals treated with CBD and THC (Bernstein et al., 
2004; Robyr and Grunstein, 2003). ChIP analysis has been used to demonstrate that 
prenatal THC exposure disrupted D2 receptor function in adult rats due to chromatin 
remodelling caused by histone 3 methylation (DiNieri et al., 2011). ChIP analysis has 
never been performed for adolescent or adult animals treated with THC or CBD and 
represents a fruitful avenue for future research.  
Adolescent cannabis use is the most reliably associated with persistent 
behavioural and neurobiological deficits. Earlier initiation of cannabis use is 
associated with greater cognitive deficits and increased positive and negative 
symptoms of psychosis (Ehrenreich et al., 1999; Pope et al., 2003; Schubart et al., 
2011b). Additionally, cognitive deficits and long-term changes in brain structure and 
function promoted by cannabis may persist long after use has ceased (Meier et al., 
2012; Tapert et al., 2007). Chapter 4 aimed to assess whether CBD could prevent 
enduring behavioural deficits promoted by repeated adolescent THC exposure. 
However, we could not discern any protective effects of CBD as adolescent THC 
exposure itself failed to promote any long-term behavioural deficits. Serendipitously 
we did discover that adolescent CBD exposure promoted a persistent reduction in 
depression-like behaviour in adulthood, long after the final CBD dose and in the 
absence of CBD being present in the brain. 
Our investigation in Chapter 4 represents the first evidence of an enduring 
CBD impact on behaviour. CBD has been shown to have antidepressant and anxiolyic 
effects following acute and repeated dosing in adult animals (El-Alfy et al., 2010; 
Linge et al., 2016; Reus et al., 2011; Sartim et al., 2016; Schiavon et al., 2016; Shoval 
et al., 2016; Zanelati et al., 2010). Here we showed adolescent CBD exposure to 
reduce depression-like behaviour, three weeks after the final CBD exposure at a point 
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in time where CBD brain concentrations were undetectable. It is noteworthy that CBD 
was administered via i.p injection in our study, which is stressful, therefore one 
possible explanation for our findings is that CBD reduced the ability of adolescent 
stress to increase depression-like behaviour in adulthood (Brzozowska et al., 2017; 
Hibicke et al., 2017; Yohn and Blendy, 2017). CBD, which has anti-stress and 
anxiolytic properties, may have been protective during the injection phase and thus 
produced more resilient adult animals. To investigate whether this occurred, a non-
injected control group could be compared to the vehicle-treated group to observe 
whether the vehicle-treated group had higher depression like behaviour. Alternatively, 
we could observe whether a non-stressful mode of delivery such as providing CBD in 
lab chow nullifies the ability of CBD to reduce depression-like behaviour. 
Another possible explanation for why adolescent CBD exposure reduced 
depression-like behaviour in adulthood is that it did so via altering neurodevelopment. 
CBD might disrupt the endocannabinoid system via its ability to inhibit FABPs or 
FAAH, thus increasing brain anandamide concentrations (Bisogno et al., 2001; Elmes 
et al., 2015; Fernandez-Ruiz et al., 2012; Leweke et al., 2012). This is significant as 
endocannabinoid signalling in corticolimbic structures influences HPA axis 
development, which regulates depression-like behaviour (Lee et al., 2016). Therefore 
CBD might facilitate healthy neurodevelopment and confer resilience against 
depression-like behaviour in adulthood. In order to test this hypothesis, a future study 
could analyse endocannabinoid concentrations in the CNS across the adolescent to 
adult developmental period, both with and without CBD treatment, with particular 
focus on corticolimbic structures implicated in mediating depression-like behaviour 
such as the amygdala, prefrontal cortex and hippocampus. BDNF levels could also be 
investigated in the same experiment as an alternative mechanism, as suppressed 
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BDNF signalling during adolescence is associated with depressive behaviours (Sher, 
2011), and CBD increases BDNF signalling (Campos et al., 2015). 
A major point of interest in Chapter 4 was the lack of long-term deficits in 
adult mice after adolescent THC exposure, particularly given the considerable 
evidence supporting that adolescent cannabis use induces persistent negative 
neurobehavioural effects (Meier et al., 2012; Renard et al., 2014; Rubino and 
Parolaro, 2008; Rubino et al., 2009b). While we have already proposed dose strength 
may be a factor, environmental or genetic elements may also be required. In rodents, 
deficits induced by adolescent THC exposure are more pronounced when combined 
with genetic susceptibilities, including knockout of Nrg1, COMT and DISC1, genes 
implicated in vulnerability to schizophrenia and cannabis addiction (Ballinger et al., 
2015; Boucher et al., 2007a; O'Tuathaigh et al., 2010). However, they are also 
worsened when combined with preadolescent environmental stress, which on its own 
disrupts endocannabinoid signalling (Ballinger et al., 2015; Behan et al., 2012; Marco 
et al., 2014; Reich et al., 2013). Gender may also contribute, as female animals 
display increased cannabinoid sensitivity at lower doses than males (Spencer et al., 
2013a; Zamberletti et al., 2014; Zamberletti et al., 2016). In humans, while males 
appear more likely to develop cannabis use disorders, females are more susceptible to 
mental health or stress-related outcomes (Aspis et al., 2015; Kosty et al., 2016; 
Llorente-Berzal et al., 2011). A bidirectional effect on cognitive outcomes has also 
been suggested, with poor short-term and working memory associated with earlier 
cannabis use onset separate from the already known detrimental effects of early use 
on memory and attention (Castellanos-Ryan et al., 2017). It may be that a complex 
combination of factors cooperate to trigger deficits following cannabis use, rather 
than cannabis use being a sufficient cause on its own. This has already been suggested 
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in epidemiological studies investigating the link between cannabis use and psychosis 
(Malchow et al., 2013; Parakh and Basu, 2013; Pelayo-Teran et al., 2012); it is 
therefore plausible this concept extends to the less severe, but still significant, 
prolonged psychiatric morbidity and cognitive impairment reported in heavy 
adolescent cannabis users.  
Rodent studies are informative as they provide greater experimental control, 
allow more detailed assessment of neurobiological mechanisms, and enable a greater 
number of parameters to be assessed quickly and efficiently. However, they may be 
limited by their translatability to humans. One limitation of our studies for translation 
is the use of drug administration via i.p. injection rather than routes used by humans 
such as inhalation or oral administration. Vaporisation technologies for cannabinoid 
administration have improved greatly in the last decade, making this a viable 
alternative to smoking, and vaporization chambers are now commercially available 
for animal studies (Abrams et al., 2007; Hazekamp et al., 2006; Solowij et al., 2014).  
Interestingly, although vaporisation induces similar hypothermia and analgesia to 
THC injection in rats (Nguyen et al., 2016), THC inhalation produces less locomotor 
suppression and catalepsy in both rats and mice (Marshell et al., 2014; Nguyen et al., 
2016), increased feeding in rats (Manwell et al., 2014b) and both preference and 
avoidance in place conditioning in rats (Manwell et al., 2014a), suggesting it might 
better approximate human cannabis effects compared to intraperitoneal injection 
(Justinova et al., 2005). Another limitation is our focus on CBD’s amelioration of the 
behavioural side-effects of THC exposure. Cannabis will be increasingly used in a 
medicinal context and so future studies could address whether CBD modulates the 
therapeutic actions of THC in animal models of disease. Thirdly, it must be 
remembered that human and rodent mechanisms are not necessarily equivalent: for 
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instance, CBD does not inhibit the human form of FAAH while it does inhibit the 
rodent version, suggesting CBD effects would be slightly different in mice compared 
to humans (Elmes et al., 2015).  
Although there is great interest in the “entourage effect”, the idea that 
cannabis extracts may promote greater effects than the sum of its parts, there exists 
scant evidence for such a phenomenon. The present thesis addressed the “entourage 
effect” and showed that CBD reduced the effects of THC on the brain and behaviour 
– but these effects were sometimes modest, especially following repeated dosing, and
not without contrary instances of CBD potentiating the effects of THC. Another 
limitation of this thesis is the neglect of the role of other cannabinoids which may also 
engender modulatory effects on THC. CBG might be examined as it has a relatively 
high concentration in cannabis (Swift et al., 2013). Moreover, CBGA, CBDA and 
THCA, the precursor molecules of CBG, CBD and THC in the plant respectively, 
might also be studied. These acidic molecules are of course not so relevant to 
vaporized or smoked cannabis, as they are decarboxylated by heat to the neutral forms 
of CBG, THC and CBD (Verhoeckx et al., 2006). However, medicinal cannabis may 
come in other dosing forms that do not involve heating and therefore the interaction 
of such molecules with THC may be very relevant (Pacifici et al., 2017; Peschel, 
2016). For instance, CBDA can both enhance THC’s reduction in nausea and 
vomiting whilst attenuating THC-induced learning deficits (Rock et al., 2016; Rock et 
al., 2015; Rock and Parker, 2015) although it did not modify THC’s anxiogenic effect 
(Rock et al 2017). In addition, other non-cannabinoid molecules in the plant could be 
examined, such as the terpenes, terpenoids and flavonoids. These molecules have also 
been hypothesised to influence the pharmacological actions of THC (Kim and 
Fishman, 2017; Russo, 2011). The sheer number of potentially therapeutic cannabis 
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constituents further suggests that whole plant experimentation with standardized 
extracts should be considered in future cannabis research.  
5.1 Conclusion 
This thesis advances our understanding of CBD and THC pharmacological 
interactions and reaffirms their complexity. CBD acutely inhibited some of the 
neurobehavioural effects of THC at human relevant doses, suggesting potential 
benefits of CBD in reducing the unwanted effects of THC. However, the unexpected 
activation of mesolimbic circuitry by THC and CBD combined suggest enthusiasm 
should be tempered until these effects are better understood. An unexpected finding 
was that adolescent mice exposed to a modest THC dose equivalent to most 
recreational and medicinal users did not display long-term behavioural deficits. CBD 
alone produced no behavioural changes following acute or repeated exposure, 
although adolescent CBD exposure reduced depression-like behaviour in adult mice, 
an intriguing effect warranting further study. 
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